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Toxin-antitoxin (TA) systems are typically encoded as bicistronic operons in a variety of 
bacterial species and archaea and act as response effectors to a variety of intra and extra-
cellular stressors. TA members are classed into 6 generic systems and type 2 TA systems are 
able to directly autoregulate their own expression via a series of complex interactions 
between the protein toxin, the protein antitoxin and the DNA upstream of the encoding genes. 
This ensures that in a non-stress environment, the protein antitoxin is in excess of the protein 
toxin resulting in neutralisation. During a state of stress, the intracellular toxin concentration 
accumulates and the toxin is able to exert its toxicity, typically resulting in bacteriostasis. 
This mechanism has been implicated in the generation of antibiotic tolerant (persister) cells, 
which can result in chronic infections. The HicAB system is one of the prototypic type 2 TA 
systems found in several bacteria and archaea, yet remains underinvestigated when compared 
to other TA systems. This thesis reports structural studies on the Burkholderia pseudomallei 
HicAB TA pair and associated DNA interactions. HicB forms a tetramer and this can interact 
with DNA upstream of the bicistronic hicAB operon to form a tight binding complex. HicA 
and HicB form a hetero-octameric complex that involves structural re-organisation of the 
carboxy-terminal (DNA binding) region of HicB. HicA therefore has a profound impact on 
binding of HicB to DNA sequences upstream of hicAB, in a stoichiometric-dependent way. 
At low ratios of HicA:HicB there is no effect on DNA binding, but at higher ratios the 
affinity for DNA declines co-operatively, driving dissociation of the HicA:HicB:DNA 
complex. This provides the first example of the molecular mechanisms by which HicA de-
represses a HicB-DNA complex and is a distinct mechanism when compared to other TA 
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1.  Introduction 
1.1.  Antibiotic resistance 
Antibiotic resistance (AR) is a widespread phenomenon enabling the survival and 
proliferation of microbes when challenged with antibiotics.
1
 AR is a considerable health and 
economic burden
2
 and a global surveillance report has revealed high rates of resistance 
amongst bacteria commonly observed across all regions studied.
3
 In 2017, it was reported 
that the current pipeline of antibiotics in development (Phase 1-3) were insufficient to stem 
the rise of antibiotic resistance.
4
 Of the fifty-one antibiotics within the pipeline, most were 
simple modifications of existing antibiotics rather than novel antibiotic classes.  Despite the 
best efforts of the WHO, antibiotic misuse by the public and indiscriminative use within 
agriculture have propagated the rise of AR. In 2018, it was reported that sub-minimum 
inhibitory concentration (MIC) levels of streptomycin can induce the generation of resistant 
Salmonella enterica over several hundred generations, with resistance conferred by a 
combination of mutations within several genes associated with aminoglycoside resistance 
(gidB, cyoB, nuoG, trkH and znuA) that confer a high level of resistance.
5
 The ability of 
bacteria to resist antibiotic treatments has enabled bacterial infections to persist and 
proliferate within the host.   
1.2.  Chronic infections 
Bacterial infections initially manifest in an acute variant form, typically cleared by the 
immune system. In some cases, the immune system does not completely eradicate this 
infection with a resultant sub-population of bacteria acting as a reservoir for future relapses. 
This gives rise to chronic infections, defined as the establishment of a persistent pathogenic 
bacterial presence.
6, 7
 Establishment can be explained by a range of factors, including evasion 
from the host immune system, the formation of biofilms and adaption to an intracellular 
environment.
8
 Each establishment factor causes a reduced efficacy of antimicrobial agents.  
Chronic infections often initially colonize at one location
7, 9-12
, but can spread throughout the 
host.
9, 11
 While modes of evasion, establishment and pathogenesis vary, it is clear that all 
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chronic infections share one common feature; they propagate from a subpopulation of cells 
that are not processed and eradicated by the immune system. Understanding the mechanisms 
of cellular survival and the resulting persistence of pathogenic bacterial infections are vital to 
efforts to combat chronic infections. 
1.3.  Persister cells 
Persister cells, referred to as dormant/antibiotic tolerant cells were first described in 1944 by 
Joseph Bigger.
13
 These are generated by a stochastic mechanism, where cells switch between 
a non-growing dormant antibiotic tolerant (persister) state and a non-dormant antibiotic 
susceptible state (Figure 1.1). The precise details of this switching mechanism are still 
unclear but population heterogeneity is believed to be a crucial factor.
14
 The creation of a 
subpopulation of persister cells, typically 1% of the total population, enables the bacteria to 
survive a lethal stress induced for example by an antibiotic. Persistence is deemed to be a 
phenotypic characteristic, rather than genotypic as daughter cells do not inherit this trait.  As 
persisters can survive numerous stressor challenges (for example, nutritional depravation or 
pH alteration), persisters are hypothesized to act as a failsafe priming mechanism to prevent 
the complete eradication of a bacterial population from a unknown future stressor.
15-17
 It is 
therefore likely that this response to a broad range of stress factors evolved in preference to 
encoding individual responses for each stressor. 
In 2017, experimental evidence suggested that antibiotic tolerance preceded resistance to 
ampicillin by several generations. The survival advantage conveyed by antibiotic tolerance 
enabled the remaining Escherichia coli to accumulate mutations in the promoter of AmpC, a 
β-lactamase, to a point where resistance was achieved.
18
 Simulations revealed that although 
similar mutations accumulated in populations of antibiotic susceptible cells, these populations 
were destroyed prior to reaching a state of antibiotic resistance. Antibiotic tolerant cells can 
therefore provide a safe haven for the accumulation of mutations, increasing the likelihood 
that resistance is achieved. The pathway of tolerance to resistance may provide a key 
checkpoint in combating antibiotic resistant cells.  
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Figure 1.1. Overview of antibiotic tolerance. Antibiotic susceptible cells (blue circles) do not survive an 
antibiotic challenge. Resistance cells (red triangles) survive an antibiotic challenge due to a genotypic variation. 
These are able to replicate to ensure the next generation of cells are all antibiotic resistant. Antibiotic tolerant 
cells (red circles) are ~1% of the population which survive an antibiotic challenge due to phenotypic variation- 
resulting in a dormant cellular state. Due to the phenotypic nature of antibiotic tolerant cells- the next generation 
of cells consist of two distinct populations of antibiotic tolerant cells and antibiotic susceptible cells. The cycle 
then repeats upon further antibiotic challenges. 
The underlying molecular mechanisms of persistence  mediated by persister cells remained 
unknown
14
, despite their ability to confer antibiotic tolerance within a range of bacterial 
biofilms.
19-27
 Toxin-antitoxin (TA) systems, initially referred to as addiction modules, were 
first described by Gerdes in 1986.
28
 These two component systems are found within 
numerous bacterial chromosomes and extrachromosomal plasmids.
29, 30
 TA systems all share 
three common features observed in addiction modules.
31-35
 First, each system is comprised of 




 and an “antidote” antitoxin 
that reverses toxicity. Secondly, each  antitoxin is labile in contrast to their stable toxin 
enabling programmed cell death/stasis in response to antibiotics.
32
 Lastly, antitoxins appear 
to autoregulate the toxin-antitoxin operon or cause plasmid addiction. 
In 1983, an extensive screening study sought to identify genes upregulated in E. coli persister 
cells.
39
 Mutations within the locus of a bicistronic operon (hipAB) enhanced persisters up to 
10,000 fold and led to the identification of the first persister related gene: hipA.
40
 This operon 
resulted in a toxic phenotype (cell death) in the absence of hipB.
40-42
  HipA and HipB were 
later shown to form a stable complex that was able to repress the transcriptional activity of 
the hipAB promoter.
43
  hipAB was proposed to encode a TA system due to the presence of the 
three archetypal features outlined above.
44
 TA systems had been implicated in programmed 
cell death, for the majority of a population of cells, in response to antibiotics prior to 2004
30, 
45, 46
 but only the HipAB system had been linked to persistence.  
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In 2004, Keren et al. investigated the gene expression profile of E. coli persister cells which 
revealed a range of persister related genes upregulated in response to stress including several 
TA systems (dinJ, mazEF and relBE).
47
 One toxin, RelE was determined to induce the 
formation of persister cells.
47
 This study was the first to link experimentally confirmed TA 
systems to persistence. Concurrent to this, microfluidic experiments
48
 confirmed two types of 
persistence within E. coli: Type 1 persister cells, generated within the stationary phase, were 
typified by the HipA7 mutant (a mutant within the hipA locus) and Type 2 persister cells, 
typified by the HipQ mutant (a mutant within an uncharacterised locus within E. coli, whose 
genes are unknown
49, 50
) were continuously generated through growth, albeit at a slower rate 
than type 1 persister cells. Overexpression of the HipA7 mutant enabled the survival of a sub-
population of bacteria in response to ampicillin. These cells were viable and able to resume 
growth upon removal of antibiotic and this elegant study was the first to display the 
generation of persister cells in real time.  Shortly after both of these studies were reported, 
HipAB was designated as a TA system
51-54
 and multiple TA systems encoded in E. coli have 
been correlated with the persister phenotype. 
55
 
Since these two studies, TA systems have been implicated in the generation of multidrug 
tolerant persister cells in extraintestinal pathogenic E. coli (ExPEC)
56
,  and Salmonella 
typhimurium.
57
. Within ExPEC, three TA systems promoted bacterial infections of the 
bladder and upregulated persister cell formation in a murine model. TA upregulation has also 





, ,  Staphylococcus aureus
60, 61
 and Streptococcus pneumoniae.
62
 
  Helaine et al. found that Salmonella persisters were induced by vacuolar acidification and 
nutritional deprivation, two stressors that caused the upregulation of fourteen TA systems and 
the persister phenotype after internalisation by macrophages. Some persister cells remained 
viable after phagocytosis by naïve macrophages, providing a localised reservoir to promote 
chronic infections.
57, 63
   
Current knowledge therefore implicates TA systems in the generation of multidrug tolerant 
persister cells and bacterial pathogenesis.
64
 More recently, however, the view that TA 




 and the role 
of persister cell formation needs to be reviewed following several key retractions of model 
studies in E. coli.
68, 69
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1.4.  Toxin-antitoxin systems 
TA systems are conserved through bacteria and archaea acting as response elements that react 
to stressors including acidic pH, amino acid/nutrient starvation and antibiotics.
70-72
 Activation 
of toxins result in programmed cell death or stasis, depending on the nature of the toxin and 
the level of its expression.
51
 Extensive research throughout the last twenty years have 
implicated TA systems in chronic infections (persister cells), plasmid maintenance 
(Programmed cell death) and biofilm formation.
51, 73, 74 
 The stringent
75
 and SOS response
76, 
77
, have also been implicated in the activation and regulation of several TA systems.
72, 78-83
 
The actions of certain toxins have been shown to induce the SOS response
84-86
, resulting in a 
feedback loop to further activate several other TA systems. Both the stringent and SOS 
response ensure that cells respond to nutritional depravation and DNA damage via hardwired 
stress response systems in a concerted manner to induce cell dormancy via the activation of 
multiple TA systems, each acting on an individual cellular target. This results in a rapid 
switch containing several layers of multiplicity to preserve the bacterial population under 
antibiotic/environmental stressors. 
At the present time (2018), individual TA members are classified into six distinct systems 
(Figure 1.2) based on the nature of the toxin and antitoxin components as well as the mode of 
toxin neutralisation. 
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Figure 1.2. An overview of the six known TA systems and how each antitoxin (blue) interacts with its 
respective toxin (red). (A) Type 1 TA systems involve a direct interaction between the mRNA that encodes the 
toxin and antitoxin RNA to cause toxin neutralisation. (B) Type 2 systems are expressed from a bicistronic 
locus where a direct protein-protein interaction between the toxin and antitoxin is required for neutralisation. 
(C) Type 3 TA systems involves a protein toxin inhibited by an RNA antitoxin. (D) Type 4 systems involves the 
antitoxin shielding the cellular targets of the toxin by directly binding to the cellular target. (E) In the Type 5 
system, the antitoxin (endonuclease) actively cleaves the toxin mRNA to prevent toxicity (F) The type 6 system 
SocAB binds the DnaN sliding clamp to inhibit DNA replication. Under normal cellular conditions, the toxin is 
degraded by SocA mediated ClpP degradation. 
Type 1 systems (Figure 1.2A) are either arranged as overlapping gene pairs or divergent gene 
pairs. Each system consists of a protein toxin and a RNA antitoxin.
28, 72, 81, 87-96
 The toxins are 
typically short hydrophobic proteins that insert into the cell membrane and induce 
depolarisation, in turn decreasing the proton motive force and the intracellular ATP 
concentration (Hok, TisB, IbsC and ShoB).
88, 97, 98
 The small RNA (sRNA) antitoxins 
typically act in trans to inhibit toxin messenger RNA (mRNA) by forming dsRNA 
complexes.
94
 These dsRNA complexes are subsequently cleaved by cellular RNases, 
preventing toxin translation and downstream toxicity.
94
  
Type 2 TA systems have been extensively probed with various type 2 TA systems identified 
due to their organisation within bicistronic operons. In contrast to other systems, direct 
protein-protein interactions are formed between the toxin and cognate antitoxin to neutralise 
toxicity (Figure 1.2B)
99
 and are covered in more detail below.   
Type 3 systems (Figure 1.2C) utilise sRNA molecules as antitoxins to directly neutralise 
1.  Introduction 1.5. Type 2 TA Systems 
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protein toxins endoribonucleases resulting in plasmid addiction and phage protection
100-103
. 




Type 4 systems consist of a bicistronic operon where the protein antitoxin directly interacts 
with the cellular target of the toxin to neutralise toxicity, rather than through the formation of 
a toxin-antitoxin complex (Figure 1.2D).
107, 108
 
To date there is only one member of the type 5 system: GhoST (Figure 1.2E). The ghoST 
operon, found in E. coli encodes a membrane lytic protein that causes the formation of ghost 
cells, by permeabilising the membrane, similar to the type 1 toxin TisB.
109, 110
  In comparison 
to other systems, the antitoxin GhoS acts as an endoribonuclease that cleaves ghoT mRNA- a 
novel mechanism with respect to current antitoxins. 
Finally, the type 6 system SocAB from Caulobacter crescentus is similar to a type 2 system, 
consisting of a bicistronic operon and the formation of a protein-protein complex, SocAB.  
Unusually, the toxin SocB inhibits DNA replication by interfering with the β-sliding clamp 
(DnaN) (Figure 1.2F) and in contrast to type 2 systems the toxin, SocB rather than the 
antitoxin (SocA) is degraded preventing SocB mediated toxicity (cell death). SocA, the 
antitoxin is an adaptor for ClpXP through the formation of a SocAB-ClpXP complex which 
mediates continuous degradation of SocB.
111
  
There are however, and likely to increasingly be, exceptions to these general classifications 
(Appendix Table 1 and 2).  
 
1.5.  Type 2 TA Systems 
 
The structure and function relationships have been characterised for many type 2 TA systems 
and are summarised in Table 1.1. Type 2 toxins have been shown to have mRNase, kinase, 
acetylase and DNA gyrase inhibitory activities leading to mRNA cleavage, phosphorylation 
of translational machinery
99, 112, 113
 (for example EF-Tu
114
), translational inhibition via the 
acetylation of charged tRNAs and inhibition of DNA replication
63, 115-117
 respectively. 
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The type 2 toxins are neutralised by complexation with an antitoxin protein and the resultant 
complexes have been shown to negatively autoregulate their own transcription by binding to 
operator regions with their 5’untranslated region (5’UTR) preventing operon transcription by 
RNA polymerase. Antitoxins are labile and readily degraded by proteases such as Lon or 
Clp.
64, 118-120
 Therefore, under normal growth conditions, the operon is continuously 
transcribed to ensure that a steady stream of antitoxin is available to neutralise its cognate 
toxin. During cellular stress such as nutritional starvation or antibiotic presence, the 
intracellular concentration of toxin rises to eventually exceed that of the less stable antitoxin 
as global translation within the cell is reduced. Insufficient antitoxin levels enable a 
population of free toxin to exert toxicity resulting in cell dormancy. 
The high-resolution three-dimensional structures of at least one component of 18 Type 2 
systems are known (Table 1.1). Figure 1.3-1.5 provides the details of the crystallised 
complexes of type 2 TA systems and individual components (toxin/antitoxin) for systems 
whose TA complexes are unknown. Within systems that share a specific function (i.e, DNA 
replication inhibition), there are structural variations for both the toxin and antitoxin, 
highlighting variability within the type 2 TA subclass. 




Toxin Function Structure Antitoxin Structure Reference 









N/A Axe N/A 121, 122 


















Hha Activates lytic 
prophage genes 
Monomer (NMR) TomB Monomer (X-ray 
crystallography) 
128-130 
HicAB HicA mRNA 
endoribonuclease 
 
Monomer (NMR) HicB Tetramer (X-ray 
crystallography) 
131 132 






HigA Dimer (X-ray 
crystallography) 
 83, 133, 134 





HipB Dimer (X-ray 
crystallography) 
 135-138 





FicA Monomer (X-ray 
crystallography) 
  139-141 









GmvAT GmvT Acetylates tRNAs Unknown GmtA N/A 143 
KacAT KacT Acetylates tRNAs Dimer (X-ray 
crystallography) 
KacA N/A 116 




Kis N/A 144 






MazE Dimer (X-ray 
crystallography) 
145, 146 














ParD Dimer (X-ray 
crystallography/
NMR) 
 150, 151 






PezA Dimer (X-ray 
crystallography) 
152 





Phd Dimer (X-ray 
crystallography) 
 133, 153 




TacA N/A  63, 154 





RelB Dimer (X-ray 
crystallography) 
 155-157 
VapBC VapC tRNA endonuclease Monomer (X-ray 
crystallography) 
 
VapB Dimer (X-ray 
crystallography) 


















Epsilon Dimer (X-ray 
crystallography) 
161, 162 
Table 1.1. A summary of characterised type 2 TA systems. The function of the toxin and the known 
structural information on the toxin and antitoxin components where present for each system are highlighted. 
Three-dimensional structures are highlighted in Figure 1.3-1.5. 
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Figure 1.3. Three-dimensional structures of type 2 toxin-antitoxin systems. Structures of current TA 
systems whose toxin exhibits an endoribonuclease activity. Solved structures of the TA complexes, where 
available, are presented with the toxin and antitoxin highlighted in red and blue respectively. PDB codes: 4Q2U 
(DinJ/YafQ), 4C26 (HicA), 4P7D (HicB), 4MCT (HigBA), 1M1F (Kid), 1UB4 (MazEF), 3H12 and 3GN5 
(MqsRA), 4FXE (RelBE), 3TND (VapBC), 2A6Q (YefM/YoeB). 
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Figure 1.4. Three-dimensional structures of type 2 toxin-antitoxin systems. Structures of current TA 
systems whose toxin inhibits DNA replication (blue outline). Solved structures of the TA complexes, where 
available, are presented with the toxin and antitoxin highlighted in red and blue respectively. PDB codes 2ADL 
(CcdA), 1VUB (CcdB), 5JFZ (FicTA) and 3KXE (ParDE). 
 
Figure 1.5.  Three-dimensional structures of type 2 toxin-antitoxin systems. Structures of toxin-antitoxin 
complexes where the toxin is a kinase (purple outline) or an acetylase (green outline). Toxins and antitoxins are 
highlighted in red and blue respectively. PDB codes: 2WIU (HipAB), 2P5T (PezAT), 3KH2 (Phd/Doc), 1GVN 
(Zeta/Epsilon), 5XUN (KacT) and 5FVJ (TacT). 
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Endoribonucleases can be classified based on their mechanism of action. These are either 
dependent on the presence of ribosomes (translation dependent endoribonucleases): HigB, 
RelE, YafQ and YoeB and those that are not (translation independent endoribonucleass): 
HicA, Kid, MazF, MqsR, Txe and VapC.
113
 Although each translation dependent 
endonuclease exerts cleavage within the ribosomal A site, the specificity of each varies. For 
example, HigB and YafQ recognise specific sequences respectively cleaving at AAA/ACA 
codons and AAA(G/A) sites.
163-166
 In contrast, both RelE and YoeB display broad sequence 
specificity, with cleavage immediately seen at the 5’ end of mRNA.
167-171
 
The translation independent endonuclease (MazF and MqsR family members) recognise and 
cleave specific mRNA sequences
71, 172-176
 and recently the M. tuberculosis MazF-mt9 
alongside VapBC family members encoded in several bacteria have been shown to primarily 
cleave tRNA, although exceptions have been reported.
177-182
 Kid specifically cleaves 
UA(A/C/U) triplets and inhibits translation as well as a ColE1 RNA II primer leading to 
inhibition of DNA replication. Kid therefore disrupts two cellular mechanisms to induce 
dormancy.
183-185
 Txe exhibits a broad specificity and in discriminatively cleaves three 
nucleotides after the start AUG codon.
186
 The specificity of HicA remains unclear and studies 
so far have observed mRNA cleavage but a recognition site has not been determined.
132, 187
 
The broad specificity within the endoribonuclease toxins allows a concerted action in 
response to stress to inhibit translation at multiple levels resulting in dormancy. The 
multiplicity of type 2 systems within bacteria suggests that inhibition of one is insufficient to 
prevent cell dormancy due to the global network of endoribonucleases.
113
 
The molecular mechanisms within toxins that act as inhibitors of DNA gyrase, kinases and 
acetylases also varies. Both CcdB and ParE bind the GyrA subunit of DNA gyrase to inhibit 
DNA replication
188-192
 whereas FicT adenylates the GyrB subunit of DNA gyrase to inhibit 
DNA replication.
141
 Within toxins that are kinases, Doc phosphorylates Ef-Tu to prevent the 
formation of the ternary (Ef-Tu-GTP-tRNA) complex.
114, 193
 HipA inhibits Glu-tRNA-
synthetase by phosphorylation to cause an accumulation of uncharged tRNAs and as a result 
both these toxins inhibit translation.
194
 Other kinases, Zeta and its homolog PezT 
phosphorylate Uridine diphosphate-N-acetylglucosamine and inhibit cell wall synthesis 
resulting in cell lysis.
162





, both toxins acetylate the amino group of an amino acid 
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attached to charged tRNAs to prevent translation via inhibition of an initiator complex (Ata) 
and peptide bond formation (TacT). 
1.6.  Conditional Cooperativity 
Transcription of prokaryotic genes is controlled by an upstream promoter region which 
enables binding of RNA polymerase in close proximity to a transcription start site (TSS, 
typically ATG/GTG).
195
 Bacterial promoters often encode two consensus sequences typically 
10 and 35 bp upstream of the TSS: the -10 Pribnow box (TATAAT)
196
 and the -35 hexameric 
sequence (TTGACA).
197
 The promoter region also contains the ribosome binding site (RBS), 
referred to as the Shine-Dalgarno sequence (consensus: AGGAGG
198
) typically between the -
10 Pribnow box and the TSS. 
Both the antitoxin and toxin-antitoxin complexes of type 2 TA systems are capable of 
binding to palindromic, imperfect-palindromic and inverted repeat sequences typically within 
the promoter region of their own bicistronic operon and are referred to as operator sites 
(Table 1.2). These often overlap with the -10 and -35 sequences or RBS to prevent 
transcription and therefore translation of the TA system A generalised model for the 
autoregulatory function of TA systems is as follows. The antitoxin alone typically binds 
weakly to the operator site, with enhanced binding upon complexation with a toxin, typically 
due to dimerization of adjacent DNA binding domains. The activity of these toxin-antitoxin 
complexes vary depending on the ratio of toxin:antitoxin and this mechanism has been 
termed conditional cooperativity (Figure 1.6). 
Under basal cell conditions, the antitoxin is typically in excess compared to the toxin and 
weakly binds to the operator site.
199
 This alone is not sufficient to result in full repression of 
the TA operon. Formation of a toxin-antitoxin complex results in the full repression of this 
operon, negating the expression of further toxin or antitoxin. Equimolar ratios of 
toxin:antitoxin are reached due to the proteolytic degradation of antitoxins by proteases.
51, 64, 
120
 Further proteolytic degradation leads to a higher toxin:antitoxin ratio, this reaches a 
critical point and further toxin modules bind to lower affinity sites on the antitoxin resulting 
in a higher order complex. In several systems the operator site cannot occupy two higher 
order complexes adjacent to each other, so these dissociate from DNA.
153, 155
 The result of 
operon de-repression is transcriptional reactivation of the operon, resulting in expression of 
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the antitoxin and restoration of toxin:antitoxin back to basal levels. These models have been 
established using a variety of structural and biophysical techniques including X-ray 
crystallography, cryo electron microscopy and NMR.  
Conditional cooperativity therefore represents a mode of bistable switching between two 
population states via transcriptional regulation and this mechanism has been proposed 
through mathematical modelling to result in bistability within bacteria to generate two 
populations of cells: normal growing antitbiotic susceptible and antibiotic tolerant persister 
cells.
200-202
 This mechanism would enable cells to switch into a persistent state as the 
intracellular concentration of toxin increases with respect to the antitoxin while also ensuring 
the process is reversible, allowing cells to switch back into a normal growth phase when the 
toxin reaches an excess. 
Conditionality and the mechanism of a bistable switch is not unique to TA systems and the 
mechanism of transcriptional regulation through protein-protein (toxin-antitoxin) interactions 
(Figure 1.6A) shares several characteristics to the bistable switches within the lactococcal 
phage TP901-1 (Figure 1.6B)
203, 204
 and the /anti-systems (Figure 1.6C).
205, 206
 /anti-
systems are are bicistronic, where the anti-factor is synthesized in excess of the factor 
and is proteolytically degraded within the cell.
199, 206-208
 Formation of a -anti-protein-
protein complex sterically prevents formation of an intact RNA polymerase holo-enzyme and 











1.  Introduction 1.6. Conditional Cooperativity 
 24 
 
Figure 1.6. Commonly viewed model of 
conditional cooperativity and other 
bistable switches that regulate 
transcription via protein-protein 
interactions. (A) Conditional 
cooperativity in Toxin-Antitixoin 
systems. 1:  When the ratio of toxin (red): 
antitoxin (blue) is low (antitoxin is in 
excess of the toxin), the operon is 
expressed as the antitoxin cannot achieve 
transcriptional repression. 2: Up to 
approximately equimolar concentrations 
of both toxin and antitoxin, formation of a 
TA complex results in tight binding to the 
promoter region and full repression of the 
operon. 3: At high toxin: antitoxin ratios, 
a result of the proteolytic degradation of 
antitoxins over time, a higher order 
protein complex is formed that is 
incapable of transcriptional 
autoregulation. (B) The TP901-1 phage 
system. Transcriptional regulation by Mor 
and CI proteins determines whether the 
temperate phage enters a lytic or 
lysogenic life-cycle. (1) The CI protein 
(blue) is capable of binding to 3 operator 
sequences upstream of the mor gene, 
termed the OL site, preventing expression 
of mor from the PL promoter. This ensures 
the phage enters the lysogenic cycle rather 
than the lytic cycle through the 
downstream actions of the CI protein.
203, 
204
 (2) Expression of both cI and mor 
genes enables the formation of a CI:Mor 
heterotetramer which is capable of 
binding the OM operator causing 
transcriptional repression of the cI gene 
by blocking the PR promoter. This enables the phage to enter the lytic cycle rather than the lysogenic cycle 
through the downstream actions of the Mor protein (red). (C) /anti- systems. These are similar to type 2 TA 
systems and are organised as bicistronic operators expressed from a single promoter. Each factor (red) is 
responsible for directly regulating a subset of genes by binding to the core subunits of RNA polymerase (grey) 
to initiate transcription. factors have been shown to regulate their own transcription via a positive feedback 
mechanism. The anti-factor (blue) specifically regulates its cognate factor by forming a tight protein-
protein complex, preventing the transcription of downstream genes via RNA polymerase. Like type 2 antitoxins, 
anti-factors are regulated by proteases in order to switch on the transcription of specific genes.
206, 209
 
While the precise nature of the DNA bound complex leading to conditional cooperativity 
often differs, the majority of TA systems adhere to this phenomenon. Exceptions include 
DinJ/YafQ and MqsRA (Table 1.2). Structural descriptions of co-repression and de-




 Structures have been 




 for full de-repressed states but these have not 
been experimentally validated. 
1.  Introduction 1.6. Conditional Cooperativity 
 25 
TA system Co-repression  
observation 






 N/A N/A N/A 
CcdAB EMSA 
212









 No N/A 
HicAB No 
214



















































 N/A EMSA 
223




 Assumed ParD2-ParE2 Yes 
224

























 N/A N/A N/A 


















Table 1.2. Overview of Conditional cooperativity in TA systems.  A list of TA systems where co-repression 
has been observed and the TA complex determined to be responsible for this. Where applicable the observation 
of de-repression and the higher order complex responsible is also noted. N/A: Not applicable  
The majority of type 2 systems studied (9/13) bind to palindromic sites (Table 1.3). In 
contrast DinJ, HicA3B3 and RelBE recognise imperfect repeat sequences while 
FitAB/VapBC in different bacterial species have been shown to recognise inverted 
sequences/imperfect palindromic sequences that overlap the -10 site. Several reports have 
detailed high resolution structures of TA complexes and TA components bound to DNA. 







 or a non-canonical motif (NCM).
160
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Operator sequence TA-DNA 
structure 
Reference 






















(FitA4FitB4)-DNA 218, 142 
























MazEF E. coli AbrB 5’-ATATA-3’ 
(4) 
MazE2-DNA 220 















E. coli phage 
P1 
























































































HTH N/A N/A 161 
Table 1.3. Summary of TA systems implicated in DNA binding and structures indicated where present. 
The host organism, DNA binding motif:  AbrB superfamily (AbrB), Helix-turn-helix (HTH), Ribbon-helix-helix 
(RHH), or a non-canonical motif (NCM) are highlighted for each TA family. The operator sequence that the 
antitoxin binds to and the specific oligomeric state of a toxin-antitoxin-DNA structure are presented. X refers to 
any nucleotide. (1): imperfect palindrome, (2): imperfect inverted repeat, (3): perfect inverted repeat, (4): perfect 
palindrome. 
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Six type 2 antitoxins (CcdB, DinJ, FitA, HicB3, ParD and RelB) contain a RHH domain with 
structural/functional data known for all except HicB3. Each RHH inserts into the major 
groove of DNA via a sheet and mediates protein-DNA interactions via polar/charged 
residues
124, 126, 150, 156, 224, 237
 (Figure 1.7). Mutation of these residues reduces DNA binding of 
each antitoxin and autoregulation to their specific operon.
83, 124, 218, 228
 
 
Figure 1.7. Antitoxins containing ribbon-helix-helix domains and their antitoxin-DNA structures. (A) 
Structure of CcdA-DNA (PDB: 2H3A), where amino acids interacting with DNA: T6, T8 and S25 are 
highlighted according to their specific subunit (red/blue). (B) Structure of DinJ-YafQ (PDB: 4Q2U), amino 
acids within DinJ implicated in DNA binding: R10 and R35 are highlighting according to their specific subunit 
(blue/green). (C) Structure of FitAB-DNA (PDB:2H10) where amino acids that contact DNA: R7, N8, S27, R33 
from each FitB subunit (green/yellow) are highlighted. (D) Model of ParD-DNA interaction (PDB: 2AN7) 
based on the homologous Arc-DNA structure (blue) from Bacillus subtilis (PDB:1PAR). Amino acids R3, T5, 
I27 and K28 from adjacent subunits of ParD (Blue/Red) are predicted to bind DNA due to their equivalent 
positions in Arc. (E) Model of RelB-DNA interaction (PDB: 4FXE) based on the homologous Arc-DNA 
structure (blue) from bacteriophage P22 (PDB: 1BDT) where R7, I8, K13 and S28 of RelB (green) project into 
the major groove. 
1.7.  Burkholderia pseudomallei 
One bacterium that is an excellent case study in relation to persistence mediated chronic 
infections is Burkholderia pseudomallei.
238, 239
 This motile Gram negative saprophyte
240
, 
exists in at least 3 sources (soil, water and zoonotic) and is the causative agent of 
melioidosis.
241-244
 Melioidosis exists in both acute and chronic forms and has been 
extensively reviewed.
239, 245, 246
 A recent worldwide analysis of melioidosis
247
 indicated that 
South Asia, in particular Northeast (NE) Thailand and Northern Australia were deemed to be 







, where both the temperature and soil have been predicted to be suitable for 
the long term survival the organism.
247
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It is estimated that worldwide there are approximately 165,000 reported cases of melioidosis 
a year with an estimated 89,000 resulting in death.
247
 Misdiagnosis is common as the initial 
symptoms (chronic pneumonia and skin lesions) are mimicked by tuberculosis.
252
 Both 
pneumonia and pulmonary melioidosis have been widely observed for both acute and chronic 
melioidosis
253
 with the development of systematic sepsis upon transition to chronic infection, 
often preceding death. Current specialised tests take more than seven days to confirm 
bacteraemic melioidosis and if the patient suffers from the chronic variant they often 
succumb to sepsis before confirmation. It is likely that the true numbers of cases/year are 
under-reported and the severity of melioidosis is higher than estimated. 
 
Figure 1.8. Endemic locations of melioidosis and suitable environments for establishment of B. 
pseudomallei. Geographical locations of melioidosis cases from 1910-2014 indicating a high prevalence in 
South Asia. Image directly taken from Figure 1 with the author’s permission.
 247
 The evidence consensus for 
countries is color coded: red indicates the presence of melioidosis with complete consensus descending to dark 
green representing the absence of melioidosis with complete consensus. 
Common routes of infection include the absorption of bacteria through skin abrasions and 
inhalation from contaminated sources.  High risk groups within South Asia include rice 
paddy farmers, the most common occupation in NE Thailand. These farmers repeatedly work 
in flooded fields with no protective footwear and commonly show signs of repeated foot 
trauma. One study reported that 85% of patients with melioidosis were rice paddy farmers.
254
  
Within endemic areas, antibodies against B. psuedomallei are widespread (60%) in children 
belonging to rice farming communities
255
, hinting that the bacteria has adapted to survive the 
immune response. B. psuedomallei is inherently resistant to antibiotics
256, 257
, and the current 
treatment for melioidosis is a course of ceftazidime/meropenem followed by trimethoprim-
sulfamethoxazole for several months.
258
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Numerous case studies on melioidosis have occurred and a selection of the larger studies are 
summarised in Table 1.4 that highlight mortality rates and risk factors.
259-264
 For each study 
sepsis shock was a good indicator of melioidosis and typically the cause of death. The 20 
year study in Darwin, Northern Australia is to date the most comprehensive melioidosis 
study. This first suggested that B. pseudomallei should be viewed as an opportunistic 
pathogen and identified many health risk factors associated with melioidosis including 
diabetes, hazardous alcohol use, chronic lung disease and chronic renal disease, with a 
resultant 15-20% mortality rate.
259
 Similar risk factors were seen in the other case studies 
with diabetes repeatedly highlighted as the highest risk factor. Rainfall was also correlated as 
an environmental risk factor for melioidosis
259-261, 264-266
 and patients with known risk factors 
were twice as likely to develop bacteraemic pneumonia in seasons with heavy rainfall (>125 




B. pseudomallei is therefore a potent pathogen that gives rise to a severe chronic infection 
(melioidosis). Experimental observations have recently reported its spread to the Caribbean, 
Central America and Mexico.
248
 It is clear that the global prevalence of melioidosis is under-
reported in several countries where B. pseudomallei is known to be endemic and further 
























No of cases 540 95 145 372 423 2,243 
       
Incidence 19.6 N/A 16.4 1.7 4.4 12.7 
Median age 
(year) 
49 50 50 55 45 49 
Male:Female 
ratio 
2.2:1 2:1 3:1 4.5:1 1.4:1 1.4:1 
       
Mortality rate 
(%)       
Overall 19 9.5 34 40 44 42.6 
Bacteremic 
cases (%) 






42 [65] N/A N/A N/A 
Sepsis 
[Deaths] (%) 
21 [50] 22 [40.9] 7.6 [42.9] 59.7 [55.4] N/A N/A 
       
Risk factors 
(%)       
Diabetes 
mellitus 
39 75.8 57 57 20 46 
Heavy 
Alcohol use 
39 13.6 N/A N/A 12.3 N/A 
Chronic lung 
disease 
26 9.5 2.8 3.8 5.9 N/A 
Chronic renal 
disease 
12 21 2.8 5.6 20.1 N/A 
Cases in the 
monsoon 
season 
81 71.6 49.6 N/A N/A N/A 
Table 1.4. Comparative epidemiology of melioidosis across 5 case studies. Risk factors are included where 
present (N/A) if not reported. 
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1.8.  HicAB 
The HicAB system was first identified in Haemophilus influenzae in 1998
268
 and in several 
bacteria and archaea in 2006.
269
 HicA was predicted to have a dsRNA binding fold, while 
HicB protein members contained a degraded nonactive RNase H fold, fused to a DNA 
binding domain (DBD). HicA was first characterised in E. coli
187
 where it was described as a 
toxin with the ability to cleave both mRNA and tm-RNA, reducing the rate of translation 
within cells. Transcription of HicB prevented RNA cleavage, providing evidence that HicB 
was an antitoxin. Like other type 2 TA systems, the hicAB locus is regulated by stress, 
upregulation of this operon was observed during amino acid starvation and from degradation 
of HicB by Lon protease.
187
 HicA from B. pseudomallei induced the formation of persister 
cells when overexpressed in E. coli and treated with ciprofloxacin and ceftazidime. 
Mutagenesis studies identified two key residues governing HicA toxicity: G22 and H24 that 
are located in the 1-2 loop and are highly conserved (97%) amongst 75 HicA homologues. 
A H24A mutant of HicA was non-toxic, did not induce persister formation and could be 
recombinantly expressed in high yield in E. coli (10 mg/L). The three-dimensional structure 
was characterised by NMR exhibiting a dsRNA binding domain-like fold (dsRBD) 
comprised of a triple stranded  sheet, two  helices and a net positive charge (Figure 
1.9).
131
 HicA-H24A was able to bind RNA but did not degrade it.  The structure of the 
homologue HicA3, HicB3 and a truncated HicA3B3-NT complex from Yersinia pestis has 
also been crystallised.
132
 HicA3 shared a conserved dsRNA binding domain (Figure 1.9A) 
and equivalent catalytic residues: G26 and H28, which were sequestered in a HicA3B3 
complex (Figure 1.9B). Mutation of this histidine in HicA3 negated toxicity and HicA3 was 
deemed to act as an mRNase in vitro.  
HicB3 was shown to autoregulate the hicA3B3 operon by binding to operator regions of DNA 
to prevent its transcription, similar to other type 2 systems.  HicB3 (Figure 1.9C) adopts a 
ring type tetramer with dimerization interfaces seen between adjacent subunits (blue, red, 
green, yellow) via their N-terminal and C-terminal domains. A crystal structure of a truncated 
complex: HicA3B3-NT indicated that HicA3 molecule bound the HicB3 N-terminal domain 
with a 1:1 stoichiometry (Figure 1.9D). The entire C-terminal domain was removed using 
subtilisin A prior to crystallisation. This complex is therefore incomplete with regards to the 
full length HicB and was not a sufficient model to explain complexation. The observed 
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Figure 1.9. Structures of the HicAB family. (A) Structure of HicA (PDB: 4C26-grey) superimposed onto 
HicA3 (PDB:4P78-red), RMSD: 2.20 Å. (B) Sequestration of G26 and H28 in HicA3HicB3-NT model. (C) The 
crystal structure of HicB3 (PDB:4P7D) with individual subunits highlighted in blue, pink, green and yellow.  
(D)  The HicA32HicB3-NT2 dimer reported HicB subunits are highlighted in blue and pink and HicA in red. 
 
The E. coli hicAB operon system was shown to be under the regulation of Sxy and cAMP 
receptor proteins.
270, 271
 Turnball and Gerdes
214
 provided an explaination of the regulation  of 
this operon via two distinct promoters. The first promoter (P1) is under the control of both 
Sxy and cAMP receptor proteins and is located within the 5’UTR resulting in the 
transcription of both HicA and HicB. The second promoter (P2) is located in the operator 
region and is under the control of HicB alone with HicA shown not to act as a co-repressor 
by EMSA or LacZ assays. HicB binding to P2 to prevented transcription of the hicAB operon 
whereas an excess of HicA destabilised the HicB-promoter complex, thereby re-activating 
hicAB transcription. 
Surprisingly, only HicB is transcribed from this promoter (P2), rather than both HicA and 
HicB. This dual promoter mechanism is an efficient strategy to ensure that levels of both 
HicA and HicB within the cell are controlled. An excess of HicA results in the upregulation 
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Figure 1.10. hicAB regulation within E. coli. HicB binds to the second promoter region (P2) to repress the 
hicAB operon. An excess of HicA destabilises this complex, causing transcription of HicB to restore the 
intracellular concentration of HicB to neutralise excess HicA. CRP, HicA, HicB, Ribosomes and Sxy are 
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1.9.  Aims 
TA systems have long been implicated in the formation of persister cells, despite this there is 
a lack of structural and functional information on the HicAB system encoded within in many 
bacteria and archaea. One HicAB system is found in B. pseudomallei with prior work 
confirming the formation of persisters induced by HicA and the first structure of HicA.
131
 
Information on B. pseudomallei HicB is unknown and yet to be investigated, including 
structure, toxin sequestration and DNA binding properties. In this work the aim was to 
characterise the HicAB system from B. pseudomallei. This was achieved by:  
- Characterising and solving the high-resolution structure of HicB using a variety of 
structural and biophysical techniques 
- Solving the first complete high-resolution structure of a HicAB complex and determining 
whether multiple complexes could be formed and how this is achieved. 
- Determining the factors governing DNA binding of HicB and HicAB and the 
identification of a possible target site for DNA binding in B. pseudomallei. 
- Proposing a model for the regulation of the HicAB TA system and determining the 
precise mode of conditional cooperativity. 
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2.   Structural studies of HicB 
 
HicB is an antitoxin that neutralises the activity of the toxin HicA and can prevent the 
formation of persister cells.
131
 Although structural studies of of HicAB TA systems have 
been reported, several of these have drawbacks. Deposited structures included the NMR 
structure of HicA from B. pseudomallei (PDB:4C26), a tetrameric crystal structure of the 
homologous antitoxin HicB3 from Y. pestis  (PDB:4P7D) and an incomplete structure of the 
associated complex with the toxin HicA (HicA3B3, PDB:4P78, 28% sequence identity).
132
 
During the writing of this work a HicAB complex (PDB: 5YRZ) from Streptococcus 
pneumoniae was also reported but lacks the uncomplexed HicB for comparison.
272
 There is 
no structural or functional data for B. pseudomallei HicB with respect to the mechanism of 
toxin sequestration and DNA recognition. More generally the molecular mechanism by 
which HicAB family members regulate their own operon is also unknown. Structural studies 
on B. pseudomallei HicB and extension to the complex of HicAB will shed light on the 
molecular mechanisms associated with this TA system that will be translatable to other 
members of the HicAB family encoded within major bacteria and archaeal clades.
187, 269
 The 
work presented in this chapter details the recombinant expression, purification, crystallisation 
and subsequent structural analysis of HicB. 
2.1.  Expression and purification of full length HicB 
 
A pET26b-HicB construct containing a N-terminal signal secretion sequence (PelB), His6-tag 
and enterokinase cleavage sequence upstream of the HicB gene was provided by Dr Aaron 
Butt (University of Exeter) (Appendix Table 3). HicB was expressed in E. coli T7 cells. 
During expression the PelB sequence exported HicB to the periplasm via the general 
secretory (Sec) pathway.
273
 During translocation, the PelB secretion sequence was cleaved by 
Signal Peptidase 1 at the AMA sequence.
274
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HicB was purified by immobilised metal affinity chromatography (IMAC) and size exclusion 
chromatography (SEC) before cleavage with enterokinase (Appendix Figure 1.A). Proteolytic 
cleavage of the N-terminal His6-tag was unsuccessful and a maximum of 50% conversion of 
His6-HicB to HicB was observed after systematic variation of reaction conditions (buffers, 
temperature, protein concentration and reaction time). It became clear that proteolytic 
cleavage of His6-HicB occurred at several sites and multiple products were observed via 
SDS-PAGE (Appendix Figure 1B). In light of this, the tagged variant (His6-HicB) was 
concentrated to 350 M (where the tetrameric concentration [HicBT] was 87.5 M) and 
screened for crystallisation conditions against 384 commercially available Molecular 
Dimension Screens (Morpheus, Proplex, JCSG+ and Structure Screen I+II) using the sitting 
drop vapour diffusion technique. No positive hits were observed. 
As N-terminal His6-tags and their associated cleavage sites are predicted to be disordered in 
solution, their presence might be sub-optimal for crystallisation of the protein. To remedy this 
full length hicB was amplified from B. pseudomallei   K96243 genomic DNA (HicB_FL 
Primer 1 and 2, Appendix Table 4) and subcloned into the pOPINE vector (pOPINE-
HicB_FL).
275
 The pOPINE vector encodes a C-terminal His6-tag, but with no cleavage 
sequence present (Appendix Table 3). Although the tag is still likely to be disordered, the 
overall appended sequence was shorter which might have less impact on crystallisation but 
facilitate protein purification. 
HicB_FL was expressed using E. coli T7 express cells (NEB) and purified by IMAC and 
SEC in a final yield of 7.5 mg/L (Figure 2.1A, B). SDS-PAGE showed the presence of 
monomeric HicB_FL (expected mass: 16,202 Da) Analytical SEC suggested that isolated 
HicB_FL existed as a single folded tetrameric species in solution (Figure 2.1C). This was 
further supported by native mass spectrometry which showed the presence of dimeric (blue) 
and tetrameric (red) charge states (Figure 2.1D). Deconvolution yielded a signal 
corresponding to the tetramer (Appendix Figure 2) with good mass agreement (observed: 
64,800 Da, expected: 64,808 Da) given the rather poor signal to noise ratio.  
Purified HicB_FL (500 µM, HicBT =125 M) was screened against 384 commercially 
available Molecular Dimension screens (Morpheus, Proplex, JCSG+ and Structure Screen 
I+II) using the sitting drop vapour diffusion technique. Crystals were observed in 0.1M 
NaOAc pH 4.6, 2 M HCOONa after six days and no further hits were observed in any of the 
other assayed conditions. Crystals were subsequently optimised via hanging drop vapour 
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diffusion to yield diffraction quality crystals that could be individually looped, before 
cryoprotection in 20% (v/v) glycerol and data collection at the Diamond Light Source 
synchrotron. It was noted that the crystals were delicate and most cracked during looping or 
freezing. The best crystals of HicB_FL only diffracted to 7 Å and could not be used for 
structural determination. Further optimisation of crystallisation and cryoprotectant conditions 
(MPD, PEG 200, 400 etc) only improved the diffraction limit to 5 Å. 
 
Figure 2.1. Initial characterisation of HicB_FL. (A) SDS-PAGE following the expression and purification of 
HicB_FL from post induction to isolation via IMAC and SEC. HicB_FLM refers to the monomeric state of 
HicB_FL.  (B) IMAC of HicB_FL eluting as a single peak. (C) SEC of HicB_FL eluting as a single oligomeric 
species on an analytical 10/300 GL Superdex 75 column. (inset) calibration curve using known standards: 
aprotinin (AP, 6.5 kDa), ribonuclease A (RA, 13.7 kDa), carbonic anhydrase (CA, 29 kDa), ovalbumin (OV, 
42.7 kDa) and conalbumin (CO, 76 kDa).  (D) Native mass spectrometry of HicB_FL. Peaks spanning 750 to 
3400 m/z were assigned based on their charge state: monomeric (black), dimeric (blue) or tetrameric (red). 
Inset: De-convoluted spectrum of the monomeric charge states within the m/z envelope shown to determine the 
monomeric mass of HicB_FL, observed: 16,201 Da, expected: 16,202 Da. 
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2.2.  Expression and purification of HicB 
Attempts to isolate and purify untagged HicB_FL from a variety of vectors (pET151, 
pOPINE and pOPINF) were unsuccessful: HicB bearing an N-terminal His6-tag (encoded 
within pET151 and pOPINF vectors) was isolated by IMAC and SEC as previously described 
however, His6-HicB and untagged-HicB could not be separated via IMAC following cleavage 
of the His6-tag despite the use of different enzymatic cleavage sites within pOPINF and 
pET151 vectors (thrombin and TEV protease respectively). Untagged HicB (encoded in a 
pOPINE vector) could not be expressed to a high yield (1 mg/5 L) despite optimation of the 
expression protocol and this construct was deemed to be impractical for crystallisation 





) remained the most promising candidate for crystallisation optimisation. 
Bioinformatic analysis via I-Tasser 
276
 and Xtal Pred 
277





 at the C-terminal of HicB_FL immediately preceeding the His6-tag. 
Therefore a construct lacking this stretch of amino acids was amplified from genomic DNA 
(Appendix Table 4, HicB Primer 1 and 2) and subsequently subcloned into pOPINE 
(pOPINE-HicB), to minimise flexibility at the C-terminus and improve crystal formation. 
This truncated construct herein termed HicB was expressed as a soluble protein using T7 
Express cells (NEB) (Figure 2.2) and this was purified by IMAC and SEC. SDS-PAGE 
revealed a single band corresponding to monomeric HicB and the mass confirmed by 
denatured electrospray mass spectrometry (ESMS) (observed, 15,738 Da: expected mass, 




, residues located at the C-terminus 
of HicB_FL, did not impact the formation of tetrameric HicB as judged by both SEC and 
native mass spectrometry; the latter displayed an equivalent profile of dimeric and tetrameric 
charge states observed for HicB_FL. Deconvolution of the tetrameric charge states yielded a 
single species (observed: 62,924 Da, expected: 62,952 Da). The final yield was 25 mg/ L, a 
significant improvement over HicB_FL. 
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Figure 2.2. Purification and initial characterisation of HicB. (A) SDS-PAGE following the expression and 
purification of HicB from post induction to isolation via IMAC and SEC. HicBM refers to monomeric HicB. (B) 
SEC of HicB_FL eluting as a single oligomeric species on an analytical 10/300 GL Superdex 75 column. (inset) 
Calibration curve using known standards: aprotinin (AP), ribonuclease A (RA), carbonic anhydrase (CA), 
ovalbumin (OV) and conalbumin (CO).  (C) Native mass spectrometry of HicB. Peaks were assigned based on 
their charge state: monomeric (black), dimeric (blue) or tetrameric (red). (D) De-convoluted spectrum of the 
tetrameric charge states shown in (C), yielding tetrameric HicB, observed: 62,924 Da, expected: 62,952 Da. 
2.3.  Crystallisation of HicB 
HicB (600 M, HicBT = 150 M) crystallised in identical conditions to HicB_FL (0.1 M 
NaOAc, pH 4.6, 2 M HCOONa). Crystals were looped and cryoprotected in 40% glycerol 
(v/v) before flash freezing. Analysis of the diffraction quality of crystals at Diamond Light 
Source was hindered as a full 360 ° dataset could not be obtained before the crystal shattered 
which was attributed to poor cryoprotection and cracking during freezing.  To reduce the 
damage caused during flash freezing, crystals were grown in a gradient of glycerol (0-6%) to 
minimise handling and exposure time during looping and freezing. Only crystals grown in the 
original crystallisation condition supplemented with 4% (v/v) glycerol were free of visible 
structural deformations and these were directly frozen for diffraction analysis.  
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A dataset of 2,000 images was collected at a wavelength of 0.9763 Å, exposure time: 0.02 s, 
oscillation: 0.15 ° and beam flux: 100% with cryogenic temperatures maintained through data 
acquisition (Table 2.1). Autoprocessing by the Diamond Pipeline (Fast DP) suggested a 
resolution limit of 2.4 Å, a substantial improvement compared to the HicB_FL crystals (best 
5 Å). HicB (1,500 M, HicBT = 375 M) also formed crystals in a second set of conditions 
via hanging drop vapour diffusion: 0.1 M NaOAc, pH 4.6, 8% (w/v) PEG 4000, 10% (v/v) 
glycerol. It was not determined if HicB_FL crystallised in this condition. Crystals were 
cryoprotected in 40% glycerol (v/v) before being flash frozen and data collection occurred at 
Diamond Light Source synchrotron (Table 2.1). Autoprocessing (Fast DP) suggested a 
resolution of 1.95 Å, an improvement over the previously collected dataset. Both datasets 
were processed as described in the Materials and Methods.
278, 279
 Numerous attempts to solve 
the phase problem and therefore the structure via molecular replacement (MR) in Phenix
280, 
281
  using ab initio models
276
 and the homologue HicB3 (PDB:4P7D) to calculate initial 
phases and then refine the solution were unsuccessful for both datasets of HicB, despite the 
high resolution of the data. At this time the HicB3 structure was the only homologous crystal 
structure of HicB available (28% sequence identity) and it was not possible to determine if a 
single subunit of HicB retained the fold observed within HicB3. In order to solve the 
structure of HicB, a combination of selenomethionine (SeMet) labelling and truncation of 
HicB to an N-terminal domain (only residues 1-85) were employed in parallel to solve the 
phase problem and obtain suitable search models for molecular replacement.  
 0.1M NAOAc, pH 4.6, 2 M HCOONa, 
4% glycerol 
0.1 M NAOAc, pH 4.6 8% (w/v) PEG 
4000, 10% (v/v) glycerol 
Cryoprotectant N/A 40% (v/v) glycerol 
Number of images 2,000 828 
Wavelength (Å) 0.9763 0.9763 
Exposure time (s) 0.02 0.057 
Oscillation (°) 0.15 0.15 




Table 2.1. Table of parameters associated with data collection at Diamond Light Source for crystals of 
HicB obtained in different crystallisation conditions. 
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2.4.  Selenomethionine labelling of HicB 
Solving crystal structures by multiple isomorphic replacement (MIR) has been widely 
documented.
282-285
 Incorporation of heavy atoms and more recently selenium via 
selenomethionine (SeMet) substitution into protein structures are both approaches undertaken 
to solve the phase problem of novel protein datasets when MR fails. For selenomethione 
substitution the general consensus is that the target protein should contain one methionine per 
fifty amino acid residues in order to maximise the success of solving the phase problem via 
this method.
286
 As the native HicB sequence only contains one methionine residue located at 
the N-terminus, and an additional methionine residue incorporated by subcloning into the 
pOPINE vector (Position 0), additional methionine residues had to be introduced. To this end 
bioinformatics searches were undertaken to identify suitable candidate positions to mutate to 
a methionine residue. Previous work by McLachlan
287
 had shown that either leucine or 
isoleucine were the most favourable amino acids to conservatively mutate to methionine 
whilst maintaining the native state of the protein.
288-290
 To identify suitable mutation sites the 
sequence of HicB was aligned to Y. pestis HicB3 and ten homologous sequences from 
different organisms that contained >70% sequence identity to HicB (identified by Clustal 
Omega)
291
 (Figure 2.3). 
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Figure 2.3. HicB (B. pseudomallei) aligned to HicB homologues from several species with a sequence 
identity >70%. Species aligned were: Burkholderia cepacia (88%), Paraburkholderia terrae (87%), 
Paraburkolderia kururiensis (86%), Burkholderia anthina (83%), Paraburkholderia oxyphila (82%), 
Paraburkholderia sacchari (82%), Pandoraea aspista (75%), Paraburkholderia bannensis (74%), 
Paraburkholderia grimmiae (74%) and Ralstonia solancearum (71%). The methionine residue incorporated by 
the pOPINE vector and the C-terminal His6-tag were not included in the bioinformatics search. The figure was 
made using Espirit after alignments with Clustal Omega.
291, 292
 Potential mutation sights to engineer in a 
methionine residue (Position 7, 43, 51, 64, 85 and 99) are highlighted in red. 
Five initial amino acid residues (V7, I43, I51, V64, L85 and I99, red boxes in Figure 2.3) 
were determined to be potential candidates for mutation as these positions showed variation 
in the hydrophobic side-chains and therefore a conservative mutation might be tolerated. As 
two amino acids were required between residues 50 and 138, positions I51 and I99 were 
selected. Both of these residues were present as methionines in HicB3 (PDB: 4P7D) and were 
known to pack inside the hydrophobic core of the structure and therefore might be tolerated 
in HicB. Importantly they were also judged not to be involved in dimerization or HicA 
binding.  
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Three mutants: I51M, I99M and an I51M/I99M double mutant (pOPINE_DM) were 
constructed by whole plasmid PCR mutagenesis using mutagenic primers (Materials and 
Methods, Appendix Table 4). Both I51M and I99M mutants were individually expressed in 
an identical manner to HicB. Each mutant remained soluble and retained a tetrameric 
organisation (Figure 2.4). Denatured ESMS confirmed the mutation of isoleucine to 
methionine (+18 Da) within individual subunits of each mutant, when compared to HicB 
(Figure 2.4). Native mass spectrometry reaffirmed the incorporation of four additional 
methionine residues within the tetramer (Appendix Figure 4).  
 
Figure 2.4. Purification of methionine mutants I51M and I99M via SEC and ESMS. (A) The I51M SEC 
profile eluted as a single species similar to the wild type. Denatured ESMS showed a similar distribution of m/z 
charge states to the wild type, with deconvolution (inset) resulting in a single species (observed mass: 15,757 
Da, expected: 15,757 Da). (B) The I99M SEC profile eluted as a single species.  Denatured ESMS showed a 
similar distribution of m/z charge states to the wild type, with deconvolution (inset) resulting in a single species 
(observed mass: 15,756 Da, expected: 15,757 Da). The expected mass for HicB is 15,738 Da. For both SEC 
traces, the inset contains the calibration curve using known standards: aprotinin (AP), ribonuclease A (RA), 
carbonic Anhydrase (CA), ovalbumin (OV) and conalbumin (CO). 
The double mutant containing I51M/I99M (HicB_DM) was expressed in T7 Express cells, as 
a soluble protein with a final yield of 20 mg/L (Figure 2.5). Denatured ESMS confirmed the 
presence of a single species and the mutation of both isoleucine residues to methionine 
(Figure 2.5C, D, observed: 15,776 Da, expected: 15,774 Da). Furthermore native mass 
spectrometry showed a tetramer with a mass increase of + 147 Da (expected + 144 Da 
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increase), corresponding to the introduction of eight methionine residues when compared to 
the wild type (Appendix Figure 5) and confirmed that the mutations did not disrupt tetramer 
formation. This construct was therefore judged to be suitable for SeMet labelling. 
 
 Figure 2.5. Initial characterisation of HicB_DM. (A) SDS-PAGE following the expression and purification 
of HicB_DM from post induction to isolation via IMAC and SEC. HicB_DMM refers to the monomeric state of 
HicB_DM. (B) SEC of HicB_DM eluting as a single oligomeric species, similar to the wild type protein, (inset) 
calibration curve using known standards: aprotinin (AP), ribonuclease A (RA), carbonic Anhydrase (CA), 
ovalbumin (OV) and conalbumin (CO). (C) Denatured mass/charge spectrum of HicB_DM. Peaks were 
assigned based on the monomeric charge state (black). (D) De-convolution of the m/z envelope, yielding 
monomeric HicB_DM (observed mass: 15,776 Da, expected mass: 15,774 Da). The expected mass for HicB is 
15,738 Da. 
pOPINE_DM was expressed in B834 (DE3) cells (NEB) and grown in the presence of SeMet 
(Materials and Methods) before purification.
293, 294
 2 mM TCEP was added to buffers 
throughout purification to prevent oxidation of the selenium atom.
295
 Oxidation has been 
linked to radiation damage of the selenomethionine side chains during data collection that 
may hinder the phasing power and subsequent structural determination. Addition of selenium 
did not severely affect the expression or purification of HicB_DM, which was isolated with 
>90% purity with a final yield of 12 mg/L as judged via SDS-PAGE and SEC (Figure 2.6). 
SEC confirmed the purified protein formed a tetramer in solution. 
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Denatured ESMS confirmed the successful labelling of methionine residues with SeMet 
(Figure 2.6). Deconvolution of the resultant m/z profile of labelled HicB_DM resulted in an 
observed monomeric mass of 15,961 Da (Expected mass: 15,961.6 Da), an increase of 187 
Da when compared to the expected monomeric mass of the double mutant: 15,774 Da. 
Incorporation of four SeMet atoms would result in an expected molecular weight increase of 
+ 187.6 Da, indicating 100% successful incorporation SeMet at each methionine residue 
within one subunit at positions 0, 1, 51 and 99. Analytical SEC further confirmed that both 
HicB_DM and the SeMet labelled variant retained the same elution profile compared to the 






Figure 2.6: Initial characterisation of SeMet labelled HicB_DM. (A) SDS-PAGE following the expression 
and purification of SeMet labelled HicB_DM from post induction to isolation via IMAC and SEC. HicB_DMM 
refers to the monomeric state of HicB_DM. (B) SEC of SeMet labelled HicB_DM eluting as a single oligomeric 
species. inset  calibration curve using known standards: Aprotinin (AP), Ribonuclease A (RA), Carbonic 
Anhydrase (CA), Ovalbumin (OV) and Conalbumin (CO). (C) Denatured ESMS of SeMet labelled HicB_DM. 
Peaks were assigned based on monomeric charge state (black). (D) De-convoluted spectrum of the envelope 
shown in (C), yielding monomeric HicB_DM labelled with SeMet. (observed mass: 15,961 Da, expected mass: 
15,961.6 Da) 
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2.4.1.  Crystallisation of SeMet HicB_DM and diffraction analysis 
Crystals of SeMet labelled HicB (600 µM, HicBT = 150 M) formed in 0.1 M NaOAc, pH 
4.6, 2 M HCOONa, 11% (v/v) glycerol and were flash frozen and analysed at Diamond Light 
Source. To determine the appropriate wavelength for a single wavelength anomalous 
dispersion (SAD) experiment, fluorescence scans centred at the selenium K-edge were 
undertaken to determine the anomalous scattering factor components f’ and f’’. Results of 
this are summarised in Figure 2.7. A dataset of 1,800 images was subsequently collected at a 
wavelength corresponding to the fluorescence peak (0.9790 Å), exposure time: 0.1 s, 
oscillation: 0.2 °, beam flux: 100% with cryogenic temperatures maintained during 
acquisition. Auto-processing by Fast DP suggested the resolution of the dataset was ≈ 3 Å. 
 
 Energy (eV) f’(e) f’’(e) 
Peak 12,658 6.76 -7.13 
Inflection 12,655 4.14 -10.86 
Figure 2.7. Fluorescence scan of HicB_DM-SeMet crystals. The point of inflection and absorbance are shown 
by the black line. X-axis: X-ray energy (eV), Y-axis: Anomalous scattering factors.  Fluorescence scan 
parameters (The anomalous scattering signal of the crystal: f’ and f’’) are presented. 
Structural determination was carried out with assistance from Dr Chris Williams (University 
of Bristol) using the Crank2
296
  pipeline in the CCP4 jsCoFE interface.
297
 Briefly, after 
collection, data were processed into P212121
278, 279
 before input into the Crank2 pipeline. 
Here, a freeR set was generated (SF Tools) and the Se structure factor |FA| was estimated 
using SHELXC.
298












  Autobuild runs (Buccaneer)
302
 yielded a partial monomeric model 
which refined
301
  to a R/Rfree value of 0.327/0.390 (Table 2.2). Manual rebuilding and 
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refinement in Phenix and Coot
303
 was unable, however, to reduce the R/Rfree value, or build in 
multiple subunits of HicB within the asymmetric unit (ASU). 
2.5.  The truncated N-terminal domain construct of HicB 
Investigation of the structural arrangement of the homologue HicB3 (PDB:4P7D) revealed 
two domains (Figure 2.8A). The N-terminal domain adopts a 1231234 fold 
(residues 1-90) that is connected to a RHH motif (residues 93-134) via a disordered hinge 
region. Previous attempts to crystallise the Y. pestis  HicA3B3 complex were only successful 
after the addition of the protease subtilisin A immediately prior to crystallisation, resulting in 
a partial complex consisting of the N-terminal of HicB3 complexed to HicA3 (HicA32-
HicB3-NT2) (PDB:4P78).
132
 Proteolytic cleavage occurred within the hinge region resulting 
in the loss of the C-terminal domain. Crystallisation of this resulting partial complex 
demonstrated however that the N-terminal domain of HicB3 formed a discrete, folded unit 
amenable to crystallisation.  
The secondary structure of HicB was predicted by PSIPRED
304
 to be composed of an N-
terminal domain (residues 1-85) and a C-terminal domain (residues 94-134) that displays a 
RHH motif linked via a long loop (residues 86-93) (Figure 2.8B). These secondary structure 
elements mirrored those observed in Y. pestis HicB3 () and by 
inference would be likely to have a similar N-terminal domain, which was amenable to 
crystallisation.  
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Figure 2.8. Domain identification of HicB. (A) Structural investigation of a HicB3 subunit indicating a 
compact N-terminal domain and a C-terminal domain bearing a RHH motif. (B) PSIPRED result for HicB. 
Results indicate that the C-terminal domain covers residues E93-E132, with a disordered loop region separating 
the N-terminal and C-terminal domain (L85-P92). Based on this result, HicB was truncated back to L85 to 
remove both the C-terminal domain and the loop region to isolate the ordered N-terminal domain of HicB. X 
refers to the location of the His6-tag. 
An N-terminal construct consisting of HicB residues 1-85 was cloned from B. pseudomallei   
K96243 genomic DNA (HicB-NT Primer 1 and 2, Appendix table 4) and sub-cloned into the 
pOPINE vector (pOPINE-HicB-NT). HicB-NT was expressed in T7 Express cells and 
purified as per HicB in a final yield of 15 mg/L (Figure 2.9A). Initial purification via IMAC 
(Figure 2.9A), yielded a major band by SDS-PAGE at ~10 kDa, corresponding to monomeric 
HicB-NT (calculated mass 10,133 Da) but this co-purified with several higher molecular 
mass impurities. HicB-NT was further purified via SEC, where it eluted as a dimeric species. 
Denatured ESMS gave an observed mass of 10,133 Da (Appendix figure 7) and native mass 
spectrometry yielded charge states originating from a mixture of monomeric and dimeric 
species (Figure 2.9C). Deconvolution of these m/z envelopes yielded an observed dimeric 
mass of 20,261 Da (expected mass: 20,266 Da). 
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Figure 2.9. Initial characterisation of HicB-NT (A) SDS-PAGE following the expression and purification of 
HicB-NT from post induction to isolation via IMAC and SEC. HicB-NTM refers to the mononomeric state of 
HicB-NT. (B) SEC of HicB-NT eluting as a single oligomeric species on a Superdex 75 10/300 GL column 
(inset) The calibration curve using known standards: aprotinin (AP, 6.5 kDa), ribonuclease A (RA, 13.7 kDa), 
carbonic anhydrase (CA, 29 kDa), ovalbumin (OV, 42.7 kDa) and conalbumin (CO, 76 kDa). (C) Native mass 
spectrometry of HicB-NT. Peaks were assigned based on monomeric charge state (black) or dimeric (blue). (D) 
De-convoluted spectrum of the envelope shown in (C), yielding dimeric HicB-NT  (observed mass: 20,261 Da, 





2.5.1.  Crystallisation of HicB-NT 
Purified HicB-NT (1,000 µM, where the concentration of dimer in solution [HicB-NTD] was 
500 M) was screened through a total of 384 conditions (Morpheus, JSCG +, Structure 
Screen I and II and PACT Premier) as previously described. Successful initial crystallisation 
hits were observed in 0.1 M NaOAc, pH 4.6, 8% (w/v) PEG 4000 using hanging drop vapour 
diffusion supplemented with 10% (w/v) glycerol as a cryoprotectant. Crystals were 
subsequently flash frozen and data collected at the Diamond Light Source synchrotron. A 
dataset of 1,800 images were collected at a wavelength of 0.9795 Å, exposure: 0.1 s, 
oscillation: 0.2 °, beam flux: 100% with cryogenic temperatures maintained during 
acquisition. Autoprocessing pipelines at Diamond Light Source indicated that the crystals 
diffracted to 1.56 Å.  
Structure determination was performed with assistance from Dr Chris Williams (University 
of Bristol) (an iterative process). The diffraction data were processed into P212121
278, 279
, 
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before MR was undertaken using a partial monomeric search model from the 
selenomethionine dataset (Figure 2.10) as a search model within Phaser-MR (Phenix)
280, 281
 
and the Autobuild pipeline.
305
 Iterative rounds of model refinement
306
 and manual model 
building were carried out using Phenix and Coot
303
 to build 4 monomers within the ASU. The 
final structure was validated with MolProbity
307
 and the PDB_REDO
308
 web server. Statistics 
are given in Table 2.2 (Located at the end of this chapter).  
 
Figure 2.10. Structural determination of HicB-NT. The partial model derived from a SeMet labelled HicB 
dataset was used as a MR model to determine the 4 monomers of HicB-NT within the ASU (black box) labelled 
red, green, blue and yellow. Neither of these formed the expected dimeric organisation; however dimers were 
formed across the ASU interface for each monomer, resulting in the formation of a further four dimer interfaces 
(expanded black box). For clarity only 3 dimer interfaces within the adjacent ASU are shown here with one 
highlighted in blue (adjacent monomer) and the others grey (adjacent ASU). (Bottom) One dimer of HicB-NT 
with a similar interface to HicB3-NT is highlighted in blue and red. Secondary structure elements are 
highlighted and X refers to the location of the His6-tag. 
The apparent ASU containing four molecules of HicB-NT, was determined to be an artefact 
of crystallisation by PISA
309
 (Appendix Table 5). Investigation of the neighbouring ASU 
within the crystal revealed the formation of dimeric interfaces across the ASU (Highlighted 
in blue for subunit 1 and grey for other monomers) - resulting in the formation of four dimers 
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(Figure 2.10). PISA analysis suggested these latter dimeric interactions had a higher stability 
in solution than the four molecule ASU assembly observed (Gdiss: 1.5 v -7.6 kcal/mol) 
(Appendix Table 6).HicB-NT forms a dimer in solution with each monomer adopting an 
antiparallel 1231234 fold, where the central helix 1 (I32-L53) lies within a cleft 
formed by the 123 strands within a single subunit (Figure 2.11A). The β4 strand (V77-
S82) and the 2 helix (V64-L67) of an individual HicB-NT subunit contact an adjacent 
subunit forming the dimerization interface (Figure 2.11B). This interface consists of a 
network of hydrophobic interactions (Figure 2.11C) including those at the N-terminus of the 
1 helix (I32, I36), the 2 helix (V64) and the 4 strand (V77-L80). This hydrophobic patch 
is supplemented by hydrogen bonds (E2-D33, I32-E65, V64-E33 and E65-D63) and one 
electrostatic interaction (E2-K37) burying a total of 1, 300 Å
2
 surface area (from a total of 10, 
500 Å
2 
over the complete dimer).
309, 310
 Convincing electron density could not be observed 
for the vector encoded C-terminal His6-tag and loop 1 in any of the four subunits and these 
were not built into the model. 
 
Figure 2.11. Hydrophobic dimerization site of the N-terminal domains of HicB. (A) The 1 helix lies within 
a cleft formed by the 1sheet within a single subunit (blue). (B) Orientation of the dimerization interface 
between adjacent HicB-NT subunits (red and blue) where the 4 strand is the central element. (C) Full overview 
of the hydrophobic dimerization interface with residues labelled for subunit 1 (black) and 2 (red). 
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2.5.1.1.  Structural comparison with the N-terminal domain of HicB3 
Comparison of HicB-NT and Yersinia HicB3-NT (PDB: 4P78) (Figure 2.12) reveal the 
structural similarities between the two proteins (RMSD: 2.02 Å) despite their low sequence 
homology (28%). Both proteins possess an identical fold (1231234), with only 
subtle differences. In particular the 2 and 3 of HicB3-NT is almost a continuous alpha 
helical element with three residues separating the two secondary structure elements. In 
contrast within HicB-NT there are five residues that separate the 2 and 3 helix. There is 
gross conservation of the hydrophobic dimerization domain with secondary structure 
elements conserved, although the specific hydrophobes vary, burying 1, 900 Å
2
 of the total 
surface area (11, 300 Å
2
) within HicB3-NT.  
 
Figure 2.12. Superimposition of the N-terminal domain of HicB3 (grey, PDB: 4P78) onto HicB_NT (blue) 
for a single subunit. (A) Cartoon representation of the subunit organisation of a HicB subunit (blue).(B) 
Cartoon representation of the subunit organisation of a HicB3 subunit (grey). (C) Ribbon superimposition of 
HicB and HicB3 (RMSD: 2.02 Å). 
2.6.  Structural determination of HicB 
With the high resolution HicB-NT data, the previously collected HicB dataset was solved at a 
resolution of 1.85 Å (Table 2.2). After processing the collected diffraction images into the 
P41 space group
278, 279
, the ASU was determined to contain four HicB subunits by the 
Matthews coefficient. The dimeric HicB-NT model was used as a search model for MR in 
Phenix
280, 281
 to identify dimers of the N-terminal domain. Subsequent iterative rounds of 
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 built the disordered hinge region 
(S85-E93) and the following C-terminal domain (R94-K132) for one subunit into the electron 
density. A single subunit of HicB (Subunit 1, Figure 2.13) was then used as a search model to 
place all four subunits of HicB within the ASU. Manual rebuilding into electron density and 
subsequent and refinement built the N-terminal and C-terminal interfaces between adjacent 
subunits resulting in the formation of a ring type tetramer, the biological unit of HicB.  The 
final structure at 1.85 Å was validated with MolProbity
307
 and the PDB_REDO web server.
308
 
This structure is subsequently referred to as crystal form A. The tetrameric model of HicB 
was then used as a search model for MR on the 2.4 Å dataset and this structure of HicB is 
referred to as crystal form B. Interestingly placement of the C-terminal domains differed in 
this dataset and the correct placement was achieved by successive rounds of manual building 
and refinement. The autobuild pipeline in Phenix
305
 could not be used as it incorrectly placed 
the C-terminal α5 and α6 helices into the electron density, so a ring type tetramer was not 
formed. Statistics for both datasets are presented in Table 2.2. 
 
Figure 2.13. Structural determination of the two crystal forms of HicB. The dimeric HicB-NT structure was 
used as a MR search model to determine the complete subunit of HicB within the ASU of the 1.85 Å dataset. 
One HicB subunit was then used as a MR search model to determine the four subunit tetramer within the ASU 
(Crystal form A). The tetrameric crystal form A of HicB was used as a MR search model to determine the 
tetrameric structure of HicB at 2.4 Å, under different crystallisation conditions (referred to as crystal form B). A 
2 fold symmetry is observed within each tetramer as subunits 1 (blue) and 4 (yellow) are equivalent as are 
subunits 2 (pink) and 3 (green). 
2.  Structural studies of HicB  2.6. Structural determination of HicB 
 54 
Within both crystal forms, HicB existed as a ring-type tetramer, with 2 fold symmetry 
resembling a dimer of dimers (Figure 2.14A). Each subunit is comprised of an N-terminal 
domain (M1-L85), a linker region (S86-E93) and a C-terminal domain (R94-K132) (Figure 
2.14B). The N-terminal domain retains the 1231234 fold seen in the HicB-NT 
structure and the N-terminal dimerization interface observed between adjacent subunits of 
HicB-NT is conserved within HicB (Figure 2.14B). The C-terminal domain contains a RHH 
motif (556) that forms a strand-swapped dimer formed between adjacent partner C-
terminal domains (Figure 2.14C). Dimerization interfaces at the N/C terminal domain of each 
subunit stabilises the topology of the ring-type tetramer. PISA analysis suggested that the 
observed tetrameric assembly of HicB within crystal form A was stable in solution based on 
the positive value of Standard Free Energy of dissociation into nearest stable assemblies 
(G_diss: 12.4 kcal/mole) (Appendix Table 7).
309
 The ring type tetramer interface was 
suggested to be unique among HicB family members, with only minor similarity to a putative 
Lactobacillus plantarum RNA binding protein (PDB: 3KWR) which resembled the HicB-NT 
structure (Appendix Table 8). DALI also calculated structural similarity with other HicB 
family members, but not non-HicB type 2 antitoxins (Appendix Table 9).
311
 Instead HicB 
resembled several RNA binding proteins and endoribonuclease/helicases, consistent with the 
observation that HicB family members contain a inactive RNase H fold and a DNA binding 
domain.
269
  Furthermore, DALI calculated that the C-terminal domain was highly similar to 
RHH domain containing proteins: Arc (PDB: 1BAZ)
312
, CopG (PDB: 2CPG)
313
, DinJ (PDB: 
4Q2U)
83
, MazF-4 (PDB: 5XE3)
314
, ORF Omega (PDB: 2BNZ)
315





 and VapB26 (PDB: 5X3T)
317
 (Appendix Table 10).  
For the tetrameric conformation of HicB within crystal form A, compelling electron density 
was not observed for the vector-encoded His6-tag of each subunit and these were omitted 
from the final model. All loops and the 2-3 helix were solvent exposed within the ASU, 
exhibiting no packing interactions with adjacent subunits.  
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Figure 2.14. Crystal form A of HicB (1.85 Å dataset). (A) The tetrameric structure of HicB coloured by 
subunit, the dimerization interfaces are formed by both the N-terminal and C-terminal domains across adjacent 
subunits. (B) Single subunit of HicB with secondary structure elements labelled.  (C) Non-symmetrical dimer 
interfaces between subunits 1 and 2 compared to subunits 1 and 3.  
 
The hydrophobic N-terminal dimerization interface between adjacent subunits is equivalent 
to the interface observed between adjacent HicB-NT subunits and is not affected by the 
presence of the C-domain. The C-terminal dimerization interface between adjacent C-
terminal domains is comprised of a hydrophobic network, supplemented by hydrogen bonds 
and tethering electrostatic interactions. Hydrophobic residues within the 5 strand (I95, V97, 
I99), 5 helix (F102, V103, L104, I107, Y110), and the 6 helix (F121, A122, A123, L127) 
form a network with corresponding C-terminal domain residues on an adjacent subunit- 
resulting in a hydrophobic patch (Figure 2.15A). R94 and N96 form side chain-side chain 
hydrogen bonds across adjacent 5 strands (Figure 2.15B), while electrostatic interactions 
between E93-R101 and E93-H105 tether the hinge region of one subunit to the 5 helix of an 
adjacent subunit (Figure 2.15C). Together these bury a total of 3, 200 Å
2
 surface area (from a 
total of 9, 100 Å
2 
over the complete dimer).
309, 310
  
2.  Structural studies of HicB  2.6. Structural determination of HicB 
 56 
 
Figure 2.15. Interactions at the C-terminal dimerization interface. (A) Surface depiction of the hydrophobic 
network at the C-terminal domain. Hydrophobes within each individual subunit (I95, V97, I99, P100, F102, 
V103, L104, I107, Y110, F121, L122, A123, A125, A126 and L127) implicated in the interface are highlighted 
in grey. For each image, Subunit 1 and 3 are highlighted blue and green respectively to depict the dimerisation 
interface. An equivalent interface is found between subunit 2 and 4. (B) Hydrogen bonds between adjacent β5 
strands. (C) Electrostatic interactions between the hinge region preceding the β5 strand (E93) and the α5 helix 
(R101, H105). 
The orientation between the N-terminal and C-terminal domains of HicB can adopt one of 
two different configurations where the N-terminal 1 helices lie either parallel to the C-
terminal domains (subunits 1 and 4) or perpendicular and subsequently are solvent exposed 
(subunits 2 and 3) (Figure 2.16A). This non-symmetric arrangement leads to two distinct sets 
of hydrophobic and electrostatic interactions between adjacent N- and C-terminal domains 
(Figure 2.16B). In HicB subunits, when the 1 helix lies parallel to the C-terminal domain 
(Subunit 1 and Subunit 4), the interface between adjacent subunits is dominated by 
electrostatic interactions between the N-terminal domain: E48, E52 (1) and D89 (hinge 
region) of a subunit and residues of the 5 helix (R101 and H105) of and adjacent subunit 
(Figure 2.16D, box 1), as highlighted for subunits 1 and 3. Surprisingly no hydrophobic 
interactions are seen at this interface (Figure 2.16D, box 2). If the 1 helix is surface 
exposed, for example within subunit 2 and 3, the interface is dominated by hydrophobic 
interactions (Figure 2.16D, box 3) and no electrostatic interactions are observed (Figure 
2.16D, box 4). Residues in and around the 1 helix and the hinge region (I51, V57, F59, L85, 
L88) form a hydrophobic network with the helix (P100 and F102) of an adjacent subunit, 
as observed between subunit 2 and 4 (Figure 2.16D, box 3). These interactions tether the C-
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terminal domains in a parallel arrangement at the base of the structure. The interface between 
pairs of adjacent C-terminal domains is comprised of A109, A112 and H115, resulting in a 
minimal interface between the two (Figure 2.16C). 
 
Figure 2.16. Tethering interactions between adjacent N-terminal and C-terminal domains of HicB 
within the crystal form A (1.85 Å dataset). (A) Cartoon representation of the hydrophobic and electrostatic 
interactions between adjacent C-terminal domains and N-terminal/hinge region. (B) Cartoon representation of 
the location of hydrophobic and electrostatic sites, dependent on the placement of the 1 helix. (C) HicB 
tetramer with the C-terminal domains rendered with a solid surface and residues at the interfaces between C-
terminal pairs annotated (D) Interaction sites across the tetramer. Box 1 highlights the electrostatic interface 
(Residues E48, E52, D89, R101 and H105) between adjacent subunits and box 2 shows the absence of the 
hydrophobic site (Residues I51, V57, F59, L85, L88, P100 and F102) between adjacent subunits when the 1 
helix lies parallel to the C-terminal domain. Box 3 and 4 show the respective presence of the hydrophobic 
interface and absence of the electrostatic interface between adjacent subunits 2 and 4 when the 1 helix is 
surface exposed. For clarity only the interfaces at subunit 1 and 2 are highlighted, but the equivalent sites are 
present at the 1 helix of subunits 3 and 4. 
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The solution of crystal form B at 2.4 Å was determined using crystal form A of HicB as a 
search model (Figure 2.17). The experimental data did not contain compelling electron 
density for the side chains of residues H7-Y15 (loop 1) or the vector encoded His6 tag and 
these were omitted from the final model.  
 
Figure 2.17. Crystal form B of HicB (2.4 Å dataset). (A) The tetrameric structure of HicB coloured by 
subunit, the dimerization interfaces are formed by both the N-terminal and C-terminal across adjacent subunits. 
(B) Single subunit of HicB with secondary structure elements labelled. (C) Non-symmetrical dimer interfaces 
between subunits 1 and 2 compared to subunits 1 and 3.   
Surprisingly, despite the conservation of the ring type tetramer, however, the two structures 
were non-identical. The conformation of crystal form B (2.4 Å) is more compact (73 x 78 Å) 
than crystal form A (1.85 Å), (63 x 99 Å) with respect to horizontal and vertical axis. The 
structure of crystal form A appeared to be elongated in comparison to the conformation of 
crystal form B. Both are now referred to as the compact (2.4 Å) and elongated (1.85 Å) form 
of HicB respectively. The placement and orientation of the C-terminal domain differs by ~ 
5°, resulting in a 9 Å displacement of the C-domain for the elongated conformation (Figure 
2.18A). Superimposition of the two structures results in a good agreement for the N-terminal 
domain and a single subunit (RMSD: 1.8 Å over the carbon backbone) but not the dimer 
(Figure 2.18 B, RMSD: 4.2 Å) or tetramer (Figure 2.18C, RMSD: 29.45 Å). Conformational 
shifts within the C-domain are propagated to the tetramer via the strand-swapped dimers 
resulting in gross variation between the pairs of dimeric C-terminal domains. Strand-
swapping has been observed in various proteins to propagate the formation of higher order 
structurers and give rise to functional units.
318
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Figure 2.18. Superimposition of the compact and elongated conformations of HicB. (A) Cartoon 
superimposition of individual subunits of HicB (RMSD: 1.8 Å). (B)  Cartoon superimposition of adjacent HicB 
N-terminal dimers (RMSD: 4.8 Å) (C) Cartoon superimposition of HicB tetramers. The compact and elongated 
conformations are highlighted in blue and green respectively and all superimpositions were made over the 
carbon backbone. 
The variation between the two structures is explained by an increased number of inter- 
subunit interactions between adjacent subunits in the compact conformation (Figure 2.19) 
and a number of additional internal interactions within subunits when compared to the 
elongated conformation.  
A myriad of hydrophobic and electrostatic interactions are conserved within the compact 
conformation of HicB, dependent on the placement of the 1 helix (Figure 2.19), as 
previously observed for the elongated conformation of HicB (Figure 2.16). The interfaces 
between adjacent subunits where the 1 helix lies parallel to the C-terminal domain are 
conserved within both conformations of HicB. When the 1 helix is surface exposed, the 
interface is dominated by hydrophobic interactions (Figure 2.19C, box 3). However, the 
orientation of the 1-loop enables D56, E58 and D89 (hinge) to form new electrostatic 
interactions with residues in the 5 helix (R101, H105 and K106) of an adjacent subunit, as 
highlighted for subunits 2 and 4 (Figure 2.19C, box 4). These interactions are not observed in 
the elongated conformation of HicB and their formation brings the 1 helix closer to the 5 
helix resulting in a more compact ring type tetramer.  
Additional internal cation- interactions (Y110-R114 and Y110-R124) between the 4 and 
5 helix within the C-terminal domain of the compact form contribute to its rigid nature. 
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These are not present in the elongated conformation, although it is likely that the C-terminal 
domains remain dynamic in solution and crystallisation may have captured two 
conformations of HicB. However, this does not preclude further conformations that might be 
adopted in the presence of HicA or DNA. 
 
Figure 2.19. Tethering interactions between adjacent N-terminal and C-terminal domains of the compact 
conformation of HicB. Interaction sites across the tetramer. Box 1 highlights the electrostatic interface 
(residues E48, D89, R101 and K106) between adjacent subunits when the 1 helix lies parallel to the C-terminal 
domain. Box 2 indicates the absence of a hydrophobic interface residues I51, V57, F59, L85, L88, P100 and 
F102) between adjacent subunits 1 and 4. Box 3 and 4 show the respective presence of the hydrophobic 
interface and absence of the electrostatic interface between adjacent subunits 2 and 4 when the 1 helix is 
surface exposed. Additional electrostatic interactions (D56-H105, E58-K106 and D89-R101). 
SAXS was used to determine the ab initio shape envelope of HicB (HicBT = 125 M) in 
solution (Materials and Methods).
319-324
 This envelope was used to further confirm the 
tetrameric organisation of HicB and determine which crystal form of HicB  best represented 
the dynamic solution structure of HicB and therefore the native state (Figure 2.20, Appendix 
Figure 8, Appendix Table 11). The three-dimensional structures of HicB were also 
quantitatively analysed to determine whether the computed scattering profile of either 
structure resembled the experimental profile of HicB observed in solution. The calculated 
Normalised Discrepancy Function (
2
) reported (analogous to the R factor) was calculated to 




value of 1 
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indicates an ideal fit to the experimental data and it is generally accepted that a 
2 
value 
greater than 3 reflects a poor fit to the experimental data (Robert Rambo Personal 
Communication).
326, 327
 The elongated conformation (crystal form A) shows a good 
agreement to the ab initio shape envelope, with a 
2 
value of 1.98 between the crystal 
structure and the raw scattering data. In comparison the compact conformation of HicB 
(crystal form B) is a poor fit with a 
2 
value of 9. From this data, it was proposed that the 
elongated conformation solved at 1.85 Å was a better model to describe the shape of HicB in 
solution.  
 
Figure 2.20. Small angle X-ray scattering of HicB. (A) Ab initio modelling of the structure of the elongated 
conformation of HicB into the shape envelope of HicB (white). The FoXS profile of the proposed scattering 
profile for the crystal structure (red) against the experimental raw scattering data is underneath (
2
= 1.98) (B) Ab 
initio modelling of the structure of the compact conformation of HicB into the shape envelope of HicB (white). 
The FoXS profile of the proposed scattering profile for the crystal structure (red) against the experimental raw 
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2.6.1.  Structural comparisons to HicB3 
As previously discussed the homologue HicB3 (PDB:4P7D) exists as a ring type tetramer and 
the gross topology is shared between the two distant homologues despite their sequence 
identity (28%) with the orientation of 1 helices conserved within individual subunits of 
HicB3.
132
 Superimposition of a subunit of the elongated conformation of HicB to HicB3 
(Figure 2.21A, RMSD: 3.6 Å) showed a good agreement at the N-terminal domain. However, 
subunits differ at the C-terminal domain, with particular deviation of the 5 strand and 6 
helix. This C-terminal domain of HicB3 represents yet another conformation that the RHH 
motif within the HicB family members can adopt, reinforcing its dynamic nature in the 
absence of DNA/HicA. The topology of the overall ring type tetramer of HicB3 varies from 
the elongated conformation of HicB (RMSD: 4.5 Å), predominantly due to the different 
orientations of the C-terminal domains (Figure 2.21B). 
 
 
 Figure 2.21. Superimposition of the elongated conformation of HicB and HicB3. (A) Cartoon 
representation of the superimposition of individual subunits of HicB (blue) and HicB3 (grey), (RMSD: 3.6 Å) 
and their tetrameric form (RMSD: 4.5 Å). The vector encoded His6-tag was not observed in either structure. (B) 
Sequence of B. pseudomallei HicB and comparison to the structural homologue, HicB3 from Y. pestis. The 
vector encoded His6-tag for HicB and HicB3 is not shown. The secondary structure elements from HicB are 
displayed at the top of the alignment, symbols indicate a conserved residue (*), conservative mutation (:) and a 
semi-conservative mutation (.).  
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). The HicB3 4 helix within the hinge 
region makes two internal interactions to the 1 helix (Y89-E39 and Y89-F42) within 
individual subunits that are not present in HicB. These additional interactions may tether the 
hinge region to the N-terminal domain, reducing the flexibility of this region and therefore 
the subsequent C-terminal domain (Figure 2.22A). Additional cation- interactions are 
observed between adjacent C-terminal domains (F96-R121, F111-K132 and Y118-K132) 
(Figure 2.22B). These additional interactions strengthen the dimerization interface between 
adjacent C-terminal domains. Both F111 and K132 are conserved in HicB but poor electron 
density was observed for K132 and the side-chain orientation could not be determined. F96 
and Y118 are replaced by I95 and K106 respectively within the 5 strand and the 4-5 loop.  
Figure 2.22. Aromatic interactions within HicB3. (A) Anchoring interactions between the 4 helix (Y89) and 
the 1 helix (E39 and F41). (B) Cation-π interactions between adjacent C-terminal domains (F96-R121, F111-
K132 and Y118-K132) stabilise the hydrophobic interface that drives dimerization. For clarity only one set of 
interactions are labelled. Adjacent HicB3 subunits are labelled blue and green respectively. 
 
While not discussed in the original publication of HicB3
132
, similar sets of tethering 
interactions are seen between adjacent subunits (Figure 2.23). Again, like those identified in 
HicB, the network of interactions are dependent on the orientation of the 1 helix and 
whether this lies parallel to the C-terminal domain (electrostatic network) or perpendicular to 
it (hydrophobic network).  
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Figure 2.23. HicB3 interaction sites across the tetramer. Interaction sites across the tetramer. Box 1 
highlights the electrostatic interface (residues D33, E39, K110 and R116) between adjacent subunits 1 and 3. An 
additional hydrogen bond is seen at the C-terminus of the 1 helix (E47) with subunit 3 (N103).  Box 2 shows 
the absence of the hydrophobic site (residues F54, P55, L104 and A107) between adjacent subunits, where the 
1 helix lies parallel to the C-terminal domain. Box 3 and 4 show the respective presence of the hydrophobic 
interface and absence of the electrostatic interface between adjacent subunits when the 1 helix is surface 
exposed highlighted for subunit 2 and 4. 
The electrostatic interface consists of interactions between the 1 helix (D33 and E39) of 
HicB3 and the 5 helix (K100 and R116) of an adjacent subunit, as highlighted between 
subunit 1 and 3 (Figure 2.23, box 1). A supplementary hydrogen bond is formed between the 
C-terminal of the 1 helix (E47) and the adjacent 5 helix (N103) that further stabilises this 
site (Figure 2.23, box 1). The hydrophobic network consists of interactions between the 1-
2 loop (P54 and F55) with residues in and around the 5 helix (L104 and A107) of an 
adjacent subunit, as highlighted between subunit 2 and 4 (Figure 2.23, box 3). Fewer 
hydrophobic contacts are present by comparison to the equivalent HicB site (Figure 2.16, box 
2) although there is an additional cation- interaction between F55 and K110. Aromatic 
amino acids responsible for the hydrophobic interface in HicB (P100 and F102) lie on the 5 
helix interacting with residues within an adjacent 1 helix (I51, V57, F59, L85, L88). In 
HicB3 these equivalent aromatic residues (F54 and P55) are found in the 1-2 loop and 
interact with hydrophobic residues around the 5 helix of an adjacent subunit.  Similar to 
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HicB, if the electrostatic interface is present the hydrophobic interface is not present (Figure 
2.23, box 2) and vice versa (Figure 2.23, box 4). Conservation of the tethering interface, 
despite the low homology between HicB and HicB3 (28%) suggests a conserved mechanism 
of spatial regulation of the tetramer between HicB family members. This may ensure that the 
HicA and DNA binding sites are surface exposed and correctly orientated for optimal 
binding.  
 
2.7.  Summary 
This chapter consists of the expression and purification of several HicB constructs and the 
structural determination of 3 HicB variants: HicB-NT dimer (1.56 Å), compact (2.4 Å) and 
elongated (1.85 Å) tetramer of HicB.  
Attempts to solve HicB by MR were initially unsuccessful and could only be solved via a 
combination of heavy atom phasing through SeMet labelling and the 1.56 Å structure of the 
HicB N-terminal domain. Subsequent MR solved the tetrameric conformation of HicB from 
two independent datasets at 2.4 Å and 1.85 Å. Each structure displayed an altered 
conformation with respect to placement of the C-terminal domain within subunits. Adjacent 
C-terminal domains dimerise to form intact RHH domains. These are predicted to be flexible 
in the absence of DNA and there are minimal interactions between individual N/C terminal 
domains and between adjacent RHH domains.  
The ring type tetramer was stabilised by a myriad of tethering interactions: hydrophobic and 
electrostatic, dependent on the position of the 1 helix, within individual subunits. Structural 
comparisons of HicB to the Yersinia HicB3 homologue suggested that these tethering 
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Project HicB SeMet HicB-NT HicB HicB 









39.42  - 1.85 (1.92 - 
1.85) 
Space group P212121 P212121 P41 P 41 
Unit cell  
58.7 59.9 172.8Å 
90 90 90° 
63.5 76.7 76.9Å 
90 90 90° 
63.1 63.1 181.2 Å 
90 90 90° 
62.6 62.6 173.5Å 
90 90 90° 
Multiplicity 12.7 (13.1) 13.2 (13.0) 5.7 (4.9) 4.7 (4.7) 
Completeness (%) 99.3 (99.3) 100.0 (100.0) 99.0 (98.0) 99.0 (99.0) 





70 40 70 50 
Rmeas 0.11 (2.09) 0.04 (1.26) 0.06 (0.87) 0.07 (3.96) 




0.493 (-0.03) - - - 
R/Rfree for partial 
model 
0.327/0.390 - - - 
Reflections used in 
refinement 
- 53900 28098 55828 
Rwork - 0.200 (0.3972) 0.221 (0.3359) 0.202 (0.4480) 
Rfree - 0.233 (0.4530) 0.269 (0.3717) 0.236 (0.4517) 
Number of protein 
atoms 
- 2502 4088 4327 
RMS (bonds) (Å) - 0.013 0.009 0.008 
RMS (angles) (°) - 1.14 1.06 0.86 
Ramachandran 
favoured (%) 
 100 95 97 
Ramachandran 
allowed (%) 
 0.32 3 2.5 
Ramachandran 
outliers (%) 
 0 1.9 0.2 
Rotamer outliers 
(%) 





    
Protein - 40 90 70 
Solvent 
 
- 50  50 
Table 2.2. Refinement statistics for HicB SeMet, HicB-NT and HicB at resolutions of 2.4 and 1.85 Å. 
Values in parenthesis correspond to the highest resolution shell. 
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3.  Structural studies on HicAB 
This chapter reports the complete three-dimensional crystallographic structure of the HicAB 
complex from B. pseudomallei. This now provides the first example of an intact HicAB 
complex and comparison with free HicB that extends our current knowledge beyond that 
provided by the partial HicA3-HicB3 complex.
132
 The truncation of the C-terminal domains 
in the hetero-tetramer reported by Bibi-Triki et al. left numerous unanswered questions 
surrounding the stoichiometry of the HicA3/HicB3 interaction, how HicA3 would be 
sterically accommodated in the complete complex and how HicA3 interacts with HicB3 to 
modulate DNA interactions and repression/de-repression of the hicA3B3 operon.
132
  During 
the writing of this work a second complete HicAB complex from S. pneumoniae was reported 
(PDB:5YRZ)
272
 but was crystallised in a distinctly different conformation than observed for 
B. pseudomallei, raising further important questions surrounding HicAB structure, dynamics 
and functional diversity between family members. 
3.1.  Expression and purification of HicA 
A pET26-b HicA construct containing HicA bearing a H24A mutation (Provided by Dr 
Aaron Butt, University of Exeter) was expressed using T7 Express cells (NEB) and purified 
by IMAC.
131
 During purification, it was apparent that previously reported yields of HicA 
could not be replicated. To improve yields, a codon optimised HicA-H24A gene was 
synthesized and cloned into a pET151-D/TOPO vector (ThermoFisherTM) to generate 
pET151-HicA. This vector encodes an N-terminal His6-tag followed by a TEV cleavage 
sequence (ENLYFQ) and the HicA-H24A gene. The gene product is herein called HicA. The 
TEV cleavage site was selected, due to the in-house availability of His6-TEV, via a pET9d-
His6-TEV construct (kindly provided by Dr Matthew Goodwin, University of Bristol).  
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Figure 3.1. Expression and purification of HicA. (A) SDS-PAGE following the expression and purification of 
HicA from post induction to isolation via IMAC. Prior to TEV cleavage, observed mass ~13 kDa, expected 
mass = 10,204 Da and post TEV cleavage, observed mass ~10 kDa, expected mass = 7,052 Da. (B) IMAC of 
HicA eluting as a single peak. (C) IMAC of HicA post TEV cleavage. Untagged HicA eluted during the flow-
through (15-45 ml). (D) Denatured ESMS of HicA. m/z signals spanning 780-1,400 were assigned based on 
their charge state. Inset: De-convoluted spectrum of the m/z envelope to determine the monomeric mass of 
HicA.  
HicA was expressed as soluble protein in E. coli T7 Express cells (NEB) and purified by 
IMAC (Figure 3.1A, B). SDS-PAGE revealed a single band corresponding to monomeric 
His6-HicA after IMAC and the mass confirmed by ESMS (observed: 10,203 Da, expected: 
10,204 Da) (Appendix Figure 9). Proteolytic cleavage (TEV) and negative purification 
(IMAC, Figure 3.1C) yielded cleaved HicA as judged by SDS-PAGE (Figure 3.1A) and 
confirmed by ESMS (Observed mass: 7,051 Da, expected: 7,052 Da) (Figure 3.1D). A small 
proportion of His6-HicA was present after negative purification via IMAC (Figure 3.1A) and 
could not be removed by subsequent purification steps (repeated negative IMAC steps and 
downstream SEC). HicA was deemed to be ~ 90% pure with a final yield of 1.5 mg/L.  





N labelled sample for study by two-dimensional heteronuclear NMR.  The 
1
H-
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15
N HSQC spectrum of HicA acquired by Professor Matt Crump and Dr Chris Williams was 




N HSQC acquired previously using 
15
N labelled protein prepared from the 
pET26-b HicA construct and from which a full solution structure was determined (Appendix 
Figure 10).
131
 However residues I7, D44, L45, K55 and S56 which were previously assigned 
in the pET26-b HicA spectrum could not be assigned for HicA. As the pH (7.5) and 
temperature (25 °C) remained constant it is likely that the unassigned peaks are close in 
proximity to those that were assigned in the pET26-b HicA spectrum and small chemical 
shift perturbations have hindered the assignment of these residues for HicA. Moreover, both 
linker regions of the proteins (HicA: GIFPFT and pET26-b HicA: DRWGSEL) upstream of 
the start methionine could not be assigned and partly account for the disparity between the 
two spectra. Despite the disparity between the two spectra, the current preparation was 
deemed to contain folded protein. 
 
3.2.  Assaying complex formation between HicA and HicB  
Prior to crystallisation trials, analytical SEC (ASEC) was used to investigate the oligomeric 
state of HicB and its interaction with HicA. A Superdex 75 10/300 GL analytical column 
(AS75) was pre-calibrated with proteins spanning 6-75 kDa including aprotinin, carbonic 
anhydrase, ovalbum, conalbumin and blue dextran (Figure 3.2, Appendix figure 11, Materials 
and Methods, equation (1)). The peak elution volume (Ve) of each sample allowed the 
calculation of the apparent molecular weight (Mwapp) and inferred the oligomeric state of 
each sample. The peak width was used to calculate the range of molecular weight values 
encompassed by each sample. HicB (50 M, HicBT = 12.5 M) eluted as a single species at 
an Mwapp of 65.6 kDa (52.3-76.5) with parenthesis indicative of the molecular weight range 
(kDa) encompassed by the peak. Similarly, HicA (50 M) eluted as a single species 
corresponding to a Mwapp of 8.2 kDa (6.5-9.8 kDa). Both proteins are in agreement with their 
expected molecular weights (63.0 and 7.1 kDa).  
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Sample Mw (Da) Mwapp (kDa) Mw range (kDa) Log10Mw Ve (ml) Kav 
HicA 7,053 8.3 6.5-9.8 0.92 14.5 0.44 
HicBT 62,952 65.6 52.3-76.5 1.82 9.03 0.11 
HicABT 77,058 71.9 46.8-95.0 1.86 8.79 0.10 
Figure 3.2. AS75 profiles of HicBT, HicABT and HicA. (Top): SEC profiles for all reported constructs and the 
corresponding SDS-PAGE of eluted samples. Arrows refer to monomeric HicB (HicBM) and HicA. (Middle): 
Calibration curve using known standards: aprotinin (AP, 6.5 kDa), ribonuclease A (RA, 13.7 kDa), carbonic 
anhydrase (CA, 29 kDa), ovalbumin (OV, 42.7 kDa) and conalbumin (CO, 76 kDa) used to determine the 
Mwapp for each analysed protein. (Bottom): Summary of results for each analysed sample reporting the expected 
molecular weight (Mw), Mwapp, Range of molecular weight values encompassed by each peak, Log10 Mw, Ve 
(Volume of elution) and Kav (Partition coefficient) determined by the calibration curve and equation (1). 
Complexation with HicA resulted in a complete loss of the HicA peak and a new peak eluted 
at a higher Mwapp than HicB alone at (71.9 kDa) (46.8 - 95.0 kDa, Figure 3.2A). SDS-PAGE 
analysis confirmed this new peak contained both HicA and HicB thereby confirming the 
proteins had formed a complex. The Mwapp of HicAB corresponds to 0.93 x the expected 
molecular weight of a HicA2HicB4 complex (77.1 kDa) and the profile also encompasses 
HicA3HicB4 (84.1 kDa) and HicA4HicB4 (91.2 kDa). In addition, the profile of HicAB 
displayed a shoulder spanning 8.05- 8.55 ml corresponding to a molecular weight of 78.6 – 
95.0 kDa. ASEC therefore confirmed that complexation had occurred, but it was not possible 
to definitively assign an oligomeric state. SEC analysis of the homologous HicA3B3 
suggested that a HicA32HicB34 complex was the major species formed in solution which is in 
close agreement with the predominant species observed here.
132
  
3.  Structural studies on HicAB  3.3. Crystallisation of HicAB 
 71 
3.3.  Crystallisation of HicAB  
The HicAB complex was screened using a variety of crystallisation concentrations (500-2000 
µM) and different preformed stoichiometric states against commercially available Molecular 
Dimensions screens (Morpheus, Proplex, JSCG+ and Structure Screen I + II).  
Small crystals of preformed HicA2HicB4 (HicA: HicB ratio = 250:500 µM) formed in 0.1 M 
MES, pH 6.5, 0.2 M NH4SO4, 30% (v/v) PEG 5000 MME, but crystals were fragile and 
could not be efficiently looped. A preformed complex 1:1 ratio of HicAB (500:500 µM, 
HicA4HicB4) formed longer thin crystals in the same conditions that could be looped. Only 
crystals free of physical deformities were looped in 25% (v/v) glycerol and directly frozen for 
diffraction analysis. A dataset of 1,800 images was collected at wavelength 0.9795 Å, 
exposure time: 0.06 s, oscillation: 0.2 ° and beam flux 100%, with cryogenic temperatures 
maintained throughout data collection.  
Autoprocessing by the FastDP pipeline suggested a resolution of 2.75 Å. Data were 
processed as described in Materials and Methods into the space group: P 2 with an ASU 
containing seven molecules of HicA/HicB using the Matthews Coefficient. Attempts to solve 
the dataset using MR with existing HicB crystal structures and the NMR structure of HicA 
(PDB: 4C26) as search models were however unsuccessful.
131, 280, 281
 Searches for individual 
N- or C-terminal domains of HicB were also unsuccessful. One N-terminal domain of HicB 
could be identified but it was not possible to manually build adjacent subunits into the 
surrounding electron density. No MR solution refined below an Rfree of ~ 50%. 
Rotation of individual domains was not initially accounted for in any search models used in 
MR or within attempts to manually rebuild subunits of the tetramer. The structural 
determination of free HicB had however, revealed that the C-terminal domains could adopt 
different orientations and might also reorient upon HicA binding. Using this notion, the 
structure was solved by Dr Michail Isupov/Professor Nic Harmer (University of Exeter) 
using the C-terminal strand-swapped dimer of the elongated conformation of HicB as a 
search model for MR in MOLREP
328
  within CCP4
329
 (Figure 3.3A). Two C-terminal dimers 
were then found within the HicAB dataset with rotation peaks 1 (5.74 ) and 5 (4.45 ). 
These C-terminal dimers were used as fixed models and four N-terminal domains of HicB 
could only be located when 200 rotation peaks were used in the translation search (Peaks 5, 
10, 162 and 4). The resultant HicB model was refined to R/Rfree 0.408/0.422 at 2.5 Å before 
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four copies of HicA (PDB:4C26) were positioned into the resultant electron density using the 
spherically averaged phased translation function and phased translation function implemented 
in MOLREP.
330
 The four-fold NCS averaging in DM
300
 was used for phase improvement of 
HicAB structure with masks and NCS operators calculated separately for HicA and each 





 Resulting electron density maps allowed building of the hinge regions of HicB 
monomers in Coot.
303
 Manual rebuilding and refinement further improved the Rfree value 
associated with the model before the final structure was validated with MolProbity
307
 and the 
PDB_REDO web server.
308
 Statistics are shown in Table 3.1. 
 
Figure 3.3. The HicAB hetero-octameric complex. (A) The strand-swapped C-terminal domain of HicB was 
used as a search model to identify electron density corresponding to these domains. The four N-terminal 
domains of HicB could then be placed by MR. Finally, four HicA subunits (PDB: 4C26) were built into the 
remaining electron density. (B) Cartoon representation of the HicAB hetero-octamer where HicA (red) binds to 
the N-terminal domain of each HicB subunit (blue, pink, green and yellow). 
The structure of the HicAB complex (Figure 3.3B) clarified the difficulties encountered 
during initial MR trials. Firstly, the initial space group assignment (P 2) was incorrect and 
was re-assigned as P 21 with an ASU of 8 molecules (four HicA and four HicB chains).The 
P21 spacegroup was not searched for during MR trials. Secondly, the C-terminal domains are 
rotated by 90° with respect to their initial orientation in HicB (Figure 2.14), but as the core of 
the strand-swapped dimers remained intact, this ultimately aided the molecular replacement.  
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The asymmetric unit of the HicAB complex is arranged as a symmetrical hetero-octamer with 
four identical HicA interaction sites at the N-terminal domains of HicB (Figure 3.3B). Here 
the positively charged face of the -sheet of HicA binds to the 1 helix of HicB. The 
conversion of HicB tetramer to the symmetric HicAB hetero-octamer requires extensive 
conformational rearrangements that generate a more open conformation (Figure 3.4A). These 
conformational rearrangements are most marked for subunits 1 (blue) and 4 (yellow) of HicB 
that undergo a domain rearrangement to flip the 1 helix from a sequestered conformation 
(1 helix tethered to a C-terminal domain via electrostatic interactions) into an exposed 
conformation required for HicA binding, in the process breaking these electrostatic 
interactions. Conversely helix 1 is already partially solvent exposed in subunits 2 (pink) and 
3 (green) of HicB and undergoes a smaller 2.4 Å lateral displacement upon HicA binding 
(Figure. 3.4A)  
For the rearrangements in subunits 2 and 3 of HicB, displacement of the 1 helix is 
accompanied by reshuffling of the hydrophobic interactions within the N-terminal domain. 
Reshuffling of these elements reduces the length of the longest axis of the symmetrical 
conformation of HicB by 14 Å compared to the unbound conformation of HicB. The most 
significant hydrophobic switch arises from L85 (HicB subunits 2 and 3) that rotates 60°, 
significantly reducing the tethering interaction to the C-domains of subunit 4 and 1 
respectively (P100 and F102) (Appendix Figure 12). Similarly, L88 rotates into an empty 
pocket created by the 2.8 Å shift of E48 (HicB) that forms a new salt-bridge with R19 of 
HicA and breaking the L88-F102 interaction between adjacent HicB subunits. 
The loss of these packing interactions allows the C-terminal domains to rotate outwards in 
HicAB (Figure 3.4A) without any significant internal rearrangements (hydrophobic packing 
is 80% conserved within the C-domains between HicB and HicAB): L85 and L88 are drawn 
into a hydrophobic network (I22, I43, V47, V57 and V83) within the N-terminal domain, 
stabilising the open conformation (Figure 3.4B). L85 acts as a direct replacement for F59 
(1-2 loop) which mediates several internal hydrophobic interactions within the N-terminal 
domain of each subunit (V47, V57, L85 and L88) in the free form of HicB (Appendix Figure 
12) and these are disrupted upon 1 helix displacement.  Residues from the C-terminal helix 
(R124 and L127) now form new intra-subunit interactions with residues F59, D84, S86 and 
Q87 from the N-terminal domain (Appendix figure 13). The hydrophobes P100 and F102 
(having lost interaction with L85 and L88) now form inter-subunit interactions with N-
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domain residues I51, V57, F59 and P92 (Figure 3.4B). Supplementary electrostatic 
interactions between adjacent subunits: D89-R101 and E58-K106 form additional inter-
subunit interactions to stabilise the symmetrical conformation of HicB.  
PISA confirmed that the hetero-octameric state of HicAB represented a biological interface 
and was not a crystal artefact (Appendix Table 12).
309
 A Gdiss of 8.8 kcal/mole suggested 
that the hetero-octamer was stable in solution with 32% of the solvent accessible area buried 
upon formation of the hetero-octamer. PISA suggested that this organisation of the tetramer 
in the absence of HicA was unlikely to be stable in solution. This implies that the 
symmetrical tetramer of HicB is a consequence of HicA binding, rather than a conformation 
adopted by free HicB alone in solution.  
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Figure 3.4. Key interactions in the HicAB hetero-octameric complex. (A) Conformation rearrangements 
induced by HicA binding and forming the complex HicAB. (left) HicA (red) interacts with the 1 helix of each 
subunit of HicB (highlighted blue, pink, green and yellow) in the unbound conformation to form the hetero-
octameric HicAB complex (right), with 5 strands of HicB also highlighted to illustrate their rotation upon 
complexation. (B) Cartoon representation of new interaction sites across the HicB tetramer. Box 1 highlights the 
new intra-subunit hydrophobic network formed due to the rotation of L85 and L88 to interact with I22, I43, V47 
and V83 within subunit 1 of HicB (blue). Box 2 indicates new inter-subunit interactions between adjacent 
subunits (1 and 3) of HicB (blue and green). P100 and F102 form hydrophobic contacts to I51, V57, F59 and 
P92, while E58 interacts with K106 (For clarity the D89-R101 interaction is not shown). Due to the symmetrical 
nature of HicB within the hetero-octamer, these interactions sites are conserved between subunits of HicB. This 
is highlighted for HicB subunit 2 (box 3 and 4). 
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Analysis of the surface charge distribution for HicB revealed a clustering of positive charge 
on each of the RHH C-terminal domains (Figure 3.5). In the free form the C-domains are 
oriented in such a way as these clusters align to form an extended positively charged patch. 
When viewed from a 90° rotated angle this patch can be seen to encompass an obvious 
groove at its centre. In the HicAB structure however, these domains reorient to move these 
clusters of charges to opposite sides of the HicAB complex, breaking the positively charged 
patch apart (Figure 3.5). 
 
Figure 3.5. Surface charge distribution of HicA and HicAB. (Top): Surface representation of HicB showing 
clustering of positive charges on one face mapped to R94, N96 and S98 of the C-terminal domain of HicB. 
(Bottom): Surface representation of HicAB highlighting perturbation of the positively charged patch of the C-
terminal domain (R94, N96 and S98) due to rotation of the two RHH domains. HicA is represented in grey.  
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HicA retains its dsRBD-like fold (RMSD: 1.22 Å, Appendix Figure 14) and binds the 1 
helix of HicB via the positively charged -sheet and 2 helix (Figure 3.6). Several 
electrostatic interactions R19-E48, R19-E52, K28-E55 tether the -sheet (HicA) to the C-
terminus of the 1 helix (HicB) (Figure 3.6A). This electrostatic interface is supplemented by 
hydrogen bonds (S22-W28 and T37-H46). P39 and P41 within the 2-3 loop of HicA stack 
against the 3 strand of HicB (W28) via CH- interactions
332
 and further hydrophobic 
residues of the HicA -sheet interact with the a1 helix of HicB (V18-L53, A23-A42, L35-
L50). HicA forms one tethering interaction outside of this region between the 2 helix (K55) 
and the 5 helix (E72) of HicB. This interaction site buries 900 Å
2
 of the total surface area 
(13,500 Å
2
) and the interactions between the two proteins are summarised in Appendix Table 
13. The symmetry of the hetero-octamer conserved this interaction site at each HicB subunit. 
PISA determined that the HicAB interface was only structurally similar to other HicAB 
family members (Appendix Table 14) 
309
 and there was no observed similarity to other 
members of the PDB (July 2018).  
 
Figure 3.6. Interaction site between HicA and HicB. (A) HicA (red) interacts with the 1 helix of HicB 
primarily through the three-stranded -sheet and connection loops bearing hydrophobic, hydrogen and 
electrostatic interactions. (B) The functionally critical residue H24 (H24A in the crystal structure) is predicted to 
project into the polar pocket of HicB formed by S27, N38 and E41. Key residues rendered as sticks. 
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3.3.1.  Sequestration of HicA functionally relevant residues 
Within canonical dsRBD proteins, there are three distinct sites of interaction which form 
interactions with the minor groove of RNA (1 helix and the 1-2 loop) and the major 
groove (2). 
333
 HicA does not contain the canonical motifs associated with these sites (E8, a 
GpxH motif and a KKxAK motif) within the 1, 1-2 loop and the 2 helix.
333
 Instead 




 motif which has been verified as the site of endoribonuclease activity 
for Y. pestis and S. pneumoniae HicA although not yet confirmed in B. pseudomallei. The 
motif is present in other HicA family members (Appendix Figure 15) with the exception of a 
GSNH motif in E. coli HicA. E8 appears to be substituted by E7 within B. pseudomallei, E. 
coli and Y. pestis HicA but is not present within S. pneumoniae   HicA. The KKxAK motif 





 motif at the 2 helix, found within these HicA family members. Residue 
K51 within Burkholderia HicA is typically conserved as either an arginine/lysine at this 
position while residue K55 within is conserved throughout HicA family members.
131
 
The HicA-HicB interactions identified here bury the functionally critical residues (G22 and 
H24) within the 1-2 loop (Figure 3.6B). A similar mechanism of complexation has been 
observed in the homologous dsRBD () HicA3B3 and HicABSP systems for Y. pestis 
and S. pneumonaie (Figure 3.7, Figure 3.8). Superimposition of the HicAB interaction site to 
HicA3B3-NT revealed a conserved mechanism of interaction: (Figure 3.7A, RMSD: 3.58 Å 
over the carbon backbone). Functional critical residues for HicA (G22 and H24) share 
equivalent positions with those of HicA3 (G26 and H28). Both H24 and H28 are buried by 
the conserved polar pocket of N38/N37 and E41/E40 of HicB/HicB3 (Figure 3.7B). Several 
electrostatic interactions within HicAB: R19-E48, K28-E55 and K55-E72 are conserved 
within HicA3B3 as R21-E46, R18-E51 and K51-E75 (Figure 3.7C, Appendix Table 15). 
Several hydrophobic and hydrogen bond interactions (L35-L50, L35-L50 and T37-H46) are 
also conserved (Figure 3.7D, E).  
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Figure 3.7. Comparison of the HicAB crystal structure to HicA3B3. (A) Superimposition of HicA (red) 
HicB (blue) to HicA3 (Light grey) HicB3 (Dark grey) (PDB:4P78). (B) Sequestration of G26 and H28 in HicA3 
(light grey) HicB3 (dark grey) by the polar pocket N37 and E40. Sequestration of G22 and H24 in HicA (red) 
by the polar pocket of N38 and E41 of HicB (blue) is highlighted and transparent for comparison. (C) 
Conservation of electrostatic residues seen at the interaction site of HicA1 (red) HicB1 (blue) and HicA31 (Light 
grey) HicB31 (Dark grey). (D) Sequence of B. pseudomallei HicA and comparison to the closest structural 
homologue, HicA3 from Y. pestis. (E) Sequence of B. pseudomallei HicB and comparison to the closest 
structural homologue, HicB3 from Y. pestis. Symbols indicate a conserved residue (*), conservative mutation (:) 
and a semi-conservative mutation (.). 
HicASP also binds in a similar conformation to HicA and buries the catalytic H36 in a polar 
pocket formed by T33 and E47 (HicBSP) (Figure 3.8A, B) and supplementary electrostatic 
and hydrophobic interactions between HicASP and HicBSP are conserved (Figure 3.8 C, 
Appendix Table 16, Appendix Figure 16). The HicABSP interaction site is roughly conserved 
(85%) at each HicBSP subunit despite the difference in subunit orientation (Appendix Table 
16). In comparison to B. pseudomallei HicAB, multiple interactions tether the 2 helix of 
HicASP to HicBSP via the 1-2 loop, 2 helix and 2-4 loop through a series of 
hydrophobic, hydrogen and electrostatic interactions that are not conserved within B. 
pseudomallei HicAB (Appendix Table 16). Only one interaction is observed between the 2 
helix of HicA and HicB (K55-E72), whereas HicABSP forms fifteen interactions at this site. 
The 2 helix seems to form interaction sites in place of the 1 strand of HicBSP which is 










) and does not form any interactions 
with HicBSP whereas HicAB forms three key interactions at this site. As these sites are not 
present, the HicABSP interaction site is laterally shifted when compared to HicAB with 
respect to the placement of the secondary structure elements, positioning 2 in an optimum 
position to form multiple contacts with HicBSP. 
 
Figure 3.8. Comparison of the HicAB and HicABSP interaction site. (A) Superimposition of HicA (red)-
HicB (blue) to HicASP (Light grey)-HicBSP (Dark grey) (PDB:5YRZ). (B) Sequestration of G34 and H36 in 
HicASP by a polar pocket of HicBSP (T33 and E47). Sequestration of HicA G22/H24 is also shown. For clarity 
HicA/HicB are transparent for comparison. (C) Conservation of electrostatic residues seen at the interaction site 
of HicAB and HicABSP. K38-D55/E58, R45-D55 and K56-D12/D15 are equivalent within HicAB (R19-
E48/E52, K28-E55 and K43-E31). (D) Sequence of B. pseudomallei HicA and comparison to the structural 
homologue HicASP from S. pneumoniae. (E) Sequence of B. pseudomallei HicB and comparison to the structural 
homologue HicBSP from S. pneumoniae. Symbols indicate a conserved residue (*), conservative mutation (:) 
and a semi-conservative mutation (.). 
Further alignment of Burkholderia HicB to 51 cognate antitoxins to toxins that bear a high 
homology to HicA (Butt 2014, Appendix Figure 17) revealed a high degree of conservation 
within the 1 helix of HicB members (Figure 3.9). Residues involved in the HicAB 
interaction site (N38, E41, A42, H46, E48, L50 and E52) are highly conserved. The 1 helix 
is therefore likely to be the main interaction site for HicA within HicB family members due 
to its role in burying the functionally critical histidine for each studied system to date.  
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Figure 3.9. A Web logo
334
 generated graphic depicting the conservation of amino acids at the a1 helix of 
HicB when aligned to 51 homologous HicB sequences using Clustal Omega
291
. The amino acid sequence of 
the 1 helix of HicB is highlighted underneath. Residues of HicB that form interactions with HicA are 
underlined and show strong conservation among HicB family members. 
Several other type 2 toxins also degrade mRNA and these toxins are classified as either 
translation independent or dependent endoribonucleases with respect to their mechanism of 







 (Figure 3.10A) appear to neutralise in a similar mechanism where the formation of a 
toxin-antitoxin complex directly occludes the functional residues of each toxin. Despite the 
similarity in neutralisation within translation independent endoribonucleases, HicA only 
displays structural homology to other HicA family members and not to non-HicA type 2 
toxins (Appendix Table 17).  
The mechanism of direct occlusion of functional residues does not apply to all type 2 TA 
systems, this is not surprising as there is considerable structural variation between different 
TA members.
112, 335, 336
  The majority of translation dependent toxins (Figure 3.10B), with the 
exception of YafQ which displays direct occlusion of functional residues
83
, are neutralised by 
other mechanisms, which prevent ribosome association as observed in HigB
165
 or disrupt the 
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Figure 3.10. Neutralisation of the toxin catalytic site by their cognate antitoxins. (A) Neutralisation of 
translation independent toxins HicA (4C26), MazF (1UB4), MqsR (3HI2) and VapC (3TND). For each 
complex, the toxin and antitoxin are highlighted red and blue respectively. Note for VapC (3TND) the toxin 
cleaves tRNA not mRNA. (B) Neutralisation of translation dependent toxins HigB (4MCT), RelE (4FXE), 
YafQ (4Q2U) and YoeB (2A6Q). For HigB, the catalytic active site is circled. Within RelB, the unbound state 
is highlighted in grey to show 3 helix displacement.  For each complex, residues that constitute the catatlytic 
site of the toxin (red) and the residues that neutralise them within the antitoxin (blue) are highlighted as sticks. 
3.3.2.  Structural comparisons to HicA3B3 
The HicA3B3 complex (HicA32-HicB3-NT2) is an incomplete structure (PDB: 4P78) due to 
the removal of the C-terminal domains of HicB3
132
. The resultant HicA3B3-NT structure 
exists as a hetero-tetramer with a 1:1 stoichiometry also observed for the Burkholderia 
HicAB complex (Figure 3.11). HicA3 displayed a dsRBD fold similar to HicA (RMSD: 2.2 
Å, Appendix Figure 14).  
Superimposition of the HicA3B3-NT heterotetramer to the full length HicB3 structure 
suggested that the orientation of HicB3 N-terminal domains in the heterotetramer were 
identical to the subunit orientation seen within the HicB3 tetramer (Figure 3.11). Steric 
clashes were seen at two interaction sites between HicA3 molecules and the C-terminal 
domains of HicB3 (Subunit 1 and 4) in a HicA34HicB34 model (Figure 3.11). Due to the 
presence of steric clashes, it was assumed that a 1:1 stoichiometry (HicA34HicB34 complex) 
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could not be adopted by the full length HicB3. The model of a HicA34HicB34 complex was 
discarded as biophysical evidence (SEC-MALS) indicated that a single complex 
(HicA32HicB34) was formed rather than a HicA34HicB34 complex. Within HicB3, two 1 
helices (Subunits 2 and 3) are solvent exposed in a similar manner to HicB and it is presumed 
that HicA3 binds at these sites to form a HicA32HicB34 complex.
132
 
Figure 3.11. Steric clashes 
in a HicA34HicB34 
complex. Extension of the 
HicA32HicB32 structure with 
C-terminal domains 
modelled. This revealed 
steric clashes between 
HicA3 monomers and the C-
terminal domains of subunit 
1 (blue) and 4 (yellow) of 
HicB3 as the N-terminal 
domains of HicB3 within 
HicA3B3 are not correctly 
rearranged as observed in 
HicAB. 
Within the HicAB crystal structure, HicA binding caused a lateral displacement of 1 helices 
within HicB subunits 2 and 3 resulting in a 90 ° rotation of the C-terminal domains, actively 
preventing steric clashes in a HicAB complex (1:1 stoichiometry) through the formation of a 
symmetrical HicB tetramer through extensive domain reorganisation. Steric clashes observed 
in the HicA34HicB34 model at the C-terminal domain may be prevented by the conversion of 
HicB3 to a symmetrical tetramer similar to HicAB. Given the structural similarities between 
the proteins, this mechanism is quite probable. Presumably Bibi-Triki and colleagues could 
not appropriately model a HicA34HicB34 complex was because they had not accounted for 
rotation of the C-terminal domains or were not aware that this could occur.  
3.3.3.  Structural comparison of B. pseudomallei HicAB and S. 
pneumoniae HicAB 
Given the steric clashes expected in a hetero-octamer that would arise without re-
arrangement of the HicB tetramer, it was expected that a similar conformational change 
would have been reported for S. pneumoniae HicAB (HicABSP).
272
 The full structure of 
HicAB, however, shares some but importantly not all structural characteristics with the 
HicABSP complex (Figure 3.12A, B). HicABSP is a hetero-octamer and the HicBSP subunits 
contain two domains, an N-terminal domain (1and a C-terminal domain 






separated by a hinge region (V104-I114) encompassing a 5 helix. 
Comparison of the HicAB to HicABSP reveal the structural similarities over the C 
backbone, particularly evident within HicA (RMSD = 1.5 Å, Appendix Figure 14), including 
a shortened 1 strand in HicASP. HicBSP lacks a 3 helix and instead displays a large loop 
region between the 2 helix and 4 strand (S73-Y90) (Figure 3.12C). The authors noted that 
no interactions were made between the C-terminal domain of HicBSP and the rest of the 
HicABSP complex, in contrast to the tethering interactions observed within HicB. Despite a 
similar organisation between individual subunits of HicB (RMSD: 2.8 Å over the C 
backbone) the structural organisation of the HicBSP tetramer within HicBSP resembles HicB 
in an unbound form (RMSD = 63 Å, Figure 3.12D), rather than the symmetrical 
conformation observed in the HicAB hetero-octamer. HicASP binds at two subunits (Subunit 
1, blue and Subunit 4, yellow) whose 1 helices project towards the C-terminal domains but 
no steric clashes are observed at these sites, due to the long hinge region between the N-
terminal and C-terminal domain that can actually accommodate two HicASP molecules.  
 
Figure 3.12. Structural 
Comparison of HicAB 
and HicABSP. (A) 
B.pseudomallei hetero-
octamer of HicAB where 
HicB subunits are arranged 
in a symmetrical manner. 
(B) S. pneumoniae HicAB 
hetero-octamer (PDB: 
5YRZ) where C-terminal 
domains lie parallel to each 
other. For both structures 
HicB subunits are 
highlighted in blue/light 
red/ green/ yellow and 
HicA subunits in red. (C) 
Superimposition of HicBSP 
(dark grey) to HicB (blue) 
over the carbon backbone 
(RMSD: 2.8 Å). (D) 
Superimposition of the 
HicBSP tetramer (dark grey) 
to the elongated 
conformation of HicB over 
the C backbone (RMSD: 
6.3 Å). 
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The C-terminal strand-swapped dimers of HicBSP within HicABSP, are organised parallel to 
each other, rather than facing inwards as observed in HicB, within HicAB (Figure 3.13). 
Inspection of the surface exposed charge suggests that a concerted patch of positive charge at 
the C-terminal domain was visible despite complexation with HicASP (Figure 3.13A). Within 
HicB, this patch had been disrupted due to C-terminal domain rotation upon HicA binding 
(Figure 3.13B). As the structure of HicBSP in the unbound form is unknown, it is not possible 
to determine precisely which rearrangements have occurred as a consequence of HicASP 
binding.  
 
Figure 3.13. Charge distribution of HicABSP and HicAB. (A)  Cartoon and surface representation of HicABSP 
showing clustering of positive charge on one face mapped to the C-terminal RHH domains of HicBSP. (B) 
Cartoon and surface representation of HicAB highlighting the positively charged patch mapped to the C-
terminal RHH domain HicAB. For both images, regions of positive, negative and no charge are coloured blue, 
red and white respectively. HicASP/HicA is represented as grey to emphasize the surface charge of HicBSP/HicB. 
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3.4.  Biophysical techniques 
To further probe the HicA4HicB4 stoichiometry observed by crystallography, HicAB 
(preformed at a 1:1 ratio of HicA:HicB, HicA (500 M): HicB (500 M)) was analysed by 
SAXS (Figure 3.14, Appendix Figure 18, Appendix Table 18). The bulk of the resultant ab 
initio shape envelope appeared to be derived from the symmetrical conformation of HicB 
(Figure 3.14A, 
2
=2.89) rather than the unbound conformation (Figure 3.13B, 
2
=8.94) 
(Figure 2.20). This suggested the symmetrical conformation of HicAB is not simply a crystal 
artefact and formation of the symmetrical HicB tetramer can be observed in solution.  
 
Figure 3.14. SAXS shape envelope of 
HicAB. (A) Ab initio modelling of the 
heterotetrameric HicB component of 
the HicAB complex into the shape 
envelope of HicAB (white). The FoXS 
profile of the proposed scattering 
profile for a HicAB heterotetramer 
(red) against the experimental raw 
scattering data (black) (
2
=2.89). (B) 
Ab initio modelling of the HicB 
tetramer into the shape envelope of 
HicAB (white). The FoXS profile of 
the proposed scattering profile for 
tetrameric HicB (red) against the 





Figure 3.15. Distinguishing between 
complexes of HicAB. (A) Ab initio 
modelling of the HicA2HicB4 complex 
into the shape envelope of HicAB 
(white). The FoXS profile of the 
proposed scattering profile for the 
HicA2HicB4 heterotetramer (red) 
against the experimental raw scattering 
data (black) (
2
=2.45). (B) Ab initio 
modelling of the HicA4HicB4 complex 
into the shape envelope of HicAB 
(white). The FoXS profile of the 
proposed scattering profile for 
tetrameric HicA4HicB4 (red) against 
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SAXS shape envelope suggested that the HicA2HicB4 complex formed by removing two 
HicA molecules from the HicAB crystal structure (Figure 3.15A, 
2
=2.45) was formed over 
the HicA4HicB4 complex (Figure 3.15B, 
2
=8.23). Attempts to fit the HicA4HicB4 complex 
were poor due to a single HicA molecule failing to fit within the shape envelope, despite the 
apparent fit of a structure where all 1 helices are surface exposed. This resulted in the high 
observed 
2 
(8.23) for this complex. The HicABSP conformation did not agree with the 
experimental SAXS data (Appendix Figure 19). 
SVAUC indicated the presence of a single oligomeric species for both HicB (Figure 3.16A, 
Materials and Methods, equation (2-6)) and HicAB (preformed at a HicA: HicB ratio = 0.5:1) 
(Figure 3.16B) with calculated molecular weights of 62.4 kDa and 68 kDa equivalent to 0.99 
x tetrameric HicB (62.9 kDa) and 0.97 x HicA1HicB4 (70 kDa). As SVAUC reports on an 
inferred molecular weight based off experimentally derived Sedimentation and Diffusion 
values 
337-339
, SEAUC was performed for HicAB (preformed at a HicA: HicB ratio = 0.5:1, 
Materials and Methods) as this directly reports on the molecular mass (Figure 3.16C).
340, 341
 
Modelling a single species of HicAB (equation (7)), inferred by SVAUC, reported a 
calculated mass of 77.6 kDa (95% confidence interval + 1.3 – 1.4 kDa) equivalent to 1.07 x 
HicA2HicB4 (77 kDa).  
Figure 3.16. AUC of HicB and HicAB. (A) SV AUC for HicB (70M) and HicA2HicB4 (50 M) preformed at 
a HicA: HicB ratio of 0.5:1. Experimental scans (symbols) and best fit models (solid lines) for HicB at 50,000 
rpm, 20 °C. For clarity only every 4th scan is shown. The lower panel shows best fit residuals of the plotted 
scans. (Bottom) Continuous size (C(s)) distribution fit for HicB.
338, 341
 The peak S value in this fit is 3.99 S with 
a frictional ratio of 1.31 and a molecular weight of 62,375 Da. (B) Experimental scans (symbols) and best fit 
models (solid lines) for HicAB at 50,000 rpm, 20 °C. For clarity only every 4th scan is shown. The lower panel 
shows best fit residuals of the plotted scans. (Bottom) Continuous size (C(s)) distribution fit for HicAB. The 
peak S value in this fit is 4.33 S with a frictional ratio of 1.286 and a molecular weight of 68,000 Da. The 
RMSD for both for HicB and for HicAB was 0.009. (C) SEAUC for HicA2HicB4 (20 M), preformed at a 
HicA:HicB ratio of 0.5:1. The experimental data (top, open circles) and fits (lines) to a single ideal species 
(equation (7), residuals (bottom) between the experimental and filled data points are seen for 15k rpm (red), 17k 
rpm (blue) and 19k rpm (green). Data was recorded at 20 °C, 280 nm.  
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The HicA4HicB4 hetero-octamer was observed by native mass spectrometry (Materials and 
Methods, Figure 3.17)
342, 343
, as well as free HicB components and sub-stoichiometric 
complexes of HicAB (HicB2, HicB4, HicA1-HicB4 and HicA2-HicB4).  
 
Figure 3.17. Native mass spectrometry of HicA4HicB4. Native mass spectrometry of HicB within the region 
2500-3800 m/z with oligomeric states: dimeric (black) and tetrameric (blue) highlighted based on their charge 
state value. (D) Native mass spectrometry of HicAB (preformed at a ratio of HicA: HicB = 1:1) within the 
region 2450-3850 m/z with oligomeric states of HicB2 (black), HicB4 (blue) HicA1-HicB4 (green), HicA2-HicB4 
(red) and HicA4-HicB4 (purple) highlighted.  
In agreement with SEC-MALS data for HicA3B3 reported by Bibi-Triki (HicA32HicB34)
132
, 
SEAUC confirms that Burkholderia HicAB forms a HicA2-HicB4 complex with SEC-SAXS 
suggesting that HicB adopts a symmetrical conformation within this complex, where each 1 
helix is surface exposed. The HicA4-HicB4 hetero-octamer is observed within native mass 
spectrometry suggesting it is a significant conformation and not simply a crystal artefact. It is 
hypothesized that initial binding of HicA forms a HicA2HicB4 complex, further exposing two 
1 helices (Subunits 1 and 4). Exposure of these sites ensures HicB can fully neutralise HicA 
at equimolar concentrations. However, in vivo it is unlikely to be as simple as this. HicB is 
flexible and can adopt several conformations in the absence of DNA. The dual ability to bind 
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3.5.  Summary 
Formation of the symmetrical HicAB complex, requires the reorganisation of tethering 
interactions between adjacent HicB subunits. The electrostatic interactions that tethered the 
1 helix of subunit 1 and 4 to the adjacent C-terminal domain within the unbound form are 
broken due to the interaction with HicA due to subunit 1 and 4 flipping their 1 helix to an 
exposed orientation. The consequence of HicA interaction is the rotation of the C-terminal 
domains to prevent steric clashes between HicA and HicB subunits. Steric clashes had 
previously been noted between Yersinia HicA3 and HicB3 in a proposed HicA34HicB34 
complex. As tethering interactions and the orientation of 1 helices within the HicB/HicB3 
tetramer are conserved, it is hypothesized that this phenomenon of C-terminal rotation upon 
toxin complexation might be a general feature of HicAB yet surprisingly the Streptococcus 
HicAB complex did not capture this and a complex resembling a compact conformation was 
reported with HicA being accommodated by longer connecting loops between the N- and C-
domains. However, the absence of tethering interactions in the crystal structure of HicAB 
suggests that this form is a snapshot within an array of different HicAB conformations as 
these free C-terminal domains will flex in solution, possibly to an open state observed for 
Burkholderia HicAB. 
  




Wavelength (Å) 0.9795 
Resolution range 
(Å)  
34.02 – 2.49 
(2.58-2.49) 
Space group P21 
Unit cell  
85.1 72.2 85.3Å 
90 90.1 90° 
Multiplicity 6.8 (6.8) 
Completeness (%) 99.9 (99.8) 
Mean I/σ(I) 14.1 (1.4) 
Wilson B-factor (Å
2
)  70 
Rmeas 0.12 (1.23) 
CC1/2 0.998 (0.692) 
Reflections used in 
refinement 
35696 
Rwork 0.181 (0.330) 
Rfree 0.220 (0.375) 
Number of protein 
atoms 
6272 
RMS (bonds) (Å) 0.034 






















Table 3.1. Final refinement statistics for HicAB. Parenthesis refer to statistics for the high resolution shell 
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4.  DNA binding of HicB  
TA systems are able to bind sequences of DNA within their promoter regions via DNA 
binding domains and this has been investigated for HicB homologues in E. coli, S. 
pneumoniae and Y. pestis.
131, 132, 272
 However, there is no structural or functional data on 
DNA binding properties of B. pseudomallei HicB and the presence or identity of the DNA 
binding motif(s) upstream of this hicAB operon have not been established. This chapter 
focuses on the identification of a DNA binding site for HicB upstream of the hicAB operon 
and the structure-function relationships for this protein-DNA interaction. 
4.1.  Identification of the DNA binding site 
A series of oligomers and electrophoretic mobility shift assays (EMSA) were used to 
determine if HicB bound to the intergenic region (279 bp) immediately upstream of the 
hicAB operon. The intergenic region was initially dissected into 48 bp double stranded 
fragments to individually investigate the -10 and -35 promoter elements and the sequences 
encompassing these. Bioinformatic searches for palindromic sequences/inverted repeats 
revealed that the 0-48 bp fragment was the most promising candidate when compared to the 
other five fragments analysed (Table 4.1).
344, 345
 This fragment contained a likely -10 
TATAAT Pribnow box
346





). Where possible a complete potential binding site was maintained to 
prevent accidental disruption of an intact binding site during fragmentation of the intergenic 
region. 
DNA Segment Sequence 
0-48 5’ 5’-GATCGTGATTGGATGTGTATAATTACACACAAGACATTCGGGGGAGCT-3’ 
0-48 3’ 5’-CTAGCACTAACCTACACATATTAATGTGTGTTCTGTAAGCCCCCTCGA-3’ 
48-96 5’ 5’-ATAGGGGCGAAACAATGTGAAAATACGCACGGCTACACAAAACTTGAG-3’ 
48-96 3’ 5’-TATCCCCGCTTTGTTACACTTTTATGCGTGCCGATGTGTTTTGAACAC-3’ 
96-144 5’ 5’-TCGAGGCCGCGCGCGATGCTTCAGTCTTGCCCAGCGGACGGGATAAAA-3’ 
96-144 3’ 5’-AGCTCCGGCGCGCGCTACGAAGTCAGAACGGGTCGCCTGCCCTATTTT-3’ 
144-192 5’ 5’-GCCGCCCGCTGGCGGCAGATTACGACGAGTGGCTACACACGAGGAATG-3’ 
144-192 3’ 5’-CGGCGGGCGACCGCCGTCTAATGCTGCTCACCGATGTGTGCTCCTTAC-3’ 
192-240 5’ 5’-GTGCCGAATAAGGGTAACTATCCTGTCAATGTTGACGGGCAAGAGGTG-3’ 
192-240 3’ 5’-CACGGCTTATTCCCATTGATAGGACAGTTACAACTGCCCGTTCTCCAG-3’ 
240-279 5’ 5’-GCCGAATCCTCAGTGGAAAATCCGCGAGGA-3’ 
240-279 3’ 5’-CGGCTTAGGAGTCACCTTTTAGGCGCTCCT-3’ 
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Table 4.1. Sequences of oligonucleotides used to determine the HicB binding site.  The predicted -10 
(Red underlined) and -35 promoter elements (blue, underlined) within the 0-48 and 48-96 bp double 
stranded DNA fragments are highlighted. 
A clear shift in DNA migration upon the addition of tetrameric HicB (HicBT), indicative of a 
protein-DNA complex, was only observed for the 0-48 bp DNA fragment and not for the 
other five fragments analysed (Figure 4.1A). EMSA was performed with HicBT (3.2 µM) and 
each DNA fragment (3.0 µM) and complete binding of 0-48 bp DNA under these conditions 
suggested a 1:1 stoichiometry (assuming intact tetramer). For each fragment, a weak band 
was observed with a slower migration time than the free DNA, irrespective of the presence of 
HicBT (Figure 4.1A, all lanes). It is hypothesized that upon formation of the double stranded 
DNA fragments (see Materials and Methods), a small proportion of free 5’ and 3’ DNA 
strands mis-annealed to form a higher order molecular weight complex, which would explain 
the presence of this band. This was observed for several other sequences described in this 
chapter (see Appendix Table 4, where sequences that displayed this additional band within 
EMSA assays are marked with an asterix (*)). Subsequent dissection of the 0-48 bp region 
initially revealed that the first forty nucleotides were sufficient for complete DNA binding 
(Figure 4.1B). Further dissection then determined that the DNA binding motif that HicB 
bound was located within a fragment spanning 17-36 bp upstream of the hicAB operon 
(Figure 4.1C). This DNA fragment also appeared to display an additional DNA band at high 
DNA concentrations (Appendix Figure 20) as observed for other DNA fragments. 
 
Figure 4.1. EMSA of DNA binding to HicB. (A) EMSA investigating individual fragments of the intergenic 
region of DNA upstream of the hicAB operon. (B) EMSA probing the DNA binding site of HicBT within the 0-
48 bp region. Within the DNA fragment 0-40 binding experiment the presence of unannealed single stranded 
DNA is observed at a lower migration than the free dsDNA. (C) EMSA probing the DNA binding site to 
identify the sequence of interest as 17-36 bp. 






-3’ contained an inverted repeat 








 (Figure 4.2A). Removal 




 abolished binding. Hereon in the 
hypothesized promoter site for the hicAB operon will be referred to as S1-2 DNA. This 











) (Figure 4.2). Binding of HicBT to S1-2 DNA was dependent on the 
presence of both intact S1 and S2 sites: individual base substitutions within either S1: 
ACACA to AGGGA (termed MS1) or S2: TGTGT to TCCCT (MS2) abolished binding of 
HicBT, when compared to the native S1-S2 sequence (Figure 4.2B). This finding was 
reinforced by earlier assays (Figure 4.1B) as DNA sequences bearing only the S1 sequence 
(0-30/35) or the S2 sequence (20-36/40) did not bind HicB at the concentrations tested. HicB-
NT, which lacks the RHH motif, did not bind S1-2 DNA at concentrations where full 
complexation was observed for HicBT confirming that the C-terminal domains were 
necessary for DNA binding (Figure 4.2C). 
 
Figure 4.2. Overview of HicB binding to S1-2. (A) Overview of the hicAB operon, the inverted repeat 
sequence within the upstream region of hicAB that binds DNA: S1 and S2 are highlighted in red and blue. The 
putative -10, -35, CRP binding site and SD sequence (SD*) are also highlighted. (B) Mutations within S1-2 (2 
µM) at either S1 or S2 abolishes binding to HicB (3.2 µM). (C) EMSA of HicBT and HicB-NTD (0-3.2 µM) 
binding to 2 µM S1-2. DNA self-dimers were present in each lane regardless of the presence of HicB-NTD. 
4.2.  Comparison to other HicAB operator sequences 
The Y. pestis homologue HicB3 and the HicA3B3 complex (HicA32HicB34 confirmed by 
SEC-MALS) were reported to bind two operator regions of DNA (BS1 and BS2) 
immediately upstream of the Shine Dalgarno sequence (SD) resulting in transcriptional 
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inhibition of the phicA3B3 operon (Figure 4.3A).
132
 Each operator contains a 15 bp inverted 
repeat bearing two half sites: GGTA-N5-CCTA (BS1) and ATCC-N6-ATGG (BS2) (Figure 
4.3A, underlined in red). Individual mutations of either BS1 or BS2 were tolerated however 
mutation of both sites prevented DNA binding by HicB3 and transcriptional repression was 
not observed. BS2, which overlaps the -10 promoter region was subsequently confirmed as 
the main operator site for hicA3B3 transcription.
132
  
Based on EMSA experiments  (Fig 4a
132
) Bibi-Triki et al. showed that both operator sites are 
individually occupied by HicB3 tetramers in a concentration dependent manner, indicating 
that there is broad specificity within the HicB3 RHH domains as they recognise two different 
sequences in BS1 and BS2, adding a layer of complexity to transcriptional regulation. There 
is a possibility that HicB3T binds exclusively to the sequence GGTA-N5-CCTA, found in 
BS1 and the reverse complement of BS2 as ATCC-N6-ATGG, and Bibi-Triki et al. suggest 
that each HicB3T recognises a TRGGTRT half-site, suggesting that there must be sequence 
plasticity in the sequence recognition by HicB3T. In comparison, the sequences of S1 and S2 
found in the B. pseudomallei putative promoter site for hicAB are equivalent; the reverse 
complement of TGTGT is ACACA. It is predicted that each RHH strand-swapped dimer, of 
which there are two in HicB, each individually bind to a single site (S1 and S2). This is to 
ensure that the HicB tetramer is coordinated in a tight complex and is highly specific to the 
S1-2 sequence. The organisation of S1-S2 is similar to the BS2 site of phicA3B3, the main 
operator site for hicA3B3 expression.
132
 There is no equivalent of BS1 within the upstream 
region of B. pseudomallei hicAB, and the S1-2 site is the only site where HicB binding is 
observed. The upstream intergenic region (279 bp) does not appear contain any other 
operator sites, based on EMSA observations (Figure 4.1A). 
The E. coli immediate intergenic region upstream of hicAB contains two promoter sites: P1 
and P2 (Figure 4.3B).
214
 P1 is under the control of both CRP-cAMP and Sxy resulting in 
transcription of the full hicAB operon. In contrast P2 contains one inverted repeat sequence 
termed hic0.  This overlaps the -35 promoter element within pHicAB and is specifically 
regulated by HicB resulting in transcriptional repression of the hicAB operon. Mutation of the 
inverted repeat (TAAACA-N4-TGTTTACTT to TGGACA-N4-TGGGACTT) abolished 
HicB binding and therefore transcriptional repression of the operon. hic0 therefore shows 
similarities to the Burkholderia hicAB S1-2 site.
214
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S. pneumoniae HicB was reported to recognise a 28 bp sequence upstream of the hicAB 
operator (Figure 4.3C). However the specific sub-sites that HicBSP binds and mutational 
studies on this DNA sequence have not been reported. Bioinformatic analysis suggests that 
this sequence contains an imperfect inverted repeat sequence (Table 4.2), which overlaps a 
predicted -10 Pribnow box
344
, although it is uncertain if this DNA sequence controls 
transcription of the hicABSP operon or if multiple operator sequence regulate this operon.
272
 








Table 4.2. The operator site for each HicB family member interaction site with sites of interest 
highlighted. (*) The half sites for S. pneumoniae are predicted by bioinformatics analysis and these have not 
been experimentally confirmed via EMSA/LacZ assays. 
 
Figure 4.3. Genetic organisation of HicA3B3, HicAB and HicABSP from Y. pestis, E. coli and S. 
pneumoniae. (A) The Y. pestis hicA3B3 operon with the elements within phicA3B3: the inverted repeats BS1 
and BS2 are highlighted (arrows) with the conserved GGTA (red) and CCTA (blue) sequences within the 
TRGGTRT half sites highlighted. The -10, -35 and the SD sequence are highlighted (underlined). (B) The E. 
coli  hicAB operon with two promoters P1, controlled by CRP-S (CRP-cAMP and Sxy)(green) and P2, 
controlled by HicB binding via the hicO inverted repeat sequence. Half sites within the inverted repeat (hicO) 
are marked by arrows and individually highlighted (red/blue). The -10 and -35 sequence for each promoter (P1 
and P2) are underlined and the SD sequence and initiator codon of HicA are highlighted. (C) The S. pneumoniae 
hicAB putative operator site. The 28 bp binding site is highlighted (green). The putative inverted repear half 
sites are highlighted (red/blue, arrows). The putative -10 sequence is highlighted (underlined) and the ATG start 
codon of HicASP. 
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4.3.  Fluorescence anisotropy Kd determination 
Anisotropy is the ratio of the polarised components of light: parallel and perpendicular to the 
excitation plane (III and I⊥) to the total intensity (Itot) (Materials and Methods, Equation (8)). 
Free fluorescent ligands have a low anisotropy value as they rapidly tumble, emitting 
randomly polarised light.
347
 DNA binding results in a higher order complex, with a greater 
molecular volume when compared to the free ligand. The tumbling of the fluorescent ligand 
decreases as it acquires the larger correlation time of the slowly tumbling protein and light is 
predominantly emitted along one axis this leads to the emission of polarised light, resulting in 











Fluorescence anisotropy was used to quantify the binding interaction between HicB and 
fluorescently labelled DNA (HEX-S1-2) and an adapted variant of the Morrison tight binding 
equation was used to extract the dissociation constant Kd 
349-352
 (Materials and Methods, 
Equation (9)). 
 
Y=  (ADP- AD) (
[X]+ Kd+ n ± √([X]+ n + Kd)
2-(4[X]n)
2n
) +  𝐴𝐷 (9) 
Where Y is the anisotropy value, AD is the response (anisotropy) in the absence of protein 
[X], while ADP is the maximal response (anisotropy) of a protein-DNA complex. n refers to 
the stoichiometry of the reaction which was assumed to be a single site mode of action. 
HicBT bound DNA with a calculated Kd of 3 ± 0.4 nM (95% confidence interval = 2. - 4 nM) 
(Figure 4.4.A). This Kd value should be regarded as an upper limit because the binding is too 
tight to accurately measure at the probe concentration used in experiments (7.5 nM). 
Simulations of Kd values (0.75 – 3 nM) for HicB-HEX-S1-2 revealed no discernible 
difference between the simulated dose response curves aside from the 0.75 nM simulated 
curve, which did not fit the experimental data (Figure 4.4.B). This Kd was much tighter than 
the equivalent Kd values of 300 nM and 8 M reported for the HicAB systems within E. coli 
and S. pneumoniae.
132, 272
 The stoichiometry was deemed to be one (HicBT binds to one 
4.  DNA binding of HicB  4.4. Probing the HicB DNA binding site 
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HEX-S1-2 DNA) based on simulation of the stoichiometry value. When the Kd was fixed at 
its experimentally determined value (3 nM), the stoichiometry was approximated as 0.973 ± 
0.04 using equation (9). This provided evidence that one tetramer binds both S1 and S2 sites 
simultaneously, as previously hypothesized and is in agreement with similar observations 
reported in S. pneumoniae and Y. pestis.
132, 272
 As observed by EMSA, increasing 
concentrations of HicB-NTD does not result in a substantial change in anisotropy, indicative 
of DNA binding, even at concentrations where HicBT elicited a maximum response (150 nM) 
(Figure 4.4C). 
 
Figure 4.4. Fluorescence anisotropy experiments of HicB and HicB-NT to HEX-S1-S2. (A) Quantification 
of HicB binding to HEX-S1-2. Samples contained 7.5 nM HEX-S1-2 in DNA binding buffer. The proportion of 
HEX-S1-2 bound by increasing concentration of HicB was followed (n=1). (B) The Kd of HicB-HEX-S1-2 were 
simulated to determine appropriate values that described the experimental data seen in panel A. (C) 
Quantification of HicB-NT binding to HEX-S1-2. The proportion of HEX-S1-2 bound by varying 
concentrations of HicB-NT was followed (n=1). For all experiments three independent fits were fit to equation 
(9) and the mean value is plotted with error bars representing the SEM. Standard errors of Kd values were 
calculated in GraphPad Prism. 
 
4.4.  Probing the HicB DNA binding site 
To determine how HicB may bind DNA, the exposed surface charge of B. psuedomallei HicB 
was investigated (Figure 4.5A, B). A patch of positively charged amino acids were identified 
on one face of the tetramer, corresponding to the RHH motif of each subunit and included the 
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Figure 4.5.  Analysis of the surface charge distribution of HicB. (A) Positively charged patch (blue) of HicB 
formed by R94, N96 and S98 in the 5 strand. This -sheet lies flat across the structure due to the parallel nature 
of the C-terminal strand swapped dimers. (B) 90 ° rotation to further highlight the patch of positive charge.  
Superimposition of HicB to structurally similar well characterised proteins that bear an RHH 
domain (and antitoxins that contain a RHH motif) (Appendix Table 10) indicated the 
structural conservation of R94, N96 and S98 (Appendix Figure 21). The equivalent amino 
acids encoded in these structurally similar proteins have been demonstrated to form protein–
DNA interactions.
83, 142, 228, 312, 313, 315, 316
  Equivalent amino acids to R94, N96 and S98 were 
observed in Yersinia HicB3 (K95, N97 and T99), but not Escherichia HicB, which encodes a 
HTH rather than a RHH, where no sequence conservation was observed (Appendix Figure 
22). Residues within these HicB homologues have not been mutated to investigate their effect 
on DNA binding. 
Alignment of HicB to 44 homologous HicB antitoxins (Appendix Figure 23) revealed 
conservation of R94, N96 and S98 within the 5 strand of the C-terminal domain within 
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Figure 4.6. A Web logo
334
 generated graphic 
depicting the conservation of amino acids at the 
5 strand of HicB when aligned to 44 homologous 
HicB sequences using Clustal Omega
291
. The 
amino acid sequence of the 5 strand of HicB is 
highlighted underneath to indicate the strong 
conservation of polar and hydrophobic residues 
among HicB family members. 
 
 
To investigate the role of these residues further, genes containing HicB encoding specific 
alanine mutations (R94A, N96A, R94N96A and S98A) and semi-conservative mutants 
(R94E, N96Q and S98T) were designed. Alanine mutants and N96Q were synthesized by 
ThermoFisher
TM
 and subcloned into the pOPINE vector (Mutant Primer 1 and 2, Appendix 
Table 4). R94E and S98T constructs were generated by PCR site-directed mutagenesis from 
pOPINE-HicB-R94/S98A constructs (R94E and S98T primer 1 and 2, Appendix Table 4). 
All mutants were individually expressed in T7 express cells (NEB) and were purified by 
IMAC and SEC, with the following yields: R94A (20 mg/L), R94E (25 mg/L) N96A (3 
mg/L), N96Q (23 mg/L) R94AN96A (2.5 mg/L), S98A (20 mg/L) and S98T (22 mg/L). 
Each purified HicB mutant (Appendix Figure 24, 25) was soluble and denatured ESMS 
confirmed the presence of each mutation (Appendix Figure 26). Deconvolution of each m/z 
envelope revealed a single species for each protein: R94A (observed 15,654, expected: 
15,653 Da), R94E (observed: 15,711, expected: 15,711 Da) N96A (observed: 15,694, 
expected: 15,695 Da), N96Q (observed: 15,751, expected: 15,752 Da), R94AN96A 
(observed: 15,609, expected: 15,610 Da), S99A (observed 15,721 Da, expected: 15,722 Da) 
and S99T (observed 15,751 Da, expected: 15,752 Da).  
Native mass spectrometry confirmed that each mutant formed a tetrameric species (Appendix 
Figure 27, 28). Interestingly, additional charge states were observed between 3,000-4,500 
m/z for the N96A and R94AN96A mutants. These could not be assigned as monomeric, 
dimeric, tetrameric or octameric charge states and are believed to be aggregates formed in 
ammonium acetate during sample preparation. These additional states were not observed in 
R94A, R94E or N96Q suggesting that conservative changes have less impact on the structure 
of the tetramer.  
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ASEC (AS75) was also used to determine the oligomeric state of each mutant (50 M, 
[HicBT] was 12.5 M) (Figure 4.7). With the exception of N96A and R94AN96A, each 
mutant gave a similar profile to the HicB tetramer (Figure 4.7A, black). N96A (Figure 4.7A, 
blue) eluted as a single species with a Mwapp of 85.9 kDa (42.7-104.6 kDa) and the elution 
profile overlapped the profile of blue dextran (Figure 4.7A, purple) which is indicative of a 
species larger than the separation size of the column (75 kDa).  R94AN96A (Figure 4.7A, 
cyan) eluted as two species, one with a Mwapp of 71.6 kDa (66.3-95.5), which overlapped the 
blue dextran profile and the other with an Mwapp of 60.4 kDa (40.9-65.4), which overlapped 
the profile of HicB. The dual species associated with R94AN96A were not observed by SEC 
on a preperative S75 column during initial purification, although it is likely that this column 
lacked the resolution to distinguish the two peaks. Complexation of each mutant with HicA at 
a 1:1 ratio (50 M HicB (HicBT =12.5 M):50 M HicA) determined that each mutant 
retained the ability to bind HicA due to the complete loss of the HicA peak, previously 
observed for the HicAB complex, although a peak shift for each HicB mutant was not 
observed (Figure 4.7B). This suggested that the N-terminal domain remained intact and any 
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Sample Mw (Da) Mwapp (kDa) Mw range (kDa) Log10Mw Ve (ml) Kav 
HicB 62,952 65.6 52.3-76.5 1.82 9.03 0.11 
R94A 62,612 56.3 43.2-77.2 1.75 9.43 0.14 
R94E 62,952 65.6 52.3-76. 5 1.82 9.03 0.11 
N96A 62,780 85. 9 47.7-104.6 1.93 8.32 0.07 
N96Q 63,008 57.5 47.08-69.3 1.76 9.38 0.13 
R94AN96A 62,436 71.6/60.4 66.3-95.5/ 40.9-
65.4 
 1.85/ 1.78 8.8/ 9.25 0.10/ 
0.13 
S98A 62,888 55.5 40.9-81.1 1.85 9.47 0.10 
S98T 63,008 56.5 46.6-68.9 1.75 9.44 0.14 
Figure 4.7. Analytical size exclusion profiles of HicB DNA binding mutants. (A) SEC profiles for all HicB 
mutants: HicB (black), R94A (red), R94E (pink), N96A (blue), N96Q (light blue), R94AN96A (cyan), S99A 
(green) and S99T (light green). Blue dextran (purple) is shown to indicate the void volume of the column (B) 
SEC profiles of HicB mutants complexed with HicA. Traces are highlighted as per panel A with HicA (brown) 
added. (C) Summary of results for each analysed sample reporting the expected molecular weight (Mw), Mwapp, 
Range of molecular weight values encompassed by each peak, Log10 Mw, Ve (Volume of elution) and Kav 
(Partition coefficient) determined by the calibration curve. The calibration curve can be seen in Figure 3.2B. 
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The DNA binding ability of each mutant was assayed using EMSA (Figure 4.8). To minimise 
the presence of concentration-dependent aggregation, protein samples used within this assay 
were not concentrated following SEC. R94A, N96A, R94A/N96A and S98A were unable to 
bind S1-2 (2 M) at concentrations where full complexation of S1-2 by HicBT was observed 
(3.2 µM) (Figure 4.8A-D). Increasing the protein concentration of R94A and S98A to 250 
M also did not result in a band shift (Appendix Figure 29). N96A and R94AN96A could not 
be assayed at these concentrations due to the low yields associated with their purification. 
R94E and N96Q did not bind S1-2 (2 M) at concentrations where a HicB-S1-2 complex was 
observed (HicBT = 3.2 M) (Figure 4.8E, F). In contrast S98T caused notable DNA smearing 
at concentrations greater than 1.6 M with a faint band seen at 3.2 M (Figure 4.8G, circled). 
The smearing suggested the ability to bind DNA, albeit at a lower affinity, forming protein-
DNA complexes that were labile and dissociated during electrophoresis.
353, 354
  
At high concentrations (250 M) smearing was also observed for N96Q, but no discrete band 
could be observed for either N96Q or S98T (Figure 4.8H). R94E showed no smearing and 
therefore any observable DNA interactions, consistent with the complete charge reversal at 
this site. 
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Figure 4.8. EMSA of HicB mutants involved in the DNA binding site. (A) EMSA of HicBT and HicBT-R94A 
(0-3.2 µM) binding to 2 µM S1-2. (B) EMSA of HicBT and HicBT-N96A (0-3.2 µM) binding to 2 µM S1-2. (C) 
EMSA of HicBT and HicBT-S98A (0-3.2 µM) binding to 2 µM S1-2. (D) EMSA of HicBT and HicBT-
R94AN96A (0-3.2 µM) binding to 2 µM S1-2. (E) EMSA of HicBT and HicBT-R94E (0-3.2 µM) binding to 2 
µM S1-2. (F) EMSA of HicBT and HicBT-N96Q (0-3.2 µM) binding to 2 µM S1-2. (G) EMSA of HicBT and 
HicBT-S98T (0-3.2 µM) binding to 2 µM S1-2. (H) EMSA of HicBT and each semi conservative mutant (250 
M) against 2 µM S1-2. 
To quantitatively determine the effect of individual mutations to the 5 strand, FA was used 
to determine Kd values for each semi-conservative mutant (Figure 4.9). Alanine mutants were 
not investigated as no binding was observed even at 250 M for R94A and S98A. A Kd value 
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could not be determined for R94E as there was no observed increase in anisotropy upon 
increasing concentrations of R94E (0-1000 nM) (Figure 4.9A). N96Q gave a Kd value of 296 
± 32 nM (95% confidence interval = 231 – 376 nM), a ~ 100-fold reduction compared to 
HicB (Figure 4.9B) whereas S98T displayed a Kd of 94 ± 8 nM (95% confidence interval = 
79.-112 nM), an ~ 30-fold reduction when compared to HicB (Figure 4.9C). This correlated 
with EMSA observations as S98T displayed DNA binding at lower concentrations (3.2 M) 
than N96Q, although as HicB DNA mutants do not appear to tightly bind S1-2 DNA, these 
Kd values are likely to be underestimation of the true value. 
 
Figure 4.9. Fluorescence anisotropy experiments of HicB-R94E, N96Q and S98T.  (A) Quantification of 
R94E binding to HEX-S1-2. (B) Quantification of N96Q binding to HEX-S1-2. (C) Quantification of S98T 
binding to HEX-S1-2. For each experiment, for 3 independent repeats (n =1). Data were fit to equation (9).  The 
mean value is plotted with error bars representing the SEM. Standard errors of Kd values were calculated in 
GraphPad Prism. 
The loss of DNA binding observed for HicB constructs containing N96 alanine mutants 
might arise mainly from structural effects on HicB. Within the strand-swapped dimer of HicB 
adjacent N96 residues are tethered together via a side chain-side chain hydrogen bond and are 
capable of forming a hydrogen bond with the side chain of R94 (Figure 2.15). Removal of 
N96 may diminish this network and the additional removal of R94 (R94AN96A) may further 
destabilize HicB, perhaps explaining the much lower yield associated with the R94AN96A 
mutant due to possible misfolding and instability. Closer analysis of the 5 strand reveals that 
R94, N96 and S98 (Figure 4.10A, B, grey) are flanked by hydrophobic residues (Figure 4.10, 
A, B, red). Mutation of either R94 or N96 to an alanine residue, or both, would increase the 
hydrophobicity of this region (Figure 4.10C). In the case of the double mutant (R94A, 
N96A), introduction of an alanine at both positions leads to a distinct hydrophobic patch 
across the 5 strand spanning 12 Å (Figure 4.10D), where S98 is the only remaining polar 
residue. Such a large patch could promote structural rearrangements to bury the surface 
exposed hydrophobic patch or create a sticky patch leading to aggregation. In comparison 
these hydrophobic patches are unlikely to be present in the R94E, N96Q and S98T mutants. 
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SAXS confirmed the presence of shape perturbations for alanine mutants but not semi-
conservative mutants, when compared to HicB (Appendix Figure 30-32, Appendix Table 19-
20). High-resolution structures of each mutant are required to confirm this hypothesis.
355-357
 
Each mutant was screened at 500 M (HicBT = 125 M) and 1,000 M (HicBT = 250 M) 
against commercially available Molecular Dimensions screens (Morpheus, Proplex, JSCG+ 
and Structure Screen I + II). To date no crystals have formed in any conditions for any 
alanine mutants and it appears their surface entropy differs from HicB (Appendix Figure 33). 
Crystals of R94E, N96Q and S98T formed in identical conditions to HicB (0.1 M NaOAc, 
pH 4.6 8% (w/v) PEG 4000, 10% (v/v) glycerol), but these have not yet been analysed due to 
a lack of beamline time. 
 
Figure 4.10. Hydrophobic analysis of HicB. (A) Location of the targeted amino acids: R94, N96 and S98 in 
the β5 ribbon-helix-helix. (B) Surface of the β5 strand with R94, N96 and S98 highlighted in grey while the 
hydrophobic residues (I95, V97 and I99) are highlighted in red. (C) The hydrophobic patch produced when N96 
is mutated to alanine. (D) Hydrophobic patch now surface exposed when both R94 and N96 are mutated to 
alanine. 
4.5.  HicB-DNA modelling 
SEC-SAXS was first used to investigate the HicB-S1-2 complex, preformed at a 1:1.6 ratio 
(HicBT: 300 M: S1-2: 500 M) (Appendix Table 21, Appendix Figure 34) but initial ab 
initio modelling of a HicB-S1-2 complex was unsuccessful (data not shown). However, an ab 
initio shape envelope was obtained for free S1-2 DNA (Figure 4.11A). A S1-2 DNA model 
was built by 3D dart
358
 and superimposed onto the ab initio shape envelope which indicated 
that free S1-2 DNA was bent and the distance between the S1 and S2 sites was 37/38 Å 
within the 5’ and 3’ strand (Figure 4.11A). Within free HicB, the distance between the 
adjacent RHH domains is 32 Å and this distance increases by 44 Å in the HicAB complex 
(Figure 4.11B, C), suggesting that only free HicB can bind S1-2. 
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Figure 4.11. Distance between DNA binding sites. (A) Model of S1-2 DNA superimposed onto an ab inito 
shape envelope of S1-2 DNA. Here the half sites (S1/S2) of the inverted repeat are separated by 33/37 Å. (B) 
Cartoon representation of free HicB highlighting the distance between adjacent RHH domains. (C) Cartoon 
representation of HicAB highlighting the distance between adjacent RHH domains. For clarity S1 and S2 
sequences on the 5’ and 3’ strand are highlighted in red and purple. 
Following discussion with Professor John McGeehan (University of Portsmouth), a 
preformed HicBT-S1-2 complex (1:1.2 stoichiometry) was screened at a variety of 
concentrations (HicBT = 125, 250 and 375 M) using S1-2 DNA and a DNA variant that 
contained an overhang (Overhang Primer 1 and Overhang Primer 2) against commercially 
available Molecular Dimensions screens (Morpheus, Proplex, JSCG+ and Structure Screen I 
+ II) and Hampton Research (Natrix HT) and Qiagen (Nucleix) screens. Small crystals were 
obtained in a number of conditions, but the best only diffracted to 8 Å and further 
optimisation is ongoing. MR was not attempted and it has not been fully determined if 
crystals contain a protein-DNA complex or just DNA. 
In the absence of a HicB-DNA crystal structure, in silico molecular docking using the High 
Ambiguity Driven protein-protein DOCKing algorithm (HADDOCK)
359
 was used to 
investigate the structure of the HicB-S1-2 complex and the interface between HicB and S1-2. 
S1-2 models were built using the 3D-DART server 
358
 before modelling onto the crystallised 
elongated conformation of HicB. Active residues of HicB were designated as R94, N96 and 
S98, inferred from EMSA and FA experiments. S1-2 active residues were designated as 









. In this HicB-S1-2 model (Figure 4.12), individual RHH 








which lies flat across the base of HicB. A model 
of the interaction site highlights the R94, N96 and S98 project into the major groove and 
suggests that R118 and S119 form interactions with the DNA backbone (Figure 4.12). This 
model was a good fit to the SAXS experimental profile of HicB-S1-2 (
2
 =2.10) and the 
resultant ab initio shape envelope (Appendix Figure 35). 
 
 
 Cluster 6 Cluster 3 
Haddock score -173.8 ± 17.4 -162.5 ± 6.8 
Cluster score 8 12 
RMSD (Å) 0.6 ± 0.3 14.4 ± 0.1 
Van der Waals energy -75.9 ± 5.0 -78.5 ± 5.1 
Electrostatic energy -513.8 ± 48.2 -410.3 ± 13.1 
Desolvation energy  -10.8 ± 6.3 -20.5 ± 9.9  
Restraints Violation energy 157.3 ± 52.27 185.2 ± 30.40 
Buried Surface Area 2124.0 ± 45.3 2165.6 ± 41.1. 
Z score -1.5 -0.9 
 
Figure 4.12. HADDOCK modelling of HicB-S1-2. (A) Cartoon representation of the complex where DNA lies 
across the two RHH domains of HicB. (B) 90° rotation to show the antiparallel -sheet of the RHH domain 
projects into the major groove of TGTGT and ACACA. (C)  Statistics shown for the HADDOCK clusters 
generated from simulation of HicB and S1-2 generated by 3D-DART. Clusters are ranked by their HADDOCK 
score, RMSD to the input models and Z-score. 
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4.6.  Conservation of the HicB-DNA binding site 
The DNA binding ability of HicB has been investigated in both Y. pestis and E. coli
132, 214
, 
however specific amino acids implicated in this interaction have not been determined. 
Recently the HicBSP-DNA interaction site was investigated by NMR and modelled by 
HADDOCK, where they also reported that DNA binds across the RHH domains of HicB in a 
similar manner to the HicB-S1-2 model (Figure 4.13).
272
 Here they report two interaction 
sites for DNA. The first: located within the 5 strand of the RHH domain (I114, K115, K116 
and T117) are directly homologous to DNA binding residues in Burkholderia HicB and are 
predicted to project into the DNA major groove (Figure 4.13). The second within the 5 helix 




) anchors the protein to the DNA phosphate backbone. The 
observations of the importance of specific 5 residues reinforce the trend observed in several 
HicB family members (Figure 4.6), where a proximal basic residue succeeded by several 
polar amino acids are conserved across HicB species. F135 and Q137 were not conserved 
across homologues to B. pseudomallei HicB (Appendix Figure 23) however; the HicB 6 
helix residues R118 and S119 were conserved throughout homologous sequences (Figure 
4.13). HADDOCK modelling implies that they constitute an equivalent secondary DNA 
binding site of HicB (Figure 4.12).    
4.  DNA binding of HicB  4.6. Conservation of the HicB-DNA binding site 
 109 
 
Figure 4.13. Comparison of HicB, HicBSP and HicB3. (A) Superimposition of the RHH domain of each HicB 
family member with residues of the central  strand involved in binding highlighted. (B) Residues of the 2 
helix of HicBSP experimentally determined to bind DNA and the close proximity residues of HicB and HicB3 
that could mediate interactions with the DNA backbone. (C) Sequence of B. pseudomallei HicB RHH domain 
and comparison to HicBSP and HicB3. Symbols indicate a conserved residue (*), conservative mutation (:) and a 
semi-conservative mutation (.). (D) Graphical representation of the amino acid residues in 44 homologous HicB 
sequences following sequence alignment corresponding to the 6 helix of HicB. The amino acid sequence of the 
6 strand of HicB is depicted underneath.  
Full verification of the orientation at which DNA binds HicB and whether the a6 helix of 
HicB constitutes a second binding site awaits a high-resolution structure of HicB-S1-2, 
however crystallisation trials to date have been unsuccessful (best diffraction 8 Å) and further 
optimisation is ongoing. Despite the differences between Burkholderia and Streptococcus 
HicAB complexes, modelling suggests that they both contact DNA in a similar manner. It is 
possible that this is a general mechanism for HicB family members that encode a RHH 
domain. 
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4.7.  Summary 
The experimental data depicted in this chapter provides a high degree of certainty that R94, 
N96 and S98 are functionally important for the formation of a stable HicB-DNA complex 
and form the “active site” of the DNA binding site. It is clear that alanine mutants (R94A, 
N96A and S98A) are not capable of binding DNA in comparison to their semi-conservative 
counterparts (R94E, N96Q and S98T). It appears that a single alanine mutation in each 
subunit (x4) may have a small effect to the tertiary structure at the local site of DNA binding. 
In comparison the presence of semi-conservative mutants has a minimal impact on the 
tertiary structure of HicBT and the reduction in DNA binding observed within EMSA and FA 
experiments are due to a knockdown of function rather than local structural perturbations.  
The specific nucleotides of the DNA binding site upstream of the hicAB operon has been 
determined as an inverted sequence (TGTGT-N6-ACACA), found within the first 48 
nucleotides upstream from the proposed transcriptional start site. Data from sequence 
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5.   DNA binding of HicAB 
The precise molecular details of HicAB-DNA interactions are not understood. Y. pestis 
HicAB (HicA32HicB34) has been shown to bind DNA to the same extent as HicB3 alone via 
EMSA experiments and an excess of HicA3 alleviated repression of phicA3B3 in vivo.
132
 
Turnbull and Gerdes then demonstrated using LacZ assays that E.coli HicB (HicBEC) is not 
dependent on E. coli HicA (HicAEC) for full transcriptional repression of the hicAB operon 
and when in excess, HicAEC acted as a de-repressor. This is in contrast to the behaviour of 
other type 2 toxins, which typically function as co-repressors.
112
 It was acknowledged that 
they could only speculate on the molecular mechanism by which HicA destabilises the HicB-
DNA complex and suggested that the mechanism of regulation may be similar to MqsRA 




This chapter probes the interaction of B. pseudomallei HicAB with S1-2 DNA and the role of 
HicA in modulating the HicB-DNA interaction. 
5.1.  HicA de-represses HicB-S1-2 
Initially a simple EMSA was used to monitor the effect of HicA on a preformed HicB-DNA 
complex. HicBT (3.2 M) and S1-2 (2 M) were mixed and formation of the HicB-S1-2 
complex confirmed by EMSA (Figure 5.1A, lanes 1 and 2). HicA was then titrated into 
solutions of this complex to give final HicA concentrations ranging from 0.8 – 50.8 M. At 
ratios of HicBT: HicA <1:1 a bandshift corresponding to the HicB-S1-2 complex persisted 
although a sizeable fraction of the HicB-S1-2 complex appeared to dissociate. At 
concentrations of HicA that equal or exceed the concentration of HicBT and where all four 
HicA binding sites are potentially occupied (HicA ≥ 12.8 M), complete dissociation of S1-2 
DNA from the HicB-S1-2 complex was observed. Qualitatively excess HicA appears to act 
as a de-repressor in a similar fashion to the HicAEC driven de-repression of the HicBEC-DNA 
complex
214
 and is hypothesized to be a consequence of the conversion of HicB to the 
HicA4HicB4 complex. HicA alone was unable to bind S1-2 (Figure 5.1B) and it was therefore 
assumed that dissociation of S1-2 was a direct consequence of complexation between HicA 
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and HicB. In the lower concentration ranges, the addition of HicA (0.8 - 6.4 M) may lead to 
the formation of initial HicA1HicB4/HicA2HicB4 complexes which significantly populated a 
non-DNA bound state. Complete quantification of unbound and bound populations of S1-2 
and HicB-S1-2 was not possible due to evident smearing on EMSA gels upon complex 
formation, seen for other type 2 TA systems when bound to DNA.
212, 219, 220, 224, 360
  
 
Figure 5.1. HicA de-repression of HicB-S1-S2 DNA. (A) EMSA of varying HicA concentrations (0.8 µM – 
50.8 µM) titrated into HicBT (3.2 µM) resulting in the complete de-repression of HicB-S1-2 binding upon an 
excess of HicA (25.6 M). (B) EMSA indicated that HicA does not bind to S1-S2 at concentrations assayed for 
HicB. 
Fluorescence anisotropy was used to further quantify these observations. A preformed 
complex of HicAB (HicA:HicB ratio = 0.5:1), was titrated (0-150 nM) into HEX-S1-2 
(Figure 5.2A). The calculated Kd was 1.9 ± 0.2 nM (95% confidence interval = 1.54-2.2 nM).  
 
Figure 5.2. Fluorescence anisotropy experiments of HicAB (<1:1, HicA:HicB = 0.5:1) to HEX-S1-S2. (A) 
Quantification of HicAB (preformed at a ratio of HicA: HicB = 0.5:1) binding to HEX-S1-2. Samples contained 
7.5 nM HEX-S1-2 in DNA binding buffer. The proportion of HEX-S1-2 bound by increasing concentration of 
HicAB was followed (n=1). Data of three independent repeats were fit to equation (9). (B) The Kd of HicAB 
was simulated to determine appropriate values that described the experimental data seen in panel A. (C) 
Quantification of HicA binding to HEX-S1-2. The proportion of HEX-S1-2 bound by varying concentrations of 
HicA was followed (n=1). Again 3 independent repeats were fit to equation (9). For each experiment the mean 
value is plotted with error bars representing the SEM. Standard errors of Kd values were calculated in GraphPad 
Prism. 
Simulation of Kd values (0.75-3 nM) for HicAB-HEX-S1-2 (Figure 5.2B-C) revealed no 
discernible difference between Kd values of 1.5-3 nM, although it was clear that a Kd of 0.75 
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nM did not fit the data. In accordance with experimental error associated with the 
experiment, there is no change in the affinity of HicB for S1-2 upon HicA binding at sub-
stoichiometric levels (HicB-S1-2 Kd = 3.0 ± 0.4 nM). The stoichiometry remained at 1 (One 
HicABT binds to 1 HEX-S1-2 DNA) based on floating the stoichiometry value and 
constraining the Kd to 1.9 nM and is similar to HicBT alone. Similar to HicB-HEX-S1-2 
assays, the Kd value is lower than the probe concentration (7.5 nM) and this value should be 
regarded as an upper limit for the Kd value. A Kd for HicA-HEX-S1-2 could not be obtained 
indicating that HicA does not bind HEX-S1-2, in agreement with EMSA observations (Figure 
5.2C). 
A preformed complex of HicAB where HicA was in excess (HicA:HicB  =1.2:1) was titrated 
into HEX-S1-2, resulting in a calculated Kd of 0.4 M ± 0.05 M (95% confidence interval = 
49-1000 nM) with binding at 150 nM only reaching ~ 30% saturation (Figure 5.3A), when 
compared to the data for HicB alone (Figure 4.4).  
 
Figure 5.3. Quantification of HEX-S1-2 binding to HicAB (>1:1, HicA: HicB = 1.2:1) for 3 independent 
repeats (n=1). Data were fit to equation (9). The mean value is plotted with error bars representing the SEM. 
Standard errors of Kd values were calculated in GraphPad Prism. 
To confirm if HicA was actively driving the dissociation of the HicB-S1-2 complex through 
the formation of a HicAB complex, two titration experiments were performed where HicA 
was titrated into a preformed HicB-S1-2 complex. Firstly, HicA was titrated into a preformed 
a HicBT (50 nM)-S1-2 complex (7.5 nM), corresponding to a ~ 95% HicB-S1-2 bound state 
(based on previous FA assays) (Figure 5.4A). No change in anisotropy was observed at 
concentrations of HicA below 200 nM (<1:1 HicA:HicB ratio). Once the titration of HicA 
exceeded 200 nM, a rapid decrease in anisotropy was observed, with approximately 0% 
HEX-S1-2 bound to HicB after the addition of 700 nM HicA. This experiment apparently 
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suggested that HicA concentrations approaching a 1:1 stoichiometry with HicB did not have 
any effect on DNA binding which did not agree with the EMSA titration experiment above. 
As the HicB-S1-2 complex was 95% bound, there would be a population of free HicB that 
HicA may preferentially interact with upon titration rather than directly interacting with HicB 
bound to S1-2 DNA. These experimental parameters were therefore not ideal for 
investigating the direct effect of HicA on HicB-S1-2 complexes. 
 
 
Figure 5.4. Fluorescence anisotropy experiments titrating HicA into HicB-HEX-S1-2. (A)  Quantification 
of HicA binding to a preformed HicBT (50 nM)-HEX-S1-2 complex (7.5 nM), HicBT refers to the tetramer 
concentration of HicB, (HicBM = 200 nM). (B) Quantification of HicA binding to a preformed HicBT (10 nM)-
HEX-S1-2 complex (7.5 nM). Here HicBM = 40 nM. For each titration experiment, the proportion of substrate 
displaced by increasing concentrations of HicA was calculated for three independent repeats via equation (10). 
For each experiment the mean value is plotted with error bars representing the SEM. Standard errors of Kd 
values were calculated in GraphPad Prism. 
The competition experiment was repeated with HicBT (10 nM) and HEX-S1-S2 (7.5 nM), 
corresponding to a ~ 80% protein-DNA complex1 (Figure 5.4B). Titration of HicA 
approaching a 1:1 stoichiometry of HicA:HicB (0-40 nM) and >40 nM caused HEX-S1-2 to 
raidly dissociate from HicB and full dissociation was observed between 200-300 nM HicA. 
Modelling of this data to equation (10) determined the IC50 as 63.5 ± 0.9 nM (95% 
confidence interval = 57-71 nM), indicating that an excess of HicA is required to drive 
                                                 
1
 Work by Huang
361
, determined that competition assays should use a protein-DNA complex 
between 50-80% bound, so that titration of the competitor directly affects the bound 
population of protein, rather than the free population of protein. The concentration of protein 
that corresponds to a 80% protein-DNA complex was determined from previous HicB-S1-2 
FA experiments using 7.5 nM HEX-S1-2 DNA. 
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dissociation of HicB from a HicB-HEX-S1-2 complex at 80% bound. The calculated Hill 
coefficient was 2.64 ± 0.33. Data for the 95% bound HicB-S1-2 competition assay gave an 
IC50 and hill coefficient value of 330 ± 1.8 nM (95% confidence interval = 317-343 nM) and 
7.1. This IC50 should be taken with caution due to the excess of free HicB in solution, which 
resulted in an approximately constant anisotropy value until an equimolar ratio of HicA:HicB 
(200 nM HicA: 200 nM HicB) was reached. Further titration of HicA resulted in a sharp 
decrease in anisotropy which resulted in the artificially high Hill coefficient value of > 7. 
A Ki value for the HicA dissociation of HicB from DNA can be modelled through a variety 
of equations (Table 5.1). The Cheng Prussof equation
362
 (Equation 11) can be used, however 
this equation relies on the assumption that free inhibitor equals the total inhibitor present, 
thus neglecting the possibility of bound and free inhibitor components. Due to this 
simplification, the Ki is often overestimated by 10 fold. Munson and Rodbard
363
  applied an 
exact correction (y0) to this equation by accounting for the ratio of bound:free ligand 
(Equation 12) for cases where the Cheng Prussof equation is not appropriate. A Ki prediction 
server BotBD
364
 can also predict the Ki through a series of equations (13-17) based on the 
free concentration of the ligand, rather than the ratio of bound:free ligand used in the Munson 
and Rodbard correction. 
 
 80% bound (HicBT 10 nM) 
Cheng Prussof 18.1 ± 1.88 nM 
Munson and Rodbard 10.5 ±1.30 nM 
BotDB Ki 12.9 ±1.46 nM 
Table 5.1. List of calculated Ki  values dependent on a range of equations (Cheng Prussof, Munson and 
Rodbard correction and BotDB webserver). This was calculated using the IC50 value calculated from the 80% 
HicB-S1-2 titration. 
The calculated Ki for 80% bound (HicBT: 10 nM) varied depending on the method used. Both 
the Munson and Rodbard correction and BotDB calculation were in close agreement for the 
experimental Ki value (10.5/12.9 nM). In comparison the Cheng-Prussof equation resulted in 
a larger Ki value (18.1 nM), suggesting an overestimation of the Ki value. 
One aspect that neither of these equations takes into account is cooperativity within the 
system. The HicAB system does not appear to adhere to a simple single site competition 
model and calculations have not considered the presence of intermediate HicAB-DNA 
complexes or cooperativity between HicA and HicB. We cannot currently discount the 
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importance of possible intermediate HicAB complexes and further work such as the 
determination of high-resolution three-dimensional structures are needed to investigate their 
role in S1-2 binding. Determination of Ki values using these equations without accounting for 
cooperativity may be inadequate and the precise apparent Ki value varies on the specific 
mode of analysis used (Table 5.1). Rather than rely on Ki values to quantitatively describe the 
dissociation of HicB-DNA by HicA, the IC50 value obtained at 80% bound (63.5 ± 0.9 nM), 
rather than 95% bound (330 ± 2 nM) is a more reliable value to describe the HicA driven 
dissociation of the HicB-S1-2 complex.  
A single HicA4HicB4 complex cannot simultaneously bind both sites (S1 and S2) and HicA 
therefore actively drives the dissociation of HicB from S1-S2. Due to the fact that both RHH 
domains are intact within the hetero-octameric HicAB complex (Figure 5.5), albeit 70 Å 
apart, it is possible that HicAB could bind to either S1 or S2 through a single RHH domain 
(Subunit 1-3 or Subunit 2-4). However, EMSA evidence previously determined that both S1 
and S2 sites need to be occupied by one tetramer (or two individual RHH domains), to result 
in tight binding (Figure 4.1B, 4.2C). Two independent hetero-octameric HicAB complexes 
cannot individually bind to S1 and S2, as the Rg of one HicA4HicB4 complex is 31.90 Å 
(Appendix Table 18), there would be large steric clashes between two HicA4HicB4 molecules 
and S1-2 DNA.  
De-repression of HicB-DNA binding has been observed in 3 separate HicAB family 
members. Both B. pseudomallei and Y. pestis HicB moieties contain a RHH domain, in 
contrast to E. coli HicB which contains a HTH domain. It is hypothesized that the mechanism 
of complex formation: rotation of DNA binding domains in response to HicA might be a 
generalised event for HicAB family members irrespective of their specific DNA binding 
domain. 
Crystal structures of HicB and HicAB reported in this work shed light on the mechanism of 
de-repression. As determined in chapter 4, residues R94, N96 and S98 are critical for S1-2 
binding by HicB and they project a positive surface of charge optimal for DNA binding 
(Figure 5.5A, B). Addition of HicA (Figure 5.5C, D, grey) to form a symmetrical 
HicA4HicB4 complex causes a 90 ° rotation of the RHH domains and disrupts the patch of 
positive surface charge observed in the unbound conformation of HicB.  This is believed to 
be an allosteric mechanism of regulating DNA binding through induced conformational 
changes. This does not follow the same mechanism of de-repression as observed for MqsA, 
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speculated by Turnbull and Gerdes as the mechanism for HicAB de-repression.
214
  The HicA 
and DNA binding sites of HicB are on separate binding domains and do not overlap, as 
opposed to MqsA.
223
 EMSA experiments here are in agreement with observations by 
Turnbull and Gerdes that an excess of HicAEC causes de-repression of the HicBEC-DNA 
complex
214
, however additional FA experiments suggest that de-repression occurs almost 
immediately upon the addition of HicA, albeit at a low level until an equimolar ratio of 
HicA:HicB is reached.  Experimental data provided within this chapter implies that formation 
of this hetero-octamer actively prevents HicB binding to S1-2 DNA.  However, further 
functional and structural studies on other HicAB pairs are required to determine how 
generalisable this mechanism of de-repression is.  
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Figure 5.5. Surface net charge of HicB and HicAB. (A) Surface representation of HicB showing clustering of 
positive charges on one face mapped to R94, N96 and S98 of the C-terminal domain of HicB. (B) A 90° rotation 
of the structure in panel (A). (C) Surface representation of HicAB highlighting perturbation of the positively 
charged patch of the C-terminal domain (R94, N96 and S98) due to rotation of the two RHH domains. HicA is 
represented as grey to emphasize the surface charge of HicB. (D) A 90 ° rotation of the structure in panel (C). 
For each image, positive charge, negative charge and neutral charge are highlighted in blue, red and white. 
5.2.  Comparisons to HicABSP  
The S. pneumoniae HicAB hetero-octameric complex recently reported
272
 does not resemble 
the open conformation of HicAB reported here (Chapter 3). As the three-dimensional 
structure of free HicBSP has not been reported, it is unknown whether conformational changes 
regarding the C-terminal RHH domains occur upon formation of a HicABSP complex. 
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However, the HicABSP complex has a positively charged DNA binding patch (Figure 3.13) 
and HicASP appeared to induce a modest increase of HicBSP:DNA binding affinity (Kd 8 M 
for HicBSP:DNA, 4 M HicABSP:DNA), inferring its activity as a co-repressor rather than a 
de-repressor. This is in stark contrast to work reported here and within E. coli and Y. pestis 
where HicA did not increase the affinity of HicB to DNA. However, as a titration experiment 
of HicASP with HicBSP-DNA was not reported, it is not possible to conclude whether an 
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6.  Conditional Cooperativity 
A generalised model for the transcriptional regulation of most type 2 TA systems has been 
introduced in Chapter 1 (Appendix Table 22). It is termed conditional cooperativity and is 
thought to be the mechanism by which cell populations undergo bistable switching between 
normal (antibiotic susceptible) and persistent (antibiotic tolerant) states.
200-202
 This regulation 
is typically dependent on two factors: first, the presence of several adjacent operator sites 
within the regulatory region upstream of the toxin-antitoxin operon and secondly the ability 
of the toxin to act as a co-repressor at a low toxin:antitoxin ratio and a de-repressor at high 
toxin-antitoxin ratios within the cell. A common misconception is that conditional 
cooperativity is a consequence of the toxin:antitoxin ratios simply changing within the cell. 
As type 2 antitoxins are synthesized at a greater rate than their cognate toxin, under normal 
growth conditions the toxin:antitoxin ratio is low.
199
 Proteolytic degradation of antitoxins 
over time
120
 coupled with the high stability of toxins eventually establishes a high 
intracellular toxin:antitoxin ratio, even if the specific TA system does not adhere to 
conditional cooperativity.  
6.1.  Molecular mechanisms of Conditional Cooperativity 
Full conditional cooperativity has been observed and demonstrated in CcdAB, Kid-Kis, 
MazEF, ParDE, Phd-Doc, RelBE and VapBC systems where multiple operator sites are 
present (Appendix table 22). Apart from ParD, Kid and VapB, the antitoxins contain an 
intriniscally disordered region (IDR) and the toxin-antitoxin complex, aside from ParDE, 
displays an alternating array of toxin and antitoxin modules.  
In 2014 Garcia-Pino and Loris proposed three distinct mechanisms to explain conditional 
cooperativity.
365
 These include steric exclusion between non-repressing TA complexes, low-
high affinity switches of toxin-antitoxin interaction sites and allosteric communication 
between antitoxin domains. The RelBE systems adheres to the first mechanism (steric 
exclusion) whereby a high affinity antitoxin-toxin-DNA complex is competitively dissociated 
by an excess of the toxin RelE (Figure 6.1A).
155
 In contrast Phd-Doc
227
 (Figure. 6.1B) and 
CcdAB
125
  both display a switch between the toxin using both high and low affinity binding 
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sites on the antitoxin to exclusively occupying high affinity binding sites that results in 
conditional cooperativity. Phd (antitoxin) is also allosterically regulated by Doc to form a 
structured DNA binding domain upon the formation of the initial Phd-Doc complex.
210, 227
 
The HicAB system described here falls into a class of TA systems including DinJ/YafQ
83
 
(Figure. 6.1C) and MqsRA
223
(Figure 6.1D) where the antitoxin can bind an individual 
operator site and where far less is known about the mechanism of de-repression. It has been 
proposed that in a subset of these systems, where conditional cooperativity operates (e.g. in 
DinJ/YafQ it does not) it does so in a simplified form in that an excess of toxin is still 
effectively countered at the transcriptional level.
365
 Although the MqsRA operator contains 
two binding sites, MqsA is able to independently bind to one of these and the toxin MqsR 
solely acts as a de-repressor to the MqsA-DNA interaction via a steric mechanism, rather 
than a co-repressor.
223
 For HicAB, sub-stochiometric levels of HicA have no discernible 
effect on DNA binding and an excess of HicA causes dissociation of the HicB-DNA complex 
through large scale conformational reorganisation of HicB to form a hetero-octameric 
complex (Figure 6E) rather than via overlapping DNA/toxin binding sites as observed for 
MqsRA.
223
 This allosteric regulation of interdomain interactions has been proposed as a 
mechanism for this single site conditional cooperativity, but not demonstrated until now. 
While the two endpoints of HicB in a DNA binding and non-binding form have been 
determined, further intermediate states are likely to exist (Figure 6.1E). Indeed we have 
observed HicA1-HicB4 and HicA2-HicB4 complexes by native mass spectrometry and AUC 
(Chapter 3) and the Y. pestis HicA32-HicB34 complex has previously been observed by size 
exclusion chromatography multi-angle light scattering (SEC-MALS)
132
 
It is proposed that conversion of HicB to the hetero-octameric HicAB complex may follow 
one of two possible pathways (Figure 6E).  
In (1), binding of sub-stoichiometric levels of HicA can be accommodated by to N-terminal 
binding sites on HicB (Subunits 2 and 3) that are predicted to be surface exposed and require 
no conformational rearrangement of HicB. This would have little or no effect on the 
thermodynamic equilibrium of HicB-DNA binding and is in agreement with the DNA 
binding asays reported under these conditions which show little change in the Kd ( 3 nM v 1.9 
nM). However in accordance with previous studies we were unable to confirm the formation 
of a stable HicA1/2-HicBT-DNA complex during EMSA competition experiments.
214
 Further 
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titration of HicA does however compete with DNA for HicB binding. Four molecules of 
HicA can be accommodated by HicB, but only when HicB adopts an open conformation that 
does not bind DNA and promotes highly cooperative binding of HicA.  
The equilibrium therefore will be influenced by the affinity of DNA for HicB and the 
stabilisation of the closed conformation of HicB versus the affinity of HicA for HicB and 
stabilisation of the open, non-binding DNA binding form of HicB. 
In pathway (2), association of two HicA molecules might stabilise the open non-DNA 
binding form of HicB and exposure of the additional toxin binding domains is the basis for 
binding of further toxin. This model seems unlikely given that HicA:HicB ratios of 0.5:1 still 
showed significant tight DNA binding, suggesting at ratios of HicA:HicB <1:1, the open non-
DNA binding form of HicB is not significantly populated. However, at this stage, we cannot 
exclude this pathway or the possibility that there is a slight equilibrium between the two 
forms of HicB upon binding of two HicA molecules. 
Pathway (1) appears to the most plausible mechanism based on the structural and 
biochemical data presented. The essentially cooperative mechanism is similar to related 
systems
148
, with the exception that de-repression of HicB-DNA binding is highly cooperative 
at high concentrations of toxin. However, further studies are required to determine the 
intervening mechanistic steps that underpin the dissociative mechanism of HicB:DNA in the 
presence of varying concentrations of HicA as well as potential structural and functional 
diversity amongst the HicAB family. 
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Figure. 6.1. Overview of de-repression models for RelBE, Phd-Doc, DinJ-YafQ, MqsRA and HicAB. For 
each panel, the toxin is highlighted in red and the antitoxin in blue. (A) The RelB2 dimer or RelB2E complex can 
bind to one of the two adjacent DNA operator sites, but it is proposed that the formation of a W-shaped hetero-
hexameric complex (RelB2E)2 may occupy both adjacent DNA operator sites simultaneously to confer full 
transcriptional repression of the relBE operon. Excess toxin (RelE) binds a second site of a RelB dimer forming 
a rigid RelB2E2 hetero-tetramer, two hetero-tetramers cannot simultaneously bind both operator sites due to 
steric hindrance resulting in transcriptional de-repression. Transcription of the relBE operon returns RelB and 
RelE to stoichiometric levels (~1:1). (B) Doc forms a hetero-pentameric complex with Phd (Phd2-Doc-Phd2) by 
binding to Phd2 via low (L) and high (H) affinity sites to confer full repression of the phd-doc operon by binding 
two operator sites. Doc allosterically regulates Phd to form a structured DNA binding domain to ensure full 
transcription repression only occurs upon formation of a Phd-Doc complex.  An excess of Doc preferentially 
binds Phd solely through H sites resulting in the formation of a rigid heterotetramer (Doc-Phd2-Doc) that cannot 
occupy both operator sites due to steric clashes between adjacent heterotetramers. In contrast both DinJ-YafQ 
(C) and MqsRA (D) do not follow the model of conditional co-operativity, as both toxins act as de-repressors 
rather than co-repressors.  (C) DinJ2 fully represses its operator via a single palindromic site. Addition of YafQ 
forms a YafQ-DinJ2-YafQ hetero tetrameric complex, but an excess of YafQ does not result in de-repression of 
the DinJ/YafQ-DNA complex and the de-repression mechanism is unknown. It has been demonstrated that 
LexA can bind to the second operator site and repress transcription in vivo, but it is uncertain if this occurs in 
vitro. (D) Likewise, MqsA fully represses in the absence of MqsR. MqsR competes with an overlapping DNA 
binding site of MqsA and formation of a proposed hetero-tetrameric MqsRA complex results in de-repression 
(the published MqsRA complex is a partial model). MqsA exclusively binds to MqsR or DNA it cannot bind 
both simultaneously. (E) Like MqsA and DinJ, HicB alone results in saturation of the palindromic sequences 
(S1-2). I hypothesize that binding of HicA is likely to result in two possible pathways. (1) HicA binds the 
surface exposed 1 helices of subunit 2 and 3 to form an intermediate HicA2HicB4 complex that does not result 
in an increase of affinity to S1-2. At concentrations of HicA > HicB, there is binding of a further two HicA 
molecules that results in the 90° rotation of the ribbon-helix-helix motifs prevents binding to the palindromic 
sequences and dissociation of HicB from DNA. (2). Binding of 2 HicA molecules causes rotation to the 
symmetrical HicAB complex. At concentrations of HicA>HicB, additional HicA molecules bind to stabilise the 
symmetrical HicAB complex. The intermediate steps of this pathway are unknown and either route, or an 
equilibrium between the two cannot be discounted as of present.   
 
6.1.1.  Reverse gene order and non-canonical transcriptional regulation 
The canonical gene organisation of type 2 TA systems is where the antitoxin gene precedes 
the toxin gene within the bicistronic operon. With the exception of DinJ-YafQ
83
, these TA 
systems adhere to conditional cooperativity. The DinJ-YafQ system is somewhat distinct as 
the promoter region contains LexA controlled operator site immediately adjacent to the 
operator site that DinJ exclusively binds (Figure 6.1B). 
However, the HicAB, HigBA, HipAB and MqsRA systems are organised in reverse (toxin 
gene followed by antitoxin gene). Evidence to date suggests that individual type 2 TA 
systems with a reverse gene organisation are transcriptionally regulated by novel mechanisms 
rather than conditional cooperativity. This was suggested by Loris
365
 but to date there has 
been no review or a generalised link between a reverse gene organisation and a novel 
transcriptional mechanism. This is in part due to the fact that the molecular mechanisms of 
de-repression have been understudied and only recently discussed at a molecular level for 










V. cholera chromosomally encoded HigBA does not adhere to conditional cooperativity and 
instead adheres to a postulated novel anti-cooperativity mechanism, the details of which are 
unpublished. It appears that HigA binding to HigB-DNA causes negative cooperativity 
resulting in transcriptional de-repression at high toxin-antitoxin ratios.
366-368
 In direct contrast 
the P. vulgaris HigBA system encoded on the Rts1 plasmid appears to adhere to conditional 
cooperativity, as the toxin HigA is a co-repressor.
215, 369, 370
 The same observation has been 
observed for the A. baumanni HigBA system encoded on the PAB120 plasmid.
216
  This 
implies that the gene organisation within the bicistronic operon is likely not the sole 
determinant for regulation by conditional cooperativity or a separate mechanism. There is a 
possibility based on findings on the HigBA systems that the genetic environment, where the 
system is located (chromosomally/ plasmid encoded) may play a factor in the regulation of 
the systems. 
It is likely that the HipAB system of E. coli and S. oneidensis do not adhere to conditional 





determined that the toxin HipA was able to form direct interactions with DNA, a novel 
interaction not observed in other type 2 TA systems. It has not yet been determined if 
transcriptional de-repression occurs for this system. 
An interesting observation links the regulation of type 2 TA systems via conditional 
cooperativity to the formation of an alternating T-AT complex (Appendix Table 22). For type 
2 TA systems that do not form an alternating complex (DinJ-YafQ, HicAB, HigBA, HipAB, 
FitAB, MqsRA, ParDE and VapBC), with the exception of the ParDE and VapBC systems, 
hallmarks of conditional cooperativity (co-repression and de-repression) have not been 
demonstrated. However, S. enterica VapBC displayed conditional cooperativity at a 




If TA complexes do not form an alternating pattern of T-AT complexes as observed for 
RelBE (Figure 6.1A), Phd-Doc (Figure 6.1B) and CcdAB, but circular closed 
complexes
365
(Like HicAB, HipAB and FitAB/VapBC, Appendix Table 22) then it is 
plausible that these act at a single operator site and are independent from any adjacent 
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operator regions due to their separation. No steric occlusion is observed between TA 
complexes bound at adjacent operator sites for these circular complexes.  Within the initial 
TA complexes formed at physiological toxin:antitoxin ratios, all toxin binding sites appear to 
be occupied, with the exception of S. enterica VapBC
2
.  The molecular mechanisms for de-
repression of these closed complexes and therefore transcriptional control of these TA 
systems, including those with a reverse gene organisation, are not yet fully understood. 
Further work is required to investigate the novel transcriptional regulation in other TA 
















                                                 
2
 Modelling of S. enterica VapBC to  N. gonorrhoea FitAB (PDB:2H10) suggests that VapBC initially forms a 
hetero-octamer (VapB4C4) and upon an excess of VapC (10:1) forms the higher order complex VapC2-VapB-
VapC2
211
. It is uncertain if other VapBC family members adhere to this proposed mechanism. 
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7.  Conclusions and future work 
7.1.  Conclusions 
This work presents for the first time the model of a molecular mechanism of the 
stoichiometric HicA dependence of HicB binding to DNA. At low ratios of HicA:HicB there 
is no effect on DNA binding, but at higher ratios the affinity for DNA declines co-
operatively, driving dissociation of the HicA:HicB:DNA complex. This has not yet been 
confirmed at a transcriptional level for Burkholderia HicAB, but the phenomenon of HicA 
driven de-repression been confirmed at a transcriptional level for E. coli HicAB
214
.  The 
molecular mechanisms within this system distinctly differ from traditional conditional 
cooperativity observed in other TA systems and instead appear to represent a novel mode of 




 TA systems which also do not adhere to 
conditional cooperativity. 
Three-dimensional crystal structures of HicB and HicAB support this molecular mechanism 
as HicAB complexation results in the rotation of the C-terminal RHH domains of HicB into a 
conformation where they cannot bind both sites of the inverted repeat of DNA (S1 and S2). 
The active site for DNA binding by HicB has been probed and the main interaction site was 
experimentally determined to consist of residues within the 5 strand (R94, N96 and S98) 








 of DNA upstream of the hicAB operon. A 
three-dimensional structure of HicB-DNA is unknown, ab initio and in silico modelling 
support a structure where DNA lies flat across the two RHH domains, in agreement with 
modelling data for the Streptococcus HicB-DNA complex.
272
  
7.2.  Future work 
Future work requires the findings presented here to be confirmed at a transcriptional level by 
a series of LacZ assays, which have been performed for both E. coli and Y. pestis HicAB 
systems. Initial crystallisation hits of HicB-S1-2 should be further optimised to obtain a 
three-dimensional structure and reinforce modelling presented for both B. pseudomallei and 
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S. pneumoniae HicAB systems. A three-dimensional structure would confirm whether the 6 
helix within the RHH domain represents a secondary DNA-binding site and R118 and S119 
residues within the 6 helix should be mutated and investigated by EMSA and FA to obtain 
suitable evidence on their involvement and importance in DNA binding. At this stage 
however, the possibility of multiple DNA binding mechanisms of HicB and HicAB cannot be 
discounted. 
There is no information regarding accurate Kd values on the HicA-HicB interaction for B. 
pseudomallei and other HicAB family members. ITC for example might provide data that 
provides a fuller thermodynamic description of the full envelope of mechanistic steps 
associated with HicA dependent dissociation of HicB from DNA, including details on the 
behaviour of intermediary HicAB/DNA complexes.  
The mechanism by which HicA family members binds and cleaves mRNA is poorly 
understood when compared to other type 2 mRNAses. As the catalytic residue implicated in 
toxicity has been identified for B. pseudomallei, E. coli, S. pneumoniae and Y. pestis HicA 
toxins, structural and functional analysis would yield crucial details regarding their 
mechanism of action. 
Further studies on HicAB family members in other bacteria and archae will enhance 
knowledge of the system, especially with respect to the structural and functional diversity 
between systems. The ultimate goal is to understand how the full complement of TA systems 
within an organism behave. To date this has not been fully elucidated, but evidence and the 
general concensus within the current literature suggests that TA systems form a highly 
regulated network that can collectively compute some output state of the cell (presumed to be 
persistence) from a network of inputs composed of both internally and externally generated 
stimuli. To date only initial primitive investiations (single TA deletions) have occurred and 
this is partly due to the emergence of new TA systems on an annual basis. Proteomics and 
transcriptomics at a whole cell level and studies on the role of TA systems within a whole 
cell population (for example, how individual cells interact within biofilms) may begin to 
unravel this network. 
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8.  Materials and Methods 
Sources of materials 
Laboratory reagents and were purchased from Sigma Aldrich, Thermo Fisher Scientific and 
Merck Millipore. Isotopically enriched 
15
NH4Cl was purchased from Goss Scientific. 
Competent cells (T7 Express and NEB 5-) were purchased from New England Biolabs or 
Merck Millipore (Novagen B834 (DE3) and Novagen BL21 (DE3) cells). Kits used 
throughout the work were the GenElute Plasmid Miniprep Kit, GenElute Gel Extraction kit 
(Both Sigma Aldrich), KOD Hot Start DNA Polymerase (Merck Millipore) and the PureLink 
PCR Purification kit (Thermo Fisher Scientific). All enzymes used were purchased from 
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Buffers and solutions 
Buffer Procedure Composition 
50x TAE Agarose gel 
electrophoresis 
242 g Trizma base, 57 ml 100% glacial acetic acid, 
100 ml of 0.5 M EDTA, up to 1 L dH2O 
10x TAE EMSA 400 mM Trizma base, 25 mM EDTA, pH 7.8 (with 
acetic acid) 
Buffer A IMAC 25 mM Tris-HCl, 0.5 M NaCl, 10% glycerol, pH 
8.0 
Buffer B IMAC 25 mM Tris-HCl, 0.5 M NaCl, 10% glycerol, 800 
mM imidazole, pH 8.0 
Buffer C SEC 25 mM Tris-HCl, 150 mM NaCl, pH 7.5 
Buffer D SEC 10 mM Na2HPO4, 2.2 mM KH2PO4, 137 mM NaCl, 
pH 7.5 
Buffer E EMSA/FA 25 mM Tris-HCL, 100 mM NaCl, 10% glycerol, pH 
7.5 
Anode buffer SDS-PAGE 200 mM Trizma base, pH 8.9 
Cathode buffer SDS-PAGE 100 mM Trizma base, 3.5 mM SDS, 100 mM 
Tricine, pH 8.25 
Gel buffer SDS-PAGE 3 M Trizma base, 10 mM SDS, pH 8.45 
Loading buffer SDS-PAGE 780 mM Trizma base,  142 mM -mercaptoethanol, 
35 mM SDS, 10% glycerol, 140 mM bromophenol 
blue, pH 6.8 
10% Separating 
solution 
SDS-PAGE 2.5 ml 40% acrylamide, 2.8 ml dH2O, 3.33 ml Gel 
buffer, 50 l 10% AMPS, 20 l TEMED 
4% Stacking 
solution 
SDS-PAGE 0.5 ml  40% acrylamide, 3.3 ml dH2O, 1.25 ml Gel 
buffer, 50 l 10% AMPS, 20 l TEMED 
Coomassie stain SDS-PAGE 2.5 g Commassie Blue (G250), 450 ml ethanol, 100 
ml glacial acetic acid, 450 ml dH2O 
Solution A ESMS 50/50 acetonitrile: dH2O 
Solution B ESMS 0.1% trifluoroacetic acid (TFA) 
Solution C ESMS 5% methanol, 0.1% TFA 
Solution D ESMS  80% acetonitrile, 0.1% TFA 
Table 8.1. Buffers and recipes used throughout the work used for all protein constructs. Where appropriate 
the buffer pH was adjusted using 1 M NaOH or 1 M HCl. 
 
Media Ingredients 
Luria Broth (LB) Tryptone (10 g/L), NaCl (10 g/L) and yeast extract (5 g/L) 
M9 Minimal media pH 7.5 KH2PO4 (3 g/L), Na2HPO4 (1.8 g/L) and NaCl (0.5 g/L).  
SelenoMet
TM
 medium base 21.6 g in 1L dH2O 
Additives for media  
1000 x Trace Metal Elements CaCl2 (20 mM), CoCl2.6H2O (2 mM), CuCl2.2H2O (2 mM), 
H3BO3, HCL (60 mM), MnCl2.4H2O (10 mM), Na2MoO4.2H2O 
(2 mM), Na2SeO3.5H2O (2 mM), NiCl2.6H2O (2 mM),  
ZnSO4.7H2O (2 mM)   
Table 8.2. Media and additive recipes. For 1000 x Trace Metal elements, parenthesis correspond to the 




8.  Materials and Methods   
 131 
Sterile technique 
Where applicable, both media and solutions were sterilised by autoclaving at 121 °, 151 psi 
for 15 minutes. Solutions that could not be autoclaved (Antibiotics and glucose solutions) 
were filter sterilised via a 0.2 M filter (Thermo Fisher), while buffer solutions were filter 
sterilised via a 0.2 M cellulse nitrate filter (Whatman, GE Healthcare) and degassed prior to 
their use.  
Preparation of LB Agar plates 




Agarose gel electrophoresis 
Agarose gels were prepared in 1x TAE buffer as previously described
372
 with the addition of 
4 l Midori Green (NIPPON Genetics). PCR samples (2 l) were mixed with 2 l of 5x 
loading dye (Bioline) before loading into wells. Gels were run at 150 V for 30 mins before 
visualising under UV light. 
Preparation of HicA and HicB plasmids. 
Preparation of pOPINE-HicB_FL 
PCR amplification: Primers were designed in-house and synthesized (IDT Technologies
TM
) 
(Appendix Table 4, HicB_FL Primer 1 and 2). hicB was amplified from K96243 genomic 
DNA with KOD Hot Start DNA Polymerase (Table 8.3) using a peqSTAR 96x Universal 
Gradient (VWR) 0.2 ml PCR tubes were heated at 95 °C, 3 minutes, then 30 cycles of 
denaturation (95 °C, 30 seconds), annealing (temperature gradient: 38-50 °C, 15 seconds) and 
extension (70 °C, 30 seconds). A final extension of 70 °C for 10 minutes was applied before 
storing at 4 °C DNA amplification was confirmed by agarose gel electrophoresis. After 
confirming the amplification of the hicB gene, samples containing the gene were further 
purified by a PCR Purification Kit according to the manufacturer’s protocol. 
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Component Volume (µl) Final concentration 
10x buffer KOD Hot start DNA polymerase 5 1X 
25mM MgSO4 3 1.5 mM 
2mM dNTPs 5 0.2 mM 
Filter sterilised dH2O 32 N/A 
5’ Primer 1.5 0.3 M 
3’ Primer 1.5 0.3 M 
Template DNA 1 N/A 
KOD DNA polymerase 1 0.02 Units/l 
Total volume 50  
Table 8.3. Reagents for a single (50 l) PCR reaction using KOD DNA polymerase. Specific primers 
outlined in Appendix Table 4 were used to amplify each construct 
Preparation of pOPINE vector: 50 l pOPINE vector (100 ng/l, provided by Dr Marisa Till, 
University of Bristol) was digested using NcoI and PmeI (5 l each) and 10 l 10x FastDigest 
Green Buffer (Thermo Scientific) overnight (37 °C). The digest reaction was analysed by 1% 
agarose gel before visualisation and isolation of the linearised vector using a scalpel under 
UV light. This was then isolated using the GeneElute gel extraction kit following the 
manufacturers protocol. 
Ligation of hicB into pOPINE: A 10 l ligation reaction mixture contained 1 l digested 
pOPINE plasmid, 3 l gene insert (hicB), 4 l dH2O and 2 l 5x In-fusion
® HD enzyme 
premix.
275
 This was incubated at 50 C for 20 minutes before 2.5 l of this mixture was 
added to 50 l NEB 5-cells. Cells were incubated on ice (30 mins), before a heat shock step 
(42 °C, 30 seconds) and 200 l LB media was added before incubation at 37 °C, 200 rpm for 
1 hour. Cells were plated on carbenicillin-LB agar plates containing 400 g/ml X-gal and 100 
mM IPTG for blue/white colony screening. Plates were incubated overnight (37 °C) before 
storing at 4 °C. 
 pOPINE-HicB_FL culture growth: A single colony of NEB 5-a cells containing the full 
length hicB gene (white colonies) was added to 10 ml LB media containing 100 g/ml 
carbenicillin. Cells were grown for 16 hours (37 °C, 200 rpm), before centrifugation (5,000 x 
g, 10 mins). The plasmid was extracted using the GenElute Plasmid Miniprep Kit according 
to the manufacturer’s protocol and sequenced by GeneWiz
TM
.  
This procedure outlined the protocol for the cloning of the full length hicB gene into pOPINE 
vector (pOPINE-HicB_FL). This exact protocol was used to generate pOPINE-HicB and 
pOPINE-HicB_NT vectors using respective primers (Appendix Table 4, HicB Primer 1 and 
2, HicB-NT Primer 1 and 2). 
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Preparation of HicB methionine mutants 
Whole plasmid mutagenesis was used to introduce methionine point mutations into the 
pOPINE-HicB plasmid. This involves an adapted procedure of PCR amplification (outline 
above, Table 8.3) with the addition of 5% DMSO to the reaction mixture and the use of 
mutagenic primers (I99M Primer 1 and 2). 0.2 ml PCR tubes were heated at 95 °C, 5 
minutes, then 30 cycles of denaturation (95 °C, 30 seconds), annealing (temperature gradient: 
57-63 °C, 15 seconds) and extension (70 °C, 6.5 minutes) then a final extension period as 
previously described.  Following confirmation that the plasmid had been amplified (agarose 
gel electrophoresis), DNA samples were pooled and digested with DpnI overnight (50 l 
product, 5 l DpnI, 5 l 10 x Tango Buffer) to remove parental template DNA before 
purifying using the PCR Purification kit. 4 l plasmid was transformed into 50 l NEB-5a 
cells as outlined above, plasmids were then isolated for individual colonies and sent for 
sequencing. Sequencing confirmed that one set of primers (I99M Primer 1 and 2) had 
generated the pOPINE-I51M, pOPINE-I99M and pOPINE-DM vectors. 
Preparation of HicB DNA mutants 
The nucleotide sequence of HicB bearing specific individual mutations (R94A, N96A, 
R94A/N96A N96Q, and S98A) was codon optimised for E. coli, then synthesized and sub-
cloned into a pMA-T vector via SacI/KpnI recognition sites by Thermo Fisher Scientific as 
whole plasmid PCR mutagenesis to generate these mutants were unsucessful. The resultant 
freeze-dried vector (5 g) was resuspended in 50 l dH2O. The plasmid was miniprepped and 
then digested using KpnI and SacI as previously described. The digested DNA product was 
then isolated as previously described.  
Isolated HicB genes were amplified with Mutant Primer 1 and 2 by PCR as previously 
described (Table 8.3) and the resultant product was further purified and subcloned into digest 
pOPINE vector as following the same procedure detailed earlier for HicB_FL. Sequencing 
confirmed the presence of each gene in the pOPINE vector. The gene had to be digested out 
of the pMA-T vector as PCR amplification of the hicB gene using the pMA-T vector as a 
template resulted in a misprimed PCR product that did not contain the correct sequence of the 
hicB gene bearing a specific mutation. 
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pOPINE-R94E and pOPINE-S98T vectors were generated by whole plasmid mutagenesis by 
Philip Marsh (University of Bristol) using the pOPINE-R94A and pOPINE-S98A vectors as 
template plasmid and R94E Primer 1/2 and S98T Primer 1/2. The protocol used was identical 
to that previously described for generation of methionine mutants, except the annealing 
temperature was modified to (47-52 °C). 
Preparation of HicA. 
The nucleotide sequence of Burkholderia hicA was codon optimised for E. coli, then 
synthesized and subcloned into a pET151-D/TOPO vector by Thermo Fisher Scientific. The 
resultant plasmid was isolated as previously described.  
Plasmid Property Source 
pET26-b-HicA pET26-b bearing a NT PelB sequence, His6-tag, Enterokinase 
cleavage site and hicA under a T7 promoter, KanR 
Aaron Butt 
pET151-HicA.6His pET151 D/TOPO bearing hicA with a cleavable NT His6-tag under a 
T7 promoter, AmpR 
Thermos 
Scientific® 
pET26-b HicB pET26-b bearing a NT PelB sequence, His6-tag, Enterokinase 
cleavage site and hicB under a T7 promoter, KanR 
Aaron Butt 
pOPINE-HicB_FL pOPINE bearing the full length hicB gene preceding a His6-tag under 
a T7 promoter, AmpR 
This work 
pOPINE-HicB pOPINE bearing hicB with a CT deletion of 4 amino acids preceding 
a His6-tag under a T7 promoter, AmpR 
This work 
pOPINE-I51M pOPINE-HicB containing a I51M mutation This work 
pOPINE-I99M pOPINE-HicB containing a I99M mutation This work 
pOPINE-DM pOPINE-HicB containing both I51M and I99M mutations  This work 
pOPINE-HicB_NT pOPINE bearing a truncated hicB with a CT deletion of 54 amino 
acids preceding a His6-tag under a T7 promoter, AmpR 
This work 
pOPINE-R94A pOPINE-HicB containing a R94A mutation This work 
pOPINE-R94E pOPINE-HicB containing a R94E mutation This work 
pOPINE-N96A pOPINE-HicB containing a N96A mutation This work 
pOPINE-N96Q pOPINE-HicB containing a N96Q mutation This work 
pOPINE-
R94A/N96A 
pOPINE-HicB containing both R94A and N96A mutations This work 
pOPINE-S98A pOPINE-HicB containing a S98A mutation This work 
pOPINE-S98T pOPINE-HicB containing a S98T mutation This work 
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Protein Expression in E. coli. 
Expression of HicA and HicB constructs. 
1 l of the appropriate plasmid (Table 8.4) was transformed into 25 l T7 Express cells and 
plated on LB-Agar plates containing an appropriate antibiotic. Overnight pre-cultures: A 
single colony was added to 200 ml LB containing 100 g/ml of appropriate antibiotic and 
incubated overnight (37 °C, 200 rpm). Overnight pre-cultures were diluted 1:100 in 1.5 L LB 
media supplemented with 100 g/ml of appropriate antibiotic and incubated (37 °C, 150 rpm) 
until approximately OD600nm = 0.7. Cells were induced with 0.5 mM IPTG (HicA) or 0.3 mM 
IPTG (HicB) and the temperature was reduced to 25 °C and incubated overnight (16 hours, 
25 C, 150 rpm). Due to the low yield associated, HicA was grown in 5 L batches. 
Expression of isotopically labelled HicA 
1 l of the pET151-D/TOPO plasmid was transformed into 25 l Novagen BL21 (DE3) cells 
following the protocol detailed above. Overnight Pre-culture: A single colony was added to 
200 ml LB media supplemented with 100 g/ml carbenicillin and incubated overnight (16 
hours, 37 °C, 200 rpm). Successive overnight pre-cultures were diluted 1:100 in 4 L LB 
media supplemented with 100 mg/ml Carbenicillin and incubated (37 °C, 150 rpm) until 
OD600nm = 2.0. Cells were harvested (5,000 x g, 10 mins) and then washed by resuspending 
the cell pellets in 200 ml M9 minimal media and centrifuging (5,000 x g, 10 mins). The cell 
pellet was then resuspended in 1 L M9 minimal media supplemented with 100 g/ml 
carbenicillin, 1x trace metal elements, 1 mM MgSO4, 0.7 mM glucose, 13.5 mM glycerol and 
1g/L 
15
NH4Cl. Cells were equilibrated for 1 hour at 25 °C before induction with 0.5 mM 
IPTG, for 16 hours at 150 rpm.  
Expression of SeMet labelled pOPINE-DM 
1 l of pOPINE-DM was transformed into 25 l B834 (DE3) cells as detailed above and used 
to inoculate 100 ml SelenoMet
TM
 medium base supplemented with 40 mg/L methionine, 
SelenoMet
TM
 Nutrient Mix (Molecular Dimensions) and 100 g/ml carbenicillin and 
incubated overnight (37 °C, 200 rpm). After incubation overnight at 37 °C, the cells were 
harvested and the pellet was washed in 200 ml dH2O three times through resuspension and 
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centrifugation (5,000 x g, 10 mins) before resuspension in 1L pre-heated and pre-aerated (37 
°C, 150 rpm, 1 hour) SelenoMetTM medium base supplemented with 100 g/ml carbenicillin, 
SelenoMet
TM
 nutrient mix and 40 mg/L selenomethionine (Molecular Dimensions). Cells 
were incubated (37 °C, 150 rpm) until an OD600nm = 0.5, where an additional 20 mg/L 
selenomethionine was added and the temperature was reduced to 25 °C. Cells were allowed 
to equilibrate to 25 °C for 1 hour and then induced with 0.5 mM IPTG and left to incubate 
overnight (25 °C, 16 hours, 150 rpm).  
Protein extraction 
After 16 hours, cells were harvested by centrifugation (5,000 x g, 10 mins) and resuspended 
in 30-40 ml Buffer A (Table 8.1), then immediately purified or stored at -20 C. Resuspended 
pellets were then sonicated in a VCX130 Vibra-Cell, (Sonics) for 15 mins: pulse on (5 s), 
pulse off (5 s) before centrifugation (17,000 x g, 30 mins). The resulting supernatant was 
collected and further purified. 
 
pET26-b-HicB purification 
The cell lysate containing His6-tagged pET26-b-HicB was purified by IMAC on a 5 ml 
HiTrap
TM 
column (GE Healthcare) pre-loaded with 10 ml 100 mM NiSO4 which was 
connected to a GE Healthcare Äkta FPLC and equilibrated in Buffer A. Following sample 
loading, the column was washed with 6% buffer B (5 column volumes) before the protein 
was eluted with an imidazole gradient (6-100% Buffer B) over 10 column volumes. The 
protein was collected in 1 ml fractions usinga GE Healthcare fraction collector (Frac-950) 
and analysed by SDS-PAGE. Fractions containing the protein of interest were pooled and 
destalted into buffer A using a HiPrep
TM
 26/10 Desalting column (GE Healthcare).  The His6-
tag was removed using bovine enterokinase (Sigma, 1 unit per 1 g protein) at 16 °C for up 
to 16 hours before analysis via SDS-PAGE As cleavage was unsuccessful, isolated pET26-b 
HicB following IMAC was injected onto a HiLoad
TM 
26/60 Superdex 75 Prep grade column 
(GE Healthcare) that had been equilibrated in Buffer C before the protein was concentrated 
by ultracentrifugation to 7 mg/ml (GE Healthcare Vivaspin, MWCO 10 kDa, 5,000 x g). 
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pOPINE-HicB purification 
All pOPINE HicB, HicB mutants and N-terminal HicB constructs were purified using the 
same procedure. Briefly, cell lysates containing pOPINE HicB were purified by Ni
2+
 IMAC 
following the procedure above and immediately further purified using a HiLoad
TM
 26/60 
Superdex 75 Prep grade column running Buffer C before concentration by ultracentrifugation 
to 20-30 mg/ml (GE Healthcare Vivaspin, MWCO 10 kDa, 5,000 x g). The purification 
protocol for SeMet labelled HicB-DM was identical except for the addition of 2 mM TCEP to 
all purification buffers. 
HicA purification 
The cell lysate containing HicA was purified by IMAC as detailed for pET26-b HicB with 
minor changes. Following IMAC, the protein was desalted into buffer A and cleaved with 
TEV protease (1:100) for 16 hours at 4 °C. The cleavage reaction was then passed through a 
Ni
2+
 IMAC to remove the His6-tagged HicA and His6-TEV before protein (HicA) was 
desalted into buffer C using a HiPrep
TM
 26/10 desalting column and concentrated by 
ultracentrifugation to 4 mg/ml (GE Healthcare Vivaspin, MWCO 3 kDa, 5,000 x g). 
Purification of 
15
N HicA was identical except after negative purification, untagged HicA was 
exchanged into Buffer D for NMR analysis. 
Protein Detection 
SDS-PAGE  
10% Tris-Tricine SDS-gels were prepared following a previously describing protocol.
373
 
Samples for analysis were prepared in a 1:1 (v/v) ratio with loading buffer before heating 
(100 ° C, 10 mins). The gel was run for 100 V, 1.5 hours and then stained in Coomassie 
brilliant blue stain for 1 hour. Gels were destained in H2O through heating and agitating 
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Denatured Electrospray Mass Spectrometry 
Ziptips
TM
 (Merck Millepore) were used to prepare protein solutions for mass spectrometry 
(typically at a 1 mg/ml concentration) using solutions A, B, C and D (Table 8.1) and multiple 
aspirations (10 l). Briefly, 2 aspirations of solution A were used to wet the Ziptip, before 
equilibration in 0.1% TFA with 5 aspirations of solution B. The protein was bound to the 
matrix with 15 aspirations before washing with 15 aspirations of solution C. The final protein 
sample was eluted with a final aspiration with solution D. Samples were analysed by ESMS 
on the Synapt G2-Si (Waters), which is coupled to a Triverse Nanomate (Advion), (an 
automated chip based spraying device), with the source operating in the positive ion mode. 
Samples were sprayed using a capillary voltage of 1.5 kV. Data was acquired over a 500 - 
4000 m/z range for 1 minute, before data analysis was performed with MassLynx 4.1 
(Waters). 
Native Mass Spectrometry 
20 M samples of HicB and HicAB were dialysed into 100 mM ammonium acetate (AmAc) 
342
 using 3.5 kDa Slide-A-lyzers (ThermoFisher) for 4 h prior to analysis on a Synapt G2-Si 
using the parameters described above. To acquire drift spectra, the ion mobility cell was 
filled with nitrogen gas at 0.5 mbar. Parameters used during data acquisition were adapted 
from those reported by 
374
: sample cone: 80 V, bias voltage: 35 V, trap collision energy: 10 
V, transfer collision energy: 5 V, ion wave velocity: 400 m/s, wave height: 5 V. The TOF 
tube vacuum pressure was maintained at 9.5 x10
-7
 mbar. Data was acquired over a 500- 4000 
m/z range for 10 minutes, before data analysis was performed with MassLynx 4.1. For 
analysis of the HicAB complex, proteins were mixed at equimolar ratios (HicA:HicB = 1:1, 
20 M:20 M  (HicA4HicB4)) for 1 hour at 16 °C prior to dialysis. 
Protein quantification  
The DeNovix DS-11 UV-Vis Spectrophotometer was used to measure the absorbance of 
protein at 280 nm. The concentration of protein was calculated by the Beer-Lambert Law and 
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, 280 nm, H2O). Triplicate microvolume 
measurements were used to assay the accuracy of the reported value.  
Crystallisation and data collection 
pET26-b-HicB (350 M, HicBT = 87.5 M), HicB_FL (500 M, HicBT =125 M), HicB 
(600 and 1,500 M, (HicBT = 150 and 375 M)), HicB-NT (1,000 M, (HicB-NTD = 500 
M)), HicAB (preformed at a 1:1 ratio, HicA (500 M): HicB (500 M) for 1 hour at 16 °C) 
and HicB-S1-2, preformed at a 1:1.2 ratio (HicBT:S1-2 = 125 M:150 M, 250 M:300 M 
and 375 M:450 M) for 1 hour at 16 °C   were crystallised via sitting drop vapour diffusion 
at 293 K with 0.5 l protein to 0.5 l reservoir solution (50 l reservoir) using a ArtRobbins 
Crystal Phoenix
TM
 crystallisation robot and 96 well MRC2 well crystallisation plates 
(Hampton Research). The sparse screens used are described in the text. Initial sparse matrix 
hits were optimised via hanging drop vapour diffusion in 24 well VDX plates (Hampton 
Research) by varying the temperature, ratio of protein: crystallisation buffer and the pH and 
salt/precipitant of the crystallisation buffer. Individual crystals were looped using 
appropriately sized litholoops (Molecular Dimensions) and cryoprotected in up to 40% (v/v) 
glycerol before flash freezing in liquid N2 for data collection using PILATUS detectors at 
Diamond Light Source beamlines (I03 and I04). 









 as described in the text where exact methods are 
described. The following is an overview of each procedure. SeMet labelled HicB-DM: The 
Crank2 pipeline within the jsCoFe interface
297
 was used to yield a partial model from the 
dataset. HicB-NT: Phaser-MR
280
 was used for MR using the model derived from SeMet 
labelled HicB-DM and the Autobuild pipeline
305
. Manual model building and further 
refinement was undertaken using Coot
303
 and Phenix. HicB: Phaser MR using the HicB-NT 
structure as a search model and further manual model building and refinement built the HicB 
tetramer. HicAB: MOLREP
328
 within CCP4 was used for molecular replacement using the C-
terminal domain dimers of HicB as a search model, before manual rebuilding and MOLREP 
was used to rebuild the N-terminal domains of HicB and place the HicA molecules 
(PDB:4C26) into the electron density before refinement using REFMAC5
301
 as described in 
Chapter 3. Final models were refined using Molprobity
307
  and PDB_Redo sever
308
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Biophysical techniques 
Analytical Size Exclusion Chromatography 
A Superdex 75 10/300 GL pre-packed column (GE Healthcare) was equilibrate with Buffer C 
prior to use and calibrated using 1 mg/ml of Aprotinin, Carbonic Anhydrase, Conalbumin, 
Ovalbumin, Ribonuclease A and Blue Dextran (GE Healthcare) in Buffer C to generate a 
calibration curve as previously described
378
 (Equation (1)). Protein samples of HicA, HicBT 
constructs (50 M) and a HicAB complex preformed at a 1:1 ratio (50 M each, where HicBT 






Here the particle coefficient value (Kav), used to plot the calibration curve is calculated 
through the elution volume of the sample (Ve), the total column volume (Vt) and the void 
volume of the column (V0). 
Analytical Ultracentrifugation 
All analytical centrifugation experiments were carried out by myself and Hannah 
Crocker/Mariya Gromova with the aid of Dr Guto Rhys and Dr Antony Burton (Both 
University of Bristol). 
Sedimentation Velocity Analytical Ultracentrifugation 
Sedimentation velocity analytical ultracentrifugation (SVAUC) experiments were carried out 
at 20 °C in a Beckman Beckman Optima XL-A analytical centrifuge (An-60 Ti rotor). 410 l 
solutions at OD280nm = 1 (70 M HicBT, 50 M HicAB, preformed at a 0.5:1 HicA: HicB 
ratio (HicA2HicB4)) and 420 l Buffer C were loaded ino a two-channel aluminium 
sedimentation velocity cell containing quartz windows.  Absorbance scans were recorded 
across a radial range (5.85-7.25 cm) at five minute intervals during centrifugation (50,000 
rpm) until a total of 100 scans.   The resultant absorbance scans were fitted to a continuous 
c(s) distribution model in SEDFIT
337
 with 95% confidence interval by modelling the  
sedimentation distribution profile to the Lamm equation
379
 (2) to determine the sedimentation 
coefficient distribution (c(s)). Within the Lamm equation the Diffusion coefficient (D) and 
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Sedimentation coefficient (S) are described by equations (3-6)
337, 338, 341
 and are used to 
compute the molecular weight (Equation 6). This fitting procedure fit the baseline, meniscus, 
frictional coefficient (𝑓/𝑓0), systematic time-invariant and radial-invariant noise were fitted. 
RMSD values obtained for the fit of samples were 0.009 for both HicB and HicAB. 
Parameters for fitting: Buffer density/viscosity and the partial specific volume (ῡ) of the 
analysed particle were  calculated using SEDNTERP (http://sednterp.unh.edu/).
380, 381
 Images 



















The concentration of the particle (c) at a given time (t) and radius (r) is described by its 














Here M(1- ῡp) is the effective buoyant molecular mass (Mb) and is described by the partial 
specific volume (ῡ) and the solvent density (p). N: avogadros constant, µ: velocity, 𝜔2r: 





















S can also be related to the frictional coefficient. 








Both S and D can be related to each other through the Svedberg Equation (6), allowing the 
indirect determination of the molecular mass
339
. 
Sedimentation Equilibration Analytical Ultracentrifugation. 
Sedimentation equilibrium analytical ultracentrifugation (SEAUC) experiments were 
conducted at 20 °C in a Beckman-Optima XL-I analytical ultracentrifuge (An-60 Ti rotor).A 
110 l solution at OD280nm = 0.4 (20 M HicAB pre-formed at a 0.5:1 HicA:HicB ratio 
(HicA2HicB4)) and 120 l buffer C were loaded into a six-channel aluminium sedimentation 
equilibrium cell containing quartz windows (three protein channels and three reference 
channels).   Samples were radially equilibrated for 16 hours before the samples were 
centrifuged in the range of 9,000-21,000 rpm, with the absorbance at 280 nm recorded for 
each channel at each centrifugation speed across a radial range (5.8-7.3 cm). The resultant 
data were fit to a single ideal species model using Ultrascan II
383
, evaluating the molecular 
mass as a function of the radial position (r) within the ultracentrifuge cell (Equation (7)).
340, 
341
 95% confidence intervals were determined by Monte Carlo analysis based on 10,000 













Electrophoretic Gel Mobility Shift Assay 
Oligonucleotides used in EMSA assays (Appendix Table 4) were resuspended to 100 M in 
Buffer E and annealed together to form a dsDNA complex (50 M) by mixing together at 95 
°C and left to anneal overnight at 4 °C. Serial dilutions of HicBT constructs (including DNA 
mutants) and HicB-NTD were prepared to give a final concentration between 0.8-3.2 M in 
Buffer E. HicA was prepared to give a final concentration of 0.8-50.8 M in buffer E. For 
determination of the DNA binding region, 3.2 M HicBT was equilibrated at room 
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temperature with specific DNA fragments described in the text (3 M) for 30 minutes in 
Buffer E and loaded onto a 10% Tris-acetate-EDTA (TAE) gel (prepared as previously 
described
385
)  in 1xTAE buffer
385
 and run at 100 V (1 hour, 16 C) before staining in ethidium 
bromide in 1x TAE buffer and visualised under UV using an E-gel Imager. For stepwise 
binding between the 0-20 bp and 0-40 bp fragments and 16-36 bp to 20-40 bp fragments, the 
mixture (2 M DNA, 3.2 M HicBT) was equilibrated in an identical manner and then loaded 
onto a 15% TAE gel and analysed in the same manner. Competition assay: A preformed 
HicB-S1-2 complex (3.2 M HicBT, 2 M S1-2 in Buffer E) was challenged with increasing 
concentrations of HicA (0.8-50.8 M) and equilibrated for 30 minutes prior to analysis on a 
15% TAE gel.  
Fluorescence Anisotropy 
Fluorescence anisotropy experiments were carried out in collaboration with Dr Oliver 
Wilkinson and Prof Mark Dillingham (Both University of Bristol). 
Fluorescence equilibrium titrations were performed (Jobin Yvon Fluorolog, Horiba 
Scientific) to determine the dissociation constants (Kd) for HicB, R94E, N96Q, S98T, HicAB, 
HicA and HicB-NT binding at 20 °C to S1-2 (5’-ATGTGTATAATTACACACAA-3’) which 
harboured the fluorescence dye Hexafluorescein (HEX) at the 5’ end (7.5 nM). The excitation 
wavelength was set at 530 nm and the emission intensity set at 554 nm. Slit widths were set 
to 5.0 nm for both excitation and emission. Following sample equilibration for 2 minutes, 3 
data points with an integration time of 0.5 s were collected for each titration point. 











Titrations were performed in Buffer E in a total volume of 200 µl in a 10 x 2 mm quartz 
cuvette (Hellma Analytics). HicB, preformed HicAB and HicB-NT were titrated into HEX-
S1-2 up to 150 nM. R94E, N96Q, S98T and HicA were titrated until an end point of 1000 
nM. For competition assays, a preformed HicBT (10 nM)-HEX-S1-2 (7.5 nM) complex (80% 
bound was formed before the addition of HicA to a final concentration of 300 nM or HicBT 
(50 nM)-HEX-S1-2 (7.5 nM) complex (95% bound) was preformed before HicA titration (0-
1000 nM). 





Data were fitted to a single-component binding equation to determine the dissociation 
binding constant Kd using GraphPad Prism 7.04: equation (9).
349, 350, 352, 386
 
 
Y=  (ADP - AD) (
[X]+ Kd + n ± √([X]+ n + Kd)2- (4[X]n)
2n
) + AD (9) 
 
 
Where ADP is the anisotropy of the fully bound HicB-S1-2 complex, AD is the anisotropy of 
unbound S1-2, n is the stoichiometry and [X] is the concentration of protein. For competition 
assays involving HicA, data were fitted to a four-component inhibition equation to determine 













Where A is the measured anisotropy, AD is the anisotropy of free HEX-S1-2, ADP is the 
anisotropy of the saturated HicB-HEX-S1-2 complex, [HA] is the concentration of HicA, H 
is the Hill slope. 
Ki values were calculated from the Cheng-Prussof equation
362
 (11), the Munson 
derivatisation to the Cheng-Prussof equation
363












Where Ki refers to the inhibitory binding constant 

















Where y0 refers to the ratio of bound: free ligand 
 
P0=







Where P refers to the total protein concentration and P0 is the free protein at 0% inhibition. 
 PL0=P- P0 (14) 






Wheree PL50 refers to the bound complex at 50% inhibition 
 L50=L- PL50 (16) 
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Nuclear Magnetic Resonance 
250 M 
15
N HicA in Buffer E supplemented with 10% D2O was transferred to a 3 mm NMR 




N HSQC was acquired at 25 °C using a Varian VNMRS equipped with a 
cryoprobe, operating at 600 MHz by Dr Chris Williams (University of Bristol). NMR data 
was processed within NMRPipe
387
 and spectra analysed in CcpNmr Analysis version 2.1.5.
388
 




Small angle X-ray scattering 
In-line SEC-SAXS for HicB, HicAB and HicB-S1-2 were collected at Beamline 21, 
Diamond Light Source using an Agilent 1200 HPLC and 2.4 mL Superdex S200 column (GE 
Healthcare). 50 L of protein at an appropriate concentration: 500 M of each HicB variant 
(HicBT = 125 M), HicAB (preformed at a 1:1 ratio, 500 M HicA: 500 M HicB 
(HicA4HicB4)) and HicB-S1-2 (preformed at a 1:1.6 ratio, 300 M HicBT: 500 M S1-2) 
were loaded (0.04 mL/min) onto a Superdex 200 column (GE Healthcare) running (Buffer 
C). Frames were collected at 3 seconds per frame at 25 °C and X-ray scattering was recorded 
(Pilatus 2M detector) with a fixed camera length of 4.014 m, at 12.4 keV. Angular range q 
data were collected between 0.006-0.042 Å
-1
. ScÅtter (www.bioisis.net) determined the 
radius of gyration (Rg), the maximum particle dimension (Dmax) and the pair distribution 
function (P(r)).
323, 389
 Ab initio bead density shape envelope models for each dataset were 
generated by DAMMIF
390
, averaging over twenty three independent runs using the program 
DAMAVER
391
, before a single DAMMIN refinement run.
392
 Ab initio bead density shape 





 was used to quantitatively compare the calculated X-ray scattering of 
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Appendix Figure 1. Purification of pET26-b HicB. (A) SDS-PAGE following the expression and purification 
of pET26-b HicB from sonication to isolation via SEC. (B) Enterokinase trials to cleave His6-HicB to HicB that 
did not result in a specific conversion and instead generated multiple species. Arrows refer to the position of 
monomeric His6-HicB (His6-HicBM) and dimeric His6-HicB (His6-HicBD). 
 
Appendix Figure 2. Native mass spectrometry of HicB_FL. (A) Mass: charge ratio spectra of HicB_FL 
spanning 1,650- 3,400 mz. Peaks were assigned based on their charge state: dimeric (blue) or tetrameric (red). 
(B) De-convolution spectrum of the m/z envelope shown in (A) to determine the tetrameric mass of HicB_FL: 
Observed mass: 64,800 Da (Expected mass: 64,809 Da). 
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Appendix Figure 3. Denatured ESMS of HicB. (A) Denatured mass/charge spectrum of HicB. Peaks were 
assigned based on the monomeric charge state (black). (B) De-convolution of the m/z envelope, yielding 
monomeric HicB: Observed mass: 15,737 Da (Expected mass: 15,738 Da). 
 
 
Appendix Figure 4. Native mass spectrometry of methionine mutants I51M and I99M. (A) Native mass 
spectrometry of I51M showed a similar distribution of m/z charge states to HicB, with deconvolution resulting 
in a single species (observed mass: 63,020 Da, expected mass: 63,027 Da). (B) Native mass spectrometry of 
I99M displayed a similar distribution of m/z charge states to HicB, with deconvolution resulting in a single 
species (observed mass: 63,028 Da, expected mass 63.027 Da). For both native mass spectrometry profiles, a 
series of m/z charge states of dimeric (blue) and tetrameric (red) states of each mutant are seen. 
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Appendix Figure 5. Native mass spectrometry of HicB_DM. (A) Native mass spectrometry of HicB_DM 
displayed a similar distribution of m/z charge states to HicB. (B) Deconvolution of the m/z envelope resulting in 
a single species (observed mass: 63,097 Da, expected mass: 63.099 Da). A series of m/z charge states of dimeric 
(blue) and tetrameric (red) states of HicB_DM are observed. 
 
Appendix Figure 6. Analytical SEC profiles of HicBT, HicB_DM and HicB_DM_SeMet. SEC profiles for 
each construct and an SDS-PAGE of eluted samples. The arrow refers to the band corresponding to monomeric 
HicB for each construct. 
 
Appendix Figure 7. Denatured ESI mass spectrometry of HicB-NT. (A) Denatured m/z spectrum of HicB-
NT. Peaks were assigned based on the monomeric charge state (black). (B) De-convolution of the m/z envelope, 
yielding monomeric HicB_NT: Observed mass: 10,133 Da (Expected mass: 10,133 Da). 
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Appendix Figure 8. SAXS of HicB (A) Log10 SAXS intensity versus scattering vector (q). (B) Dimensionless 
Kratky plot. Cross-hair marks the Guinier-Kratky plot (1.732, 1.1), the main peak for folded globular particles. 
(C) Pair-distance, P(r) distribution function. Maximum dimension, dmax is the largest non-negative value that 
supports a smooth distribution function. (D) Fit of the parameters computed by the P(r) distribution (red line) to 
the raw scattering data (green). 
 
Appendix Figure 9. Denatured ESI mass spectrometry of His6-HicA. (A) Denatured m/z spectrum of His6-
HicA. Peaks were assigned based on the monomeric charge state (black). (B) De-convolution of the m/z 
envelope, yielding monomeric His6-HicA: Observed mass: 10,203 Da (Expected mass: 10,204 Da). 
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Appendix Figure 10. HSQC of HicA. (A) Sequence alignment between the pET151-HicA construct (HicA) 
and the pET26b-HicA construct (HicA*). 100% conservation is seen by the presence of a black box. * 




N HSQC. (B) Cartoon 




N HSQC spectra of HicA that were 




N HSQC of HicA (black) overlayed onto the previous 





9.  Appendix   
 152 
 
Sample Mw (kDa) Log10Mw Ve (ml) Kav 
Blue dextran 2000 6.3 7.14 0.00 
Conalbumin 75 1.87 9.02 0.11 
Ovalbumin 44 1.64 9.78 0.16 
Carbonic anhydrase 29 1.46 11.13 0.24 
Ribonuclease A 13 1.11 13.07 0.35 
Aprotinin 6 0.78 15.58 0.50 
Appendix Figure 11. Analytical SEC profiles of calibrants. (Top) SEC profiles for all reported constructs. 
(Middle): Calibration curve using known standards: Aprotinin (AP), Ribonuclease A (RA), Carbonic Anhydrase 
(CA), Ovalbumin (OV) and Conalbumin (CO) used to determine the Mwapp for analysed proteins. (Bottom) 
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Appendix Figure 12. Disruption of the hydrophobic tethering interaction across adjacent subunits 
induced in HicB upon binding HicA. (A) Interaction sites across the tetramer with electrostatic and 
hydrophobic sites highlighted in black and red boxes. Box 1 highlights the electrostatic interaction site 
(Residues E48, E52, D89, R101 and H105) and box 2 shows the absence of the hydrophobic site (Residues I51, 
V57, F59, L85, L88, P100 and F102) between adjacent subunits when the 1 helix lies parallel to the C-
terminal domain. Box 3 and 4 shows the respective presence of the hydrophobic interface and absence of the 
electrostatic interface between adjacent subunits 2 and 4 when the 1 helix is surface exposed.  Subunits are 
highlighted blue, red, green and yellow respectively for subunits 1-4.  (B) Rotation of L85 and L88 to maintain 
the hydrophobic core. Box1 highlights the positions of L85 and L88 in the unbound form for subunit 2, forming 
tethering interactions with P100 and F102 of subunit 4 (yellow). Box 2 highlights the rotation of L85 and L88 of 
subunit 2 away from P100 and F102 to interact with residues maintaining the hydrophobic core: I22, I43, V47 
and V83. Due to the interaction of HicA at each subunit, these changes are mimicked in subunit 3 where the 1 
helix is orientated in an exposed manner. (C) Comparison of the unbound (grey) and bound (red) orientations of 
subunit 2. Lateral displacement (2.4 Å) of the 1 helix results in a lateral shift of E47 and an upward shift of 
F59 of the 1-2 loop.  
Appendix Figure 13. Intrasubunit interactions between 
individual N-terminal and C-terminal domains within subunit 
1 of HicAB. R124 forms an electrostatic interaction with D84, 
whose position is stabilised by hydrogen bonds to S86 and Q87. 
L127 forms a hydrophobic interaction with F59. Due to the 
symmetrical nature of HicB within the HicAB complex, each set 
of intersubunit and intrasbunit interactions are conserved 
throughout HicB. 
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Appendix Figure 14. Conservation of the dsRBD fold within HicA family members.  (A) Superimposition 
of the solution state of Burkholderia HicA (PDB: 4C26, blue) onto the crystalline conformation of HicA (red) 
with an RMSD of 1.2 Å. (B) Superimposition of the crystalline conformation of HicA (red) onto the crystalline 
conformation of Yersinia HicA3 (PDB: 4P78, purple), RMSD: 2.2 Å. (C) Superimposition of the crystalline 
conformation of HicA (red) onto the crystalline formation  of Streptoccocus HicA (PDB: 5YRZ, green), RMSD: 
1.5 Å. HicA (red), HicA3 and HicASP are representative of their conformations when bound to their cognate 
HicB antitoxin. 
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Appendix Figure 15. Conservation of residues within dsRBD proteins. (A) Multiple sequence alignment of 
various dsRBD within proteins encoded in several organisms: Homo sapiens (Hs), Drosophila melanogaster 
(Dm), Saccharomyces cerevisiae (Sc), Xenopus leavis (Xl), Arabidopsis thaliana (At), E. coli (Ec) and Aquifex 
aeolicus (Aa). The name of each protein, their UniProt accession code and the sequence rnge corresponding to 
the location of thhe dsRBD in the protein are given. Sequences are highlighted according to their amino acid 
conservation (>40%) and thhe resultant consensus sequence that describes these dsRBDs is depicted 
underneath. The three distinct regions of interaction for dsRBDS (with RNA) and the consensus second 
structure elements for the dsRBDs are highlighted below the consensus sequence. Taken directly from Figure 
1
333
  with the authors direct permission. (B) Sequence alignment of HicA to HicA family members whose have 
been experimentally investigated: Yersinia HicA, E. coli HicA (HicAEC) and Streptococcus HicA (HicASP). 
Symbols indicate a conserved residue (*), conservative mutation (:) and a semi-conservative mutation (.). 
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Appendix Figure 16. Conservation of the hydrophobic patch of P39/P41-W28 between HicAB and 
HicABSP. (A) The hydrophobic patch between the 3 strand of HicB (blue) and HicA (red) (P39/P41-W28) is 
conserved within HicABSP. Y57 (2) within HicASP (light grey) forms several hydrophobic interactions with 
F22, F80, F86, Y90 (all 2-4 loop) of HicBSP (dark grey). For clarity only interactions between Y57 and 
F22/Y90 are shown. (B) This hydrophobic patch within HicABSP is supplemented by a hydrogen bond network 
between the 2 helix of HicASP (E53, N55 and T58) interacting with the 3 strand of HicBSP (Q34). The side 








9.  Appendix   
 157 
Burkholderia_pseudomallei                 ------MEFPIAVH-K-DDGSVYGVTVPDI----PGVHSWGETIDDAIKNTREAIVGHVE  48 
Burkholderia_ambifaria                    ------MRFFVAVD-K-QEGTDYGVVVPDF----PGCNSWGTTLEQALENTQEAIEGWVE  48 
Pseudomonas_Syringae                      ------MKYPICIE-WGDETTAFGIQIPDI----PGAITAGDTFEEAHAAAVEIAHIML   49 
Burkholderia_thailandensis_E264           ------MEFPIAVH-K-DDGSVYGVTVPDI----PGVHSWGETIDDAIKNTREAIVGHVE  48 
Microcystis_aeruginosa_NIELS-843          -----MITYLATVH-KDN-HSDYGVQFYDF----PGCISAGETIEEAKKMATEALKGHIS  49 
Polaromonas_napthalenivorans_CJ2          ------MRYPITIE-PGNDTTAWGVVVPDL----PGCFSAGDTLEEAMIQAEDAVTAWIE  49 
Neisseria_gonorrhoaea_FA1090              ------MFIPAALH-K-DEHSAYGVTIPDL----PGCFSCGDTVEEAVANARSAAYMHID  48 
Gluconobacter_oxydans_621H                ------MRYPVVIE-RGSETTAFGVVFPDL----PGCFSAGDTLDEALSCAEEAAAAWID  49 
Rhodopseudomonas_palustris_HaA2           --MSATSGYLALVY-KDR-DTSYGVAFPDV----PGCISAGDTFEQAIDNAAEALGGHLA  52 
Pseudomonas_fluorescens_SBW25             ------MLYPIAIS-TGDNDHAWGVEVPDI----PGCYSAGDDLDDAMAMAREAIEGHFE  49 
Roseiflexus_castenholzii_DSM_13941        ------MHYPVVIH-KDT-ESDYGVTVPDL----PGCFSAGETLDEALQEAIEAIECHLE  48 
Carboxydothermus_hydrogenoformas_Z-2901   -MYKDLYVFPAIFD-YAE--DGISVEFPDL----PGCLTCGDNTEEALKNAKEALELHLY  52 
Mesorhizobium_loti_MAFF303099             -----MKQYIGLIH-KDA-GSDFGVSFPDF----PGVITAGKDLDDARSMAEEALTLHIE  49 
Bordetella_parapertussis_12822            ------MLYPIHVS-K-DEGSAYGAAFPDF----PGCFAAADELQDLPRAAQEAVEAHFY  48 
Clostridium_perfringens_13                MKKKDTYIFPAIVT-TES--DGITITFPDL----EGCITCAYSDDEIMKVSKEALGLHLY  53 
Yersinia_pestis_biovar_Medievalis_91001   -----MAIYPAYVH-VDNDGSASG-YFPDV----KGCIFAINAGEDLFAEASSALDAHFE  49 
Haemophilus_somnus_129PT                  ------MLYPIAIE-PGDETHAFGVIVPDI----PGCHSAGDTLEEAYANAKEAIKGHLE  49 
Nitrobacter_hamburgensis_X14              -----MRQFIALIH-KDA-DSDYGVSFPDL----PGCVTAGTTLDEARDMAAEALALHLE  49 
Serratia_proteamaculans_568               ------MFYPAYVH-SEHDGSASG-FFPDV----PGCYFAGDTLDRAFEDAKSALDAHFE  48 
Yersinia_pestis_C092                      -----MAIYPAYVH-VDNDGSASG-YFPDV----KGCIFAINAGEDLFAEASSALDAHFE  49 
Yersinia_pestis_Antiqua_JGI               -----MAIYPAYVH-VDNDGSASG-YFPDV----KGCIFAINAGEDLFAEASSALDAHFE  49 
Yersinia_pestis_KIM                       -----MAIYPAYVH-VDNDGSASG-YFPDV----KGCIFAINAGEDLFAEASSALDAHFE  49 
Yersinia_pestis_Nepa1516                  -----MAIYPAYVH-VDNDGSASG-YFPDV----KGCIFAINAGEDLFAEASSALDAHFE  49 
Caulobacter_crescentus_CB15               -----MADYIALIH-KDA-DSAFGVSFPDL----PGCISVGETLEEARANAEEALALHVE  49 
Finegolida_magna_ATCC_29328               --MKNDILYPVVMS-KED--GRYFAQCYDY----EEIYAEGDTIEEALKNIKEVFGLIFY  51 
Haemophilus_somnus_2336                   ------MLYPIAIE-PGDETHAFGVIVPDI----PGCHSAGDTLEEAYANAKEAIKGHLE  49 
Legionella_pneumophila_Lens               ------MRYPVVIH-KDE-HSDFGVIVPDI----PGCYSSGSTYDEALTNVIEAIECHL   48 
Escherichia_coli_UMN026                   ------MFYPAYIH-SDPDGSASG-FFPDV----PGCYFAGDTLDNAFQDARSALVAHFE  48 
Clostridium_botulinum_B_Eklund_17B        MNAKDMYVFPAIFT-YDN--DGISIEFPDL----PGCLSCADTTDEAIKMAKEALALHLY  53 
Treponema_denticola_ATCC_35405            MKKQERFFYPAIFT-YNG-KKEIAVVFPDL-----GCATSGKDEADALLSARELLGCVLC  53 
Rhodospirillum_rubum_ATCC_11170           ----MNYTYAVVIE-TDD-LGGFSAFFPDL----PGCVGAGDSVEACFQDALDALALHLA  50 
Bartonella_tribocorum_cIP105476           -----MKRFFALVH-KDE-DSAFGVQFPDF----EGLFSASDEEENLIINATEALQLY--  47 
Nostoc_sp._PCC7120                        ------MRYAVVIE-KGE--TSYGAYVPDL----PGCVAVGETLEEVKQLITEAIEFHIE  47 
Maricaulis_maris_MCS10                    -----MPNFYAIVT-QEG-DSAHGIHFPDL----PGCFSAADTLDEVPAKAREALSLW--  47 
Pelotomaculum_thermopropionicum           ---MDKYIFPAIFE-VGE-IKGYCVTFPDL----PGCITEGNTLEEALQMAREALELHLY  51 
Leptotrichia_goodfellowii_F0264           -MTKDSYLYPAIFK-YGE--DGITITFPDL----PGCISCGKNDEEALYMARDVLGGWMY  52 
Clostridium_kluyveri_DSM_555              ---MDKYMYPALFE-AYE-DGGYTVSFPDL----PGCITEGDSLTEALTMAKEALELFLW  51 
Candidatus_methanoregula_boonei_6A8       -----MVSYTVIIE-TGK--HNCSAYCPDL----PGVIATGRTQEETFENMKSAITFHLE  48 
Methanospirillum_hungatei_JF-1            -----MYRFLIVIE-KAE--TNYAAYSPDL----PGCVATGKTREEAEEQMHEAIAFHIE  48 
Alkalilimnicola_ehrlichei_MLHE-1          ------MKYAIVIE-KAG--QNYSAYVPDL----PGCVATGDSIPEAEALIREAIEWHLA  47 
Syntrophomonas_wolfei_subsp.              ---MHKLTYFAVFE-PVA--TGYSVYFPDI----PGCVSYGEDFEEAQKQAADALGLHLY  50 
Geobacter_uraniireducens_Rf4              -----MYRFLVVIE-KTD--TGFSAYSPDL----PGCIATGLTREETEKNMHEAIEFHIH  48 
Bartonella_henselae_Houston-1             -----MKRFFALVH-KDE-DSAFGVQFPDF----EGLFSAADEEENLIINATEALQLY--  47 
Shewanella_baltica_OS195                  ------MLFMVGIETPADETEAFGIIVPVFEKLGYGCFSATDSQEEILFKAKEAILLMAE  54 
Haemophlus_influenzae_PittEE              ------MIFTVGVETPENENQAYGMIVPALCQLDYGCFSGADDVDDLLPMVTEAITMMLE  54 
Salinispora_arenicola_CNS-205             -----MNAYVVIIE-RAE-DGGYGAWSPDL----PGCVALGETRREALAEMRAAIAFHLE  49 
Haemophilus_influenza_86_028NP            ------MLFTIGIETPTNENEAYGITVPALFTEEYSCFSAADTLEEIPTQVTDAIHSILE  54 
Rhodobacter_sphaeroides_ATCC_17029        -----MHYFTAIVH-KDP-NSAYGLTFPDL----PGCFAAADDWSEIPAKAAEALDLW--  47 
Vibrio_vulnificus_YJ016                   ------MWFTLGVETPKDKDSSYGIVVPALCNDRYSCYSASDSSKEIAAHSAEAIESILE  54 
8Escherichia_coli_0157:H7_str._EC41       ------MFFSVGVETPKDDHTAYGITVPAFDRFDFGCVSAADTQSEIPVMAREAILAIVE  54 
Thermus_thermophiles_HB27                 ----MRRRYRVVVE-RDE-EGYFVAHVPEL-----HAHTQAQSFEELLRRLQEAIAVSLE  49 
Yersinia_pseudotuberculosis_IP_31758      ------MIYPIFIF-KTVEG--FDGYFPDI----DGCFFAGNTFADISKNAEEAFAVHIE  47 
Yersinia_pestis_angola                    ------MIYPIFIF-KTVEG--FDGYFPDI----DGCFFAGNTFADISKNAEEAFAVHIE  47 
                                                      .                                                
 
Burkholderia_pseudomallei                 TLIELG-----EDVEFTCSTVEE-LVAK--PEYAGA--VWA-------LVSVD----LSQ  87 
Burkholderia_ambifaria                    TSVEAG-----DEVRFEPTSFEE-LRDN--PDYAGS--FWA-------VVDID----PSK  87 
Pseudomonas_Syringae                      EIAASG-----GSIPKVGTVAEH-AKN---PDFSGM--GWG-------MLEID----VTP  87 
Burkholderia_thailandensis_E264           TLIELG-----DDVEFTCSTVEE-LVAK--PEYAGA--VWA-------LVSVD----LSQ  87 
Microcystis_aeruginosa_NIELS-843          FMLADG-----DEIPTPSTLETI-L-TD--ADHQDA--I---------AFLLI----EVS  85 
Polaromonas_napthalenivorans_CJ2          VALDAG-----QDIPAPSHIEAL-RTAH--PEFDGW--LWA-------LVKVD----PAM  88 
Neisseria_gonorrhoaea_FA1090              GMIEDG-----GFKNLAVSSIAD-LSQE--PDYHGA--TWV-------MIEID----PAK  87 
Gluconobacter_oxydans_621H                ATLDAG-----EAVPSPSSLDAI-Q-SN--PDYQGW--TVG-------IVTID----PAI  87 
Rhodopseudomonas_palustris_HaA2           LLRADG-----DPIPQPRSLEQL-R-DD--PEFVAE--AADA-----VVAFVR----PQA  92 
Pseudomonas_fluorescens_SBW25             ILAEDG-----APIPSAQKVTLH-AAN---PQYAGC--TWA-------VVDID----VTK  87 
Roseiflexus_castenholzii_DSM_13941        GLLADG-----EPIPTPKPVELH-Q-SN--PDYAGG--IWA-------FVTVD----VTK  86 
Carboxydothermus_hydrogenoformas_Z-2901   GMEKDN-----EPIPEPTPIDKIKI--E--P---NQ--VLV-------LVEAWMPLVRSE  91 
Mesorhizobium_loti_MAFF303099             GLVEDG-----EAIPEPSSLQAV-M-AD--ADNRDG--V---------AILVA----AKT  85 
Bordetella_parapertussis_12822            G---ET-----ERIPAPSAPEAW-AND---EDYQGG--YWM-------MVDID----LSK  83 
Clostridium_perfringens_13                GLETDEEIEGKELIPVPSKLNDLKL--E--K---NQ--ATT-------LVEVYMPVIRQV  97 
Yersinia_pestis_biovar_Medievalis_91001   ALVSEG-----IEIPEAHDMPYH-VYRNPCDYADGG--QWY-------NVNID----MSK  90 
Haemophilus_somnus_129PT                  LLVEMG-----EEVPLPTSINNH-RNN---PDFTEYDMFFG-------FVDVD----ITH  89 
Nitrobacter_hamburgensis_X14              GMAEDG-----EGVPEPASLEEV-M-AD--PVNRDG--V---------AVLVA----APA  85 
Serratia_proteamaculans_568               LLSEDN-----QSIPRPQAVSFH-LAQES-DTLNGG--QWL-------LVDIN----MDK  88 
Yersinia_pestis_C092                      ALVSEG-----IEIPEAHDMPYH-VYRNPCDYADGG--QWY-------NVNID----MSK  90 
Yersinia_pestis_Antiqua_JGI               ALVSEG-----IEIPEAHDMPYH-VYRNPCDYADGG--QWY-------NVNID----MSK  90 
Yersinia_pestis_KIM                       ALVSEG-----IEIPEAHDMPYH-VYRNPCDYADGG--QWY-------NVNID----MSK  90 
Yersinia_pestis_Nepa1516                  ALVSEG-----IEIPEAHDMPYH-VYRNPCDYADGG--QWY-------NVNID----MSK  90 
Caulobacter_crescentus_CB15               GMIEDG-----ETLPAPSALDEV-M-AA--PGNRDG--V---------VILVP----LKT  85 
Finegolida_magna_ATCC_29328               DFEEDE-------YKKASNIEDIMKELK--E---GE--FVV-------YVNVWLPYEFSK  90 
Haemophilus_somnus_2336                   LLVEMG-----EEVPLPTSINNH-RQN---PDFTEYDMFFG-------FVDVD----ITH  89 
Legionella_pneumophila_Lens               GLLIDN-----EPLPVGTTIDRW-I-ND--EEFQGG--VWA-------FVDID----LSQ  86 
Escherichia_coli_UMN026                   TLCEMN-----EELPLPGSVETH-LVQRA-QDFIGG--QWL-------LVDIN----MNQ  88 
Clostridium_botulinum_B_Eklund_17B        GMEEDN-----ESIPKDTPINNLTL--L--E---NQ--IPM-------LIEVYMPLYRTA  92 
Treponema_denticola_ATCC_35405            GLEDDG-----EPIPKASHLSNIKT--G--K---NE--KSV-------LIDVYLPTYRM   92 
Rhodospirillum_rubum_ATCC_11170           GMIEDG-----DSLPAPTPLSDV-E-VD--PDIQVA--AIL-------L---A----SVP  85 
Bartonella_tribocorum_cIP105476           --CEDM-----DTVPVPLKFE------E--VIQQKA--VKKALSEGAFLIQVP----FIE  86 
Nostoc_sp._PCC7120                        GMIVDG-----LPIPQPTSMTHE-VEVL--M---------------------------S-  71 
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Maricaulis_maris_MCS10                    --FEDE-----AMIA-PSSLADV-H-EK--IRNDLG--YIDLMSSGSFLMSIP----VVS  89 
Pelotomaculum_thermopropionicum           GMEEDE-----DEIPSPTPPERVDV--P--E---KG--FVA-------IVEARMPLIRDR  90 
Leptotrichia_goodfellowii_F0264           QIERAK-----EKIPKSSSLNMINL--N--F---DE--KVL-------LIDVWMPSVRKS  91 
Clostridium_kluyveri_DSM_555              NMEDDN-----EEIPEPTPPEKIET--K--K---GN--FIV-------PVEADMALIRAK  90 
Candidatus_methanoregula_boonei_6A8       GLLEDN-----QEIPTPVSKAKT-IRIS--R---------------------------KH  73 
Methanospirillum_hungatei_JF-1            GMKEDG-----LPIPQACSSASW-VLV---------------------------------  69 
Alkalilimnicola_ehrlichei_MLHE-1          GLREDG-----APIPQPSSHVEY-VDVA--------------------------------  69 
Syntrophomonas_wolfei_subsp.              GMEKDG-----DEIPTPSKVPQVDTETA--P---GY--IIS-------PVSIFPSIVRNE  91 
Geobacter_uraniireducens_Rf4              GLLEDH-----LSVPESSSFAEF-MAVA--------------------------------  70 
Bartonella_henselae_Houston-1             --CEDM-----DTVPVPLKFE------E--VIQQKA--VKKALSEGAFLIQVP----FIE  86 
Shewanella_baltica_OS195                  EVINDG-----HL-IDALNEGYRDYRAT--H--PEFE-QWV-------AVEVP----LEA  92 
Haemophlus_influenzae_PittEE              AMVED-----GFDLTTLKDKGVTHYKAD--PEYADFD-TWL-------LVDVD----ISE  95 
Salinispora_arenicola_CNS-205             GLREAG-----EPVPAPKAVGVD-L-IA--A-----------------------------  71 
Haemophilus_influenza_86_028NP            MMFED-----GIDINELQDKGYRHYQTQ--EDFNYCD-TWL-------LLDVD----ISA  95 
Rhodobacter_sphaeroides_ATCC_17029        --FEDE-----PAVE-PASIDAI-Q-SR--E----D--VRKALAEGASLMTFA----YVP  85 
Vibrio_vulnificus_YJ016                   EMLAD-----GFDVLGLEDQGALAYRED--EAYRFCD-VWL-------QIEID----VSR  95 
Escherichia_coli_0157:H7_str._EC41        EMVLSG----SYSVDDIHDDGCLTYAAN--QDYSHCD-SWF-------VIDVD----LSE  96 
Thermus_thermophiles_HB27                 EERAEV-----VGLEGALEIEAA-------------------------------------  67 
Yersinia_pseudotuberculosis_IP_31758      ALMNEG-----FPLPSPPKDPHR-YIDDPRLKEEGG--ILG-------FVEID----PAK  88 
Yersinia_pestis_angola                    ALMNEG-----FPLPSPPKDPHR-YIDDPRLKEEGG--ILG-------FVEID----PAK  88 
                                                                                                          
 
Burkholderia_pseudomallei                 LDSKPERINVSIPRFVLHKIDAYVAS-RH--ETRSGFLARAALEALNEGKVRHA 138 
Burkholderia_ambifaria                    FDMKPERVNISLPRFVLTQIDAFAEA-HK--ETRSGFLVRAALEAIRHEQTAV- 137 
Pseudomonas_Syringae                      YLGKTEKVNVTLPGFVIRQIDRYVRD-HS-IKSRSTFLADAALEKLGRA----- 134 
Burkholderia_thailandensis_E264           LDSKPERINVSIPRFVLHKIDAYVAS-RH--ETRSGFLARAALEALNEGKVRHA 138 
Microcystis_aeruginosa_NIELS-843          EAILNHQE-LCVKN---------------------------------------- 98 
Polaromonas_napthalenivorans_CJ2          LDDTVERVNISLPRRVLRRLDARART-AG--ETRSGFIARMAVEGREPAAHA-- 137 
Neisseria_gonorrhoaea_FA1090              ISRQQIRFNVSWPQYLLDRVDEYTSA-NH--ETRSGFLAKAALLTMNQA----- 133 
Gluconobacter_oxydans_621H                LDDRVERANISLPRRVLERLDALARA-SR--ESRSGMIAAMTLQAKLTPDTKSR 138 
Rhodopseudomonas_palustris_HaA2           ERAAAE------------------------------------------------ 98 
Pseudomonas_fluorescens_SBW25             YLGKAQKLNITLPGYLLNRIDEYVLH-HPEEKSRSGFLASAALKVLQQEH---- 136 
Roseiflexus_castenholzii_DSM_13941        LSGKTRRINITLPERVLHLVNKYASE-RG--ESRSGLITQAVLEYIGSRETLAR 137 
Carboxydothermus_hydrogenoformas_Z-2901   MDNKAVKKTLTLPKWLNDL----AEK-KK--INFSRVLQQALKEQLGIKEREI- 137 
Mesorhizobium_loti_MAFF303099             EARKAVRINVTLPDDVLRRIDAFAEA-HG--YTRSGFLAKAAEKAMELESA--- 133 
Bordetella_parapertussis_12822            VNTKAVRLNISLPENLVHRIDEEAKA-R--RLSRSAFLAMAAEHEMADA----- 129 
Clostridium_perfringens_13                LDNKAVKKTVTIPNWLDVQ----AKK-YE--INFSQLLQESIRNLLQL------ 138 
Yersinia_pestis_biovar_Medievalis_91001   YDGKVERINVTLPHRLIHQIDTIVKV-RPEYASRSNFLAEAARKELQKLA---- 139 
Haemophilus_somnus_129PT                  LLGKAEKINITMPAYLIKRIDEFVAT-HKEYKSRSGFLAQIAADKILSD----- 137 
Nitrobacter_hamburgensis_X14              PAVKSVRINVTLPADVLEQIDRHAAS-EG--FTRSGFLAHAAKKALAA------ 130 
Serratia_proteamaculans_568               FDGRAERINITLPHRLLNRIDSMVQQ-HPGYGSRSAFLAAAARNELLNAG---- 137 
Yersinia_pestis_C092                      YDGKVERINVTLPHRLIHQIDTIVKV-RPEYASRSNFLAEAARKELQKLA---- 139 
Yersinia_pestis_Antiqua_JGI               YDGKVERINVTLPHRLIHQIDTIVKV-RPEYASRSNFLAEAARKELQKLA---- 139 
Yersinia_pestis_KIM                       YDGKVERINVTLPHRLIHQIDTIVKV-RPEYASRSNFLAEAARKELQKLA---- 139 
Yersinia_pestis_Nepa1516                  YDGKVERINVTLPHRLIHQIDTIVKV-RPEYASRSNFLAEAARKELQKLA---- 139 
Caulobacter_crescentus_CB15               VQPRTVRVNITLPETTLREIDAFAET-YG--YTRSGLLARAAKQMIDAA----- 131 
Finegolida_magna_ATCC_29328               VKVVNTKKTLTIPNHLNML----GQY-KN--INFSKILTEALEKELNVK----- 132 
Haemophilus_somnus_2336                   LLGKAEKINITMPAYLIKRIDEFVAT-HKEYKSRSGFLAQIAADKILSA----- 137 
Legionella_pneumophila_Lens               ISGKAKRINITMPERILSLIDLYAKN-HA-IKNRSSFLADAALSYMESHK---- 134 
Escherichia_coli_UMN026                   FEGRAERINITMPKRLLNKIDTYVRN-NPDYANRSAFLAEAARRVLPGV----- 136 
Clostridium_botulinum_B_Eklund_17B        IENQSIKKTLTIPQWLNKL----AEK-NE--INFSQILQAALKEQLGIHSTLNK 139 
Treponema_denticola_ATCC_35405            QKTRSVNRTVTLPAWLNAL----ASE-HN--INCSQLLQESLKKQFQTVLQTR- 138 
Rhodospirillum_rubum_ATCC_11170           VTGRTMRVNITMDATLVAAIDGVT-------SNRSAWLADAALRALRSNR---- 128 
Bartonella_tribocorum_cIP105476           NDSEVVRTNISIERGLLRAIDNCAQE-RG--LTRSAFLATAARHELNI------ 131 
Nostoc_sp._PCC7120                        ------------------------------------------------------ 71 
Maricaulis_maris_MCS10                    MTGRTVKANLTMDAGLLQAIDETARE-RG--ITRSAFLADLARREIAA------ 134 
Pelotomaculum_thermopropionicum           MAKKAVKKTVTLPKWLNDL----AEK-EK--VNFSQLLQTAIKEKLHIRENH-- 135 
Leptotrichia_goodfellowii_F0264           IRNKAVKKTLTIPQWLNER----AIE-KN--LNFSHILQEALKEELGIK----- 133 
Clostridium_kluyveri_DSM_555              MNNKTVNTTVTMPQWLKYQ----AEK-KK--INFSQVLQAALKEQLNIKN---- 133 
Candidatus_methanoregula_boonei_6A8       LCETVPA----------------------------------------------- 80 
Methanospirillum_hungatei_JF-1            ------------------------------------------------------ 69 
Alkalilimnicola_ehrlichei_MLHE-1          ------------------------------------------------------ 69 
Syntrophomonas_wolfei_subsp.              LDNRAVKTNLTIPAWLKEI----AEA-QG--VNYSKIFQSALMDYLGIKTK--- 135 
Geobacter_uraniireducens_Rf4              ------------------------------------------------------ 70 
Bartonella_henselae_Houston-1             NDSEVVRTNISIERGLLRAIDNCAQE-RG--LTRSAFLATAARHELNI------ 131 
Shewanella_baltica_OS195                  LKAKQKRLNITLPESQLARIDSYVEF-HSEFKDRSDFLSKAADKLMYNADLSR- 144 
Haemophlus_influenzae_PittEE              YLGKKQRINVSLPEYLLTRIDRRVAAMGNYYKDRSHFLANAAHRELHAHSDKEM 149 
Salinispora_arenicola_CNS-205             ------------------------------------------------------ 71 
Haemophilus_influenza_86_028NP            YQGKRHRINISLPEYLIKRIDSRVAS-NPIYKDRSHFLAIASQKELRQ------ 142 
Rhodobacter_sphaeroides_ATCC_17029        ADGKLERVNVSMDRGLLRAIDATASA-RG--MTRSAFLAAVARREIAGF----- 131 
Vibrio_vulnificus_YJ016                   YSGKSQRVNISLPESLLAVIDRKVEN-SDLYRDRSHFLAIAARNELC------- 141 
Escherichia_coli_0157:H7_str._EC41        IEGKQQRINIALPDVLIRRIDGFVRESGGVYRDRSHFLAQAARHELSYK----- 145 
Thermus_thermophiles_HB27                 ------------------------------------------------------ 67 
Yersinia_pseudotuberculosis_IP_31758      YESKAVKFNLTMSQNLLTAIDKFIAT-NRGYKNRSQFLAELAREKIIS------ 135 
Yersinia_pestis_angola                    YESKAVKFNLTMSQNLLTAIDKFIAT-NRGYKNRSQFLAELAREKIIS------ 136 
Appendix Figure 17.  Alignment of HicB to 51 homologous sequences across different bacterial strains. 
Sequences were aligned using Clustal W
291
 and conservation at specific amino acid positions are shown: 
conserved (*), conservative mutation (:) and a semi-conservative (.).  
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Appendix Figure 18. SAXS of HicAB (A) Log10 SAXS intensity versus scattering vector (q). (B) 
Dimensionless Kratky plot. Cross-hair marks the Guinier-Kratky plot (1.732, 1.1), the main peak for folded 
globular particles. (C) Pair-distance, P(r) distribution function. Maximum dimension, dmax is the largest non-
negative value that supports a smooth distribution function. (D) Fit of the parameters computed by the P(r) 
distribution (red line) to the raw scattering data (red). Within each figure (apart from (D)) HicB and HicAB are 

























Appendix Figure 20. Gel-shift analysis investigating if mis-annealed higher order states of S1-2 DNA 
form at higher concentrations of DNA.  
Appendix Figure 19. Ab initio modelling of 
the shape envelope of the HicAB SAXS 
profile with the crystal structure of 
S.pneumoniae HicAB complex. Ab initio 
modelling of the hetero-octameric state of 
HicABSP into the shape envelope of HicAB 
(white). (Underneath) The FoXS profile of the 
proposed scattering profile for a HicABSP 
hetero-octamer (red) against the experimental 
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Appendix Figure 21. Superimposition of 
structures with a high structural similarity 
to the RHH domain of HicB with functional 
residues of high importance highlighted. 
(A) Superimposition of HicB (Blue) with Arc 
(PDB: 1BAZ, red). (B) CopG (PDB:2CPG, 
green) superimposed onto HicB. (C) Omega 
(PDB: 2BNZ, yellow) superimposed to HicB. 
(D) PutA (PDB:2AY0, Orange) superimposed 
with HicB. (E) Superimposition of HicB with 
RHH containing antitoxins: DinJ (PDB: 
4Q2U, orange), HicB3 (PDB: 4P7D, red), 












HicB            R--IN-------VSIPRFVLHKIDAYVASRHE--T-RSGF--LARAALEA 
HicB3           AVKFN-------LTMSQNLLTAIDKFIATNRGYKN-RSQF--LAELARE- 
HicB_EC         SE-ITQQELARRIGKPKQ---EITRLFNLHHA--T-KIDAVQLAAKALG- 
HicB_SP         IK-KT-------LTIPKWA-DKLGREMGLNFS--QTLTDAI-----ADK- 
                    .       :  .:     :   .  .                *    
 
HicB            LNEGKVRH---A 
HicB3           ----KIIS---- 
HicB_EC         ----KELSLVMV 
HicB_SP         ----KVQ----A 
                    *        
Appendix Figure 22. Conservation between the C-terminal domains of Burkholderia, Yersinia, 
Escherichia and Streptococcus HicB. Symbols indicate a conserved residue (*), conservative mutation (:) and 
a semi-conservative mutation (.). 
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Burkholderia_pseudomallei                 ------MEFPIAV-HKDD-GSVYGVTVPDIP----GVHSWGETIDDAIKNTREAIVGHVE  48 
Burkholderia_ambifaria                    ------MRFFVAV-DKQE-GTDYGVVVPDFP----GCNSWGTTLEQALENTQEAIEGWVE  48 
Pseudomonas_Syringae                      ------MKYPICI-EWGDETTAFGIQIPDIP----GAITAGDTFEEAHAAAVEIAHIMLQ  49 
Burkholderia_thailandensis_E264           ------MEFPIAV-HKDD-GSVYGVTVPDIP----GVHSWGETIDDAIKNTREAIVGHVE  48 
Polaromonas_napthalenivorans_CJ2          ------MRYPITI-EPGNDTTAWGVVVPDLP----GCFSAGDTLEEAMIQAEDAVTAWIE  49 
Neisseria_gonorrhoaea_FA1090              ------MFIPAAL-HKDE-HSAYGVTIPDLP----GCFSCGDTVEEAVANARSAAYMHID  48 
Gluconobacter_oxydans_621H                ------MRYPVVI-ERGSETTAFGVVFPDLP----GCFSAGDTLDEALSCAEEAAAAWID  49 
Pseudomonas_fluorescens_SBW25             ------MLYPIAI-STGDNDHAWGVEVPDIP----GCYSAGDDLDDAMAMAREAIEGHFE  49 
Roseiflexus_castenholzii_DSM_13941        ------MHYPVVI-HKDT-ESDYGVTVPDLP----GCFSAGETLDEALQEAIEAIECHLE  48 
Carboxydothermus_hydrogenoformas_Z-2901   -MYKDLYVFPAIF-DYAE--DGISVEFPDLP----GCLTCGDNTEEALKNAKEALELHLY  52 
Mesorhizobium_loti_MAFF303099             -----MKQYIGLI-HKDA-GSDFGVSFPDFP----GVITAGKDLDDARSMAEEALTLHIE  49 
Bordetella_parapertussis_12822            ------MLYPIHV-SK-DEGSAYGAAFPDFP----GCFAAADELQDLPRAAQEAVEAHFY  48 
Clostridium_perfringens_13                MKKKDTYIFPAIV-TTES--DGITITFPDLE----GCITCAYSDDEIMKVSKEALGLHLY  53 
Yersinia_pestis_biovar_Medievalis_91001   -----MAIYPAYV-HVDNDGSASG-YFPDVK----GCIFAINAGEDLFAEASSALDAHFE  49 
Haemophilus_somnus_129PT                  ------MLYPIAI-EPGDETHAFGVIVPDIP----GCHSAGDTLEEAYANAKEAIKGHLE  49 
Nitrobacter_hamburgensis_X14              -----MRQFIALI-HKDA-DSDYGVSFPDLP----GCVTAGTTLDEARDMAAEALALHLE  49 
Serratia_proteamaculans_568               ------MFYPAYV-HSEHDGSASG-FFPDVP----GCYFAGDTLDRAFEDAKSALDAHFE  48 
Yersinia_pestis_C092                      -----MAIYPAYV-HVDNDGSASG-YFPDVK----GCIFAINAGEDLFAEASSALDAHFE  49 
Yersinia_pestis_Antiqua_JGI               -----MAIYPAYV-HVDNDGSASG-YFPDVK----GCIFAINAGEDLFAEASSALDAHFE  49 
Yersinia_pestis_KIM                       -----MAIYPAYV-HVDNDGSASG-YFPDVK----GCIFAINAGEDLFAEASSALDAHFE  49 
Yersinia_pestis_Nepa1516                  -----MAIYPAYV-HVDNDGSASG-YFPDVK----GCIFAINAGEDLFAEASSALDAHFE  49 
Caulobacter_crescentus_CB15               -----MADYIALI-HKDA-DSAFGVSFPDLP----GCISVGETLEEARANAEEALALHVE  49 
Finegolida_magna_ATCC_29328               --MKNDILYPVVM-SKED--GRYFAQCYDYE----EIYAEGDTIEEALKNIKEVFGLIFY  51 
Haemophilus_somnus_2336                   ------MLYPIAI-EPGDETHAFGVIVPDIP----GCHSAGDTLEEAYANAKEAIKGHLE  49 
Legionella_pneumophila_Lens               ------MRYPVVI-HKDE-HSDFGVIVPDIP----GCYSSGSTYDEALTNVIEAIECHLE  48 
Escherichia_coli_UMN026                   ------MFYPAYI-HSDPDGSASG-FFPDVP----GCYFAGDTLDNAFQDARSALVAHFE  48 
Clostridium_botulinum_B_Eklund_17B        MNAKDMYVFPAIF-TYDN--DGISIEFPDLP----GCLSCADTTDEAIKMAKEALALHLY  53 
Treponema_denticola_ATCC_35405            MKKQERFFYPAIF-TYNG-KKEIAVVFPDL-----GCATSGKDEADALLSARELLGCVLC  53 
Rhodospirillum_rubum_ATCC_11170           ----MNYTYAVVI-ETDD-LGGFSAFFPDLP----GCVGAGDSVEACFQDALDALALHLA  50 
Bartonella_tribocorum_cIP105476           -----MKRFFALV-HKDE-DSAFGVQFPDFE----GLFSASDEEENLIINATEALQLYCE  49 
Maricaulis_maris_MCS10                    -----MPNFYAIV-TQEG-DSAHGIHFPDLP----GCFSAADTLDEVPAKAREALSLWFE  49 
Pelotomaculum_thermopropionicum           ---MDKYIFPAIF-EVGE-IKGYCVTFPDLP----GCITEGNTLEEALQMAREALELHLY  51 
Leptotrichia_goodfellowii_F0264           -MTKDSYLYPAIF-KYGE--DGITITFPDLP----GCISCGKNDEEALYMARDVLGGWMY  52 
Clostridium_kluyveri_DSM_555              ---MDKYMYPALF-EAYE-DGGYTVSFPDLP----GCITEGDSLTEALTMAKEALELFLW  51 
Syntrophomonas_wolfei_subsp.              ---MHKLTYFAVF-EPVA--TGYSVYFPDIP----GCVSYGEDFEEAQKQAADALGLHLY  50 
Bartonella_henselae_Houston-1             -----MKRFFALV-HKDE-DSAFGVQFPDFE----GLFSAADEEENLIINATEALQLYCE  49 
Shewanella_baltica_OS195                  ------MLFMVGIETPADETEAFGIIVPVFEKLGYGCFSATDSQEEILFKAKEAILLMAE  54 
Haemophlus_influenzae_PittEE              ------MIFTVGVETPENENQAYGMIVPALCQLDYGCFSGADDVDDLLPMVTEAITMMLE  54 
Haemophilus_influenza_86_028NP            ------MLFTIGIETPTNENEAYGITVPALFTEEYSCFSAADTLEEIPTQVTDAIHSILE  54 
Rhodobacter_sphaeroides_ATCC_17029        -----MHYFTAIV-HKDP-NSAYGLTFPDLP----GCFAAADDWSEIPAKAAEALDLWFE  49 
Vibrio_vulnificus_YJ016                   ------MWFTLGVETPKDKDSSYGIVVPALCNDRYSCYSASDSSKEIAAHSAEAIESILE  54 
Escherichia_coli_0157:H7_str._EC41        ------MFFSVGVETPKDDHTAYGITVPAFDRFDFGCVSAADTQSEIPVMAREAILAIVE  54 
Yersinia_pseudotuberculosis_IP_31758      ------MIYPIFI-FKTVEG--FDGYFPDID----GCFFAGNTFADISKNAEEAFAVHIE  47 
Yersinia_pestis_angola                    ------MIYPIFI-FKTVEG--FDGYFPDID----GCFFAGNTFADISKNAEEAFAVHIE  47 
                                                         .                                       .        
 
Burkholderia_pseudomallei                 TLIELG-----ED-VEFTCSTVE-ELV-AK---PEYAGA--V-------WALVSVDLSQL  88 
Burkholderia_ambifaria                    TSVEAG-----DE-VRFEPTSFE-ELR-DN---PDYAGS--F-------WAVVDIDPSKF  88 
Pseudomonas_Syringae                      EIAASG-----GS-IP-KVGTVA-EHA-KN---PDFSGM--G-------WGMLEIDVTPY  88 
Burkholderia_thailandensis_E264           TLIELG-----DD-VEFTCSTVE-ELV-AK---PEYAGA--V-------WALVSVDLSQL  88 
Polaromonas_napthalenivorans_CJ2          VALDAG-----QD-IP-APSHIE-ALRTAH---PEFDGW--L-------WALVKVDPAML  89 
Neisseria_gonorrhoaea_FA1090              GMIEDG-----GF-KNLAVSSIA-DLS-QE---PDYHGA--T-------WVMIEIDPAKI  88 
Gluconobacter_oxydans_621H                ATLDAG-----EA-VP-SPSSLD-AIQ-SN---PDYQGW--T-------VGIVTIDPAIL  88 
Pseudomonas_fluorescens_SBW25             ILAEDG-----AP-IP-SAQKVT-LHA-AN---PQYAGC--T-------WAVVDIDVTKY  88 
Roseiflexus_castenholzii_DSM_13941        GLLADG-----EP-IP-TPKPVE-LHQ-SN---PDYAGG--I-------WAFVTVDVTKL  87 
Carboxydothermus_hydrogenoformas_Z-2901   GMEKDN-----EP-IP-EPTPID-KIKI--------EPN--QVLVLVEAWM--PLVRSEM  92 
Mesorhizobium_loti_MAFF303099             GLVEDG-----EA-IP-EPSSLQ-AVM-AD---ADNRDG--V-------AILVAAK--TE  86 
Bordetella_parapertussis_12822            G---ET-----ER-IP-APSAPE-AWA-ND---EDYQGG--Y-------WMMVDIDLSKV  84 
Clostridium_perfringens_13                GLETDEEIEGKEL-IP-VPSKLN-DLKL--------EKN--QATTLVEVYM--PVIRQVL  98 
Yersinia_pestis_biovar_Medievalis_91001   ALVSEG-----IE-IP-EAHDMP-YHV-YRNPCDYADGG--Q-------WYNVNIDMSKY  91 
Haemophilus_somnus_129PT                  LLVEMG-----EE-VP-LPTSIN-NHR-NN---PDFTEYDMF-------FGFVDVDITHL  90 
Nitrobacter_hamburgensis_X14              GMAEDG-----EG-VP-EPASLE-EVM-AD---PVNRDG--V-------AVLVAAP--AP  86 
Serratia_proteamaculans_568               LLSEDN-----QS-IP-RPQAVS-FHL-AQES-DTLNGG--Q-------WLLVDINMDKF  89 
Yersinia_pestis_C092                      ALVSEG-----IE-IP-EAHDMP-YHV-YRNPCDYADGG--Q-------WYNVNIDMSKY  91 
Yersinia_pestis_Antiqua_JGI               ALVSEG-----IE-IP-EAHDMP-YHV-YRNPCDYADGG--Q-------WYNVNIDMSKY  91 
Yersinia_pestis_KIM                       ALVSEG-----IE-IP-EAHDMP-YHV-YRNPCDYADGG--Q-------WYNVNIDMSKY  91 
Yersinia_pestis_Nepa1516                  ALVSEG-----IE-IP-EAHDMP-YHV-YRNPCDYADGG--Q-------WYNVNIDMSKY  91 
Caulobacter_crescentus_CB15               GMIEDG-----ET-LP-APSALD-EVM-AA---PGNRDG--V-------VILVPLK--TV  86 
Finegolida_magna_ATCC_29328               DFEEDE--------YK-KASNIE-DIMKEL------KEG--EFVVYVNVWL--PYEFSKV  91 
Haemophilus_somnus_2336                   LLVEMG-----EE-VP-LPTSIN-NHR-QN---PDFTEYDMF-------FGFVDVDITHL  90 
Legionella_pneumophila_Lens               GLLIDN-----EP-LP-VGTTID-RWI-ND---EEFQGG--V-------WAFVDIDLSQI  87 
Escherichia_coli_UMN026                   TLCEMN-----EE-LP-LPGSVE-THL-VQRA-QDFIGG--Q-------WLLVDINMNQF  89 
Clostridium_botulinum_B_Eklund_17B        GMEEDN-----ES-IP-KDTPIN-NLTL--------LEN--QIPMLIEVYM--PLYRTAI  93 
Treponema_denticola_ATCC_35405            GLEDDG-----EP-IP-KASHLS-NIKT--------GKN--EKSVLIDVYL--PTYRMMQ  93 
Rhodospirillum_rubum_ATCC_11170           GMIEDG-----DS-LP-APTPLS-DVE-VD---PDIQVA--A-------ILLASV---PV  86 
Bartonella_tribocorum_cIP105476           D----M-----DT-VP-VPLKFE------E---VIQQKA--VKKALSEGAFLIQVPFIEN  87 
Maricaulis_maris_MCS10                    D----E-----AM-IA--PSSLA-DVH-EK---IRNDLG--YIDLMSSGSFLMSIPVVSM  90 
Pelotomaculum_thermopropionicum           GMEEDE-----DE-IP-SPTPPE-RVDV--------PEK--GFVAIVEARM--PLIRDRM  91 
Leptotrichia_goodfellowii_F0264           QIERAK-----EK-IP-KSSSLN-MINL--------NFD--EKVLLIDVWM--PSVRKSI  92 
Clostridium_kluyveri_DSM_555              NMEDDN-----EE-IP-EPTPPE-KIET--------KKG--NFIVPVEADM--ALIRAKM  91 
Syntrophomonas_wolfei_subsp.              GMEKDG-----DE-IP-TPSKVP-QVDTET------APG--YIISPVSIFP--SIVRNEL  92 
Bartonella_henselae_Houston-1             D----M-----DT-VP-VPLKFE------E---VIQQKA--VKKALSEGAFLIQVPFIEN  87 
Shewanella_baltica_OS195                  EVINDG------HL-I-DALNEGYRDYRAT---H--PEF--------EQWVAVEVPLEAL  93 
Haemophlus_influenzae_PittEE              AMVED------GFDLT-TLKDKGVTHYKAD---PEYADF--------DTWLLVDVDISEY  96 
Haemophilus_influenza_86_028NP            MMFED------GIDIN-ELQDKGYRHYQTQ---EDFNYC--------DTWLLLDVDISAY  96 
Rhodobacter_sphaeroides_ATCC_17029        D----E-----PA-VE--PASID-AIQ-SR---E----D--VRKALAEGASLMTFAYVPA  86 
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Vibrio_vulnificus_YJ016                   EMLAD------GFDVL-GLEDQGALAYRED---EAYRFC--------DVWLQIEIDVSRY  96 
Escherichia_coli_0157:H7_str._EC41        EMVLSG-----SYSVD-DIHDDGCLTYAAN---QDYSHC--------DSWFVIDVDLSEI  97 
Yersinia_pseudotuberculosis_IP_31758      ALMNEG-----FP-LP-SPPKDP-HRY-IDDPRLKEEGG--I-------LGFVEIDPAKY  89 
Yersinia_pestis_angola                    ALMNEG-----FP-LP-SPPKDP-HRY-IDDPRLKEEGG--I-------LGFVEIDPAKY  89 
                                                                                                          
 
Burkholderia_pseudomallei                 DSKPERINVSIPRFVLHKIDAYVAS-RH--ETRSGFLARAALEALNEGKVRHA 138 
Burkholderia_ambifaria                    DMKPERVNISLPRFVLTQIDAFAEA-HK--ETRSGFLVRAALEAIRHEQTAV- 137 
Pseudomonas_Syringae                      LGKTEKVNVTLPGFVIRQIDRYVRD-HS-IKSRSTFLADAALEKLGRA----- 134 
Burkholderia_thailandensis_E264           DSKPERINVSIPRFVLHKIDAYVAS-RH--ETRSGFLARAALEALNEGKVRHA 138 
Polaromonas_napthalenivorans_CJ2          DDTVERVNISLPRRVLRRLDARART-AG--ETRSGFIARMAVEGREPAAHA-- 137 
Neisseria_gonorrhoaea_FA1090              SRQQIRFNVSWPQYLLDRVDEYTSA-NH--ETRSGFLAKAALLTMNQA----- 133 
Gluconobacter_oxydans_621H                DDRVERANISLPRRVLERLDALARA-SR--ESRSGMIAAMTLQAKLTPDTKSR 138 
Pseudomonas_fluorescens_SBW25             LGKAQKLNITLPGYLLNRIDEYVLH-HPEEKSRSGFLASAALKVLQQEH---- 136 
Roseiflexus_castenholzii_DSM_13941        SGKTRRINITLPERVLHLVNKYASE-RG--ESRSGLITQAVLEYIGSRETLAR 137 
Carboxydothermus_hydrogenoformas_Z-2901   DNKAVKKTLTLPKWLNDL----AEK-KK--INFSRVLQQALKEQLGIKEREI- 137 
Mesorhizobium_loti_MAFF303099             ARKAVRINVTLPDDVLRRIDAFAEA-HG--YTRSGFLAKAAEKAMELESA--- 133 
Bordetella_parapertussis_12822            NTKAVRLNISLPENLVHRIDEEAKA-R--RLSRSAFLAMAAEHEMADA----- 129 
Clostridium_perfringens_13                DNKAVKKTVTIPNWLDVQ----AKK-YE--INFSQLLQESIRNLLQL------ 138 
Yersinia_pestis_biovar_Medievalis_91001   DGKVERINVTLPHRLIHQIDTIVKV-RPEYASRSNFLAEAARKELQKLA---- 139 
Haemophilus_somnus_129PT                  LGKAEKINITMPAYLIKRIDEFVAT-HKEYKSRSGFLAQIAADKILSD----- 137 
Nitrobacter_hamburgensis_X14              AVKSVRINVTLPADVLEQIDRHAAS-EG--FTRSGFLAHAAKKALAA------ 130 
Serratia_proteamaculans_568               DGRAERINITLPHRLLNRIDSMVQQ-HPGYGSRSAFLAAAARNELLNAG---- 137 
Yersinia_pestis_C092                      DGKVERINVTLPHRLIHQIDTIVKV-RPEYASRSNFLAEAARKELQKLA---- 139 
Yersinia_pestis_Antiqua_JGI               DGKVERINVTLPHRLIHQIDTIVKV-RPEYASRSNFLAEAARKELQKLA---- 139 
Yersinia_pestis_KIM                       DGKVERINVTLPHRLIHQIDTIVKV-RPEYASRSNFLAEAARKELQKLA---- 139 
Yersinia_pestis_Nepa1516                  DGKVERINVTLPHRLIHQIDTIVKV-RPEYASRSNFLAEAARKELQKLA---- 139 
Caulobacter_crescentus_CB1                QPRTVRVNITLPETTLREIDAFAET-YG--YTRSGLLARAAKQMIDAA----- 131 
Finegolida_magna_ATCC_2932                KVVNTKKTLTIPNHLNML----GQY-KN--INFSKILTEALEKELNVK----- 132 
Haemophilus_somnus_2336                   LGKAEKINITMPAYLIKRIDEFVAT-HKEYKSRSGFLAQIAADKILSA----- 137 
Legionella_pneumophila_Len                SGKAKRINITMPERILSLIDLYAKN-HA-IKNRSSFLADAALSYMESHK---- 134 
Escherichia_coli_UMN026                   EGRAERINITMPKRLLNKIDTYVRN-NPDYANRSAFLAEAARRVLPGV----- 136 
Clostridium_botulinum_B_Eklund_17B        ENQSIKKTLTIPQWLNKL----AEK-NE--INFSQILQAALKEQLGIHSTLNK 139 
Treponema_denticola_ATCC_35405            KTRSVNRTVTLPAWLNAL----ASE-HN--INCSQLLQESLKKQFQTVLQTR- 138 
Rhodospirillum_rubum_ATCC_1117            TGRTMRVNITMDATLVAAIDGVT-------SNRSAWLADAALRALRSNR---- 128 
Bartonella_tribocorum_cIP10547            DSEVVRTNISIERGLLRAIDNCAQE-RG--LTRSAFLATAARHELNI------ 131 
Maricaulis_maris_MCS10                    TGRTVKANLTMDAGLLQAIDETARE-RG--ITRSAFLADLARREIAA------ 134 
Pelotomaculum_thermopropionicum           AKKAVKKTVTLPKWLNDL----AEK-EK--VNFSQLLQTAIKEKLHIRENH-- 135 
Leptotrichia_goodfellowii_F0264           RNKAVKKTLTIPQWLNER----AIE-KN--LNFSHILQEALKEELGIK----- 133 
Clostridium_kluyveri_DSM_555              NNKTVNTTVTMPQWLKYQ----AEK-KK--INFSQVLQAALKEQLNIKN---- 133 
Syntrophomonas_wolfei_subsp               DNRAVKTNLTIPAWLKEI----AEA-QG--VNYSKIFQSALMDYLGIKTK--- 135 
Bartonella_henselae_Houston-1             DSEVVRTNISIERGLLRAIDNCAQE-RG--LTRSAFLATAARHELNI------ 131 
Shewanella_baltica_OS195                  KAKQKRLNITLPESQLARIDSYVEF-HSEFKDRSDFLSKAADKLMYNADLSR- 144 
Haemophlus_influenzae_PittEE              LGKKQRINVSLPEYLLTRIDRRVAAMGNYYKDRSHFLANAAHRELHAHSDKEM 149 
Haemophilus_influenza_86_028NP            QGKRHRINISLPEYLIKRIDSRVAS-NPIYKDRSHFLAIASQKELRQ------ 142 
Rhodobacter_sphaeroides_ATCC_17029        DGKLERVNVSMDRGLLRAIDATASA-RG--MTRSAFLAAVARREIAGF----- 131 
Vibrio_vulnificus_YJ016                   SGKSQRVNISLPESLLAVIDRKVEN-SDLYRDRSHFLAIAARNELC------- 141 
Escherichia_coli_0157:H7_str._EC41        EGKQQRINIALPDVLIRRIDGFVRESGGVYRDRSHFLAQAARHELSYK----- 145 
Yersinia_pseudotuberculosis_IP_31758      ESKAVKFNLTMSQNLLTAIDKFIAT-NRGYKNRSQFLAELAREKIIS------ 135 
Yersinia_pestis_angola                    ESKAVKFNLTMSQNLLTAIDKFIAT-NRGYKNRSQFLAELAREKIIS------ 135 
                                               . .::                       *  :                 
Appendix Figure 23.  Alignment of HicB to 44 homologous sequences across different bacterial strains. 
Sequences were aligned using ClustalW 
291
 and conservation at specific amino acid positions is highlighted: 
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Appendix Figure 24. 
SDS-PAGE following the 
purification of all HicB 
alanine mutants via 
IMAC and SEC. (A) 
R94A. (B) N96A. (C) 
R94AN96A. (D) S99A. 
Arrows refer to the band 
corresponding to 









Appendix Figure 25. 
SDS-PAGE following the 
purification of all HicB 
alanine mutants via 
IMAC and SEC. (A) 
R94E. (B) N96Q (C) 
S99T. Arrows refer to the 
band corresponding to 
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Appendix Figure 26. Denatured ESMS of all HicB mutants. (A) (left) Denatured ESMS of R94A showed a 
similar distribution of m/z charge states to HicB, with deconvolution resulting in a single (observed mass: 
15,654, expected: 15,653 Da). (right) Denatured ESMS of R94E indicated a single species (observed mass: 
15,711, expected: 15,711 Da). (B) (left) Denatured ESMS of N96A indicated a single species (observed mass: 
15,694, expected: 15,695 Da). (right) Denatured ESMS of N96Q indicated a single species (observed mass: 
15,751, expected: 15,752 Da). (C) Denatured ESMS of R94AN96A indicated a single species (observed mass: 
15,609, expected: 15,610 Da). An additional mass adduct (+122 Da) was observed for R94AN96A which was 
not present after SEC (D) (left) Denatured ESMS of S98A indicated a single species (observed mass: 15,721 
Da, expected mass: 15,722 Da). (right) Denatured ESMS of S98T indicated a single species (observed mass: 
15,751, expected: 15,752 Da). Each mutant showed a similar distribution of m/z charge states to HicB. 
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Appendix Figure 27. Native mass spectrometry of HicB alanine mutants: R94A (A), N96A (B), 
R94AN96A (C) and S98A (D).  Peaks were assigned based on their charge state: monomeric (black), dimeric 
(blue) or tetrameric (red). Deconvolution of each spectrum where shown and tetrameric species for R94A 
(observed mass: 62,606, expected: 62,612 Da) and S98A (observed mass: 62,886, expected: 62,888 Da). The 
m/z envelopes of N96A and R94AN96A could not be deconvoluted into accurate tetrameric species, although 
charge states attributed to tetrameric species are observed. 
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Appendix Figure 28. Native mass spectrometry of HicB alanine mutants: R94E (A), N96Q (B) and S98T 
(C).  Peaks were assigned based on their charge state: monomeric (black), dimeric (blue) or tetrameric (red). 
Deconvolution of each spectrum showed tetrameric species for R94A (observed mass: 62,835 expected: 62,844 
Da), N96Q (observed mass: 63,004, expected 63,008 Da and S98T (observed mass: 63,017, expected: 62,008 
Da).  
 
Appendix Figure 29. Gel-shift assay of HicBT and R94A/S98A mutants at 250 M to investigate their 
binding against 2 M S1-2. 
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 HicB R94A R94E N96A N96Q S98A S98T 
Start 28 72 49 62 42 64 62 
End 750 1000 1000 1000 1000 1000 1000 
Io Real 3.78E-3 2.39E-1 5.89E-2 8.80E-2 3.98E-2 1.66E-1 5.20E-2 
Io Reciprocal 3.82E-3 2.36E-1 5.98E-2 9.15E-2 4.08E-2 1.72E-1 5.35E-2 
Rg Real (Å) 30.12 29.79 29.54 32.21 30.02 31.75 30.11 
Rg Reciprocal (Å) 30.67 29.51 29.76 32.24 30.82 31.99 30.85 
R average (Å) 39.7 38.7 38.4 41.7 38.9 41.1 39.1 
Dmax (Å) 97 96 97 104.5 97.5 106.5 98 
χ
2
 1.94 0.55 0.95 1.46 0.45 1.87 1.51 
 
Appendix Figure 30. SAXS analysis of the HicB binding mutants. (A-B) SEC-SAXS of HicB, R94A, N96A 
and S98A. (A) Dimensionless Kratky plot for each protein. Cross hairs marks the Guinier-Kratky plot (1.732, 
1.1)- the main peak for globular particles. (B) Pair-distance P(r) distribution function for each protein. The 
maximum particle dimension (dmax) is the largest non-negative value that supports a smooth distribution 
function (x axis intercept). (C-D) SEC-SAXS of HicB, R94E, N96Q and S98T. (C) Dimensionless Kratky and 
(D) P(r) distribution of each mutant. (E) Parameters obtained from the P(r) distribution fitting for HicB and 
DNA binding mutants. For each particle both the Io (Maximum scattering intensity) and Rg are calculated in the 
real and reciprocal domain, while the R average, Dmax and resulting χ
2
 value of the fit are reported. 
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Appendix Figure 31. Ab initio modelling of each shape envelope. (left) Superimposition of the elongated 
conformation of HicB onto the resultant calculated shape envelope (white) for each mutant. (right) Quantitative 
analysis of the fit of each HicB conformation: compact (red), elongated (blue) and symmetrical HicB (green) to 
the raw scattering data of each curve (black). χ
2




 Compact  Elongated Symmetrical 
HicB 9 1.99 7.96 
R94A 278.56 36.72 328.70 
R94E 13.25 2.34 17.56 
N96A 153.01 55.05 51.41 
N96Q 12.11 2.62 10.69 
S98A 370.56 114.92 136.89 
S98T 15.84 2.89 13.91 
Appendix Figure 32. 
2
 values for each HicB conformation against the raw scattering data of each analysed 
mutant to determine the validity of ab initio modelling and if mutants retained the same scattering 
characteristics as HicB. 
 
 
9.  Appendix   
 171 
 
Appendix Figure 33.  Surface entropy of all HicB mutant. (A) Normalised sidechain entropy average at each 
residue position as given by Sternberg, computed in a three residue window for one subunit of each HicB 
mutant compared to HicB as computed by the SERp server.
394, 395
 Residues with entropy average above 0.2 
contribute to the overall score. The axis is normalised so alanine = 0 and lysine = 1. The region encompassing 
the 5 strand is highlighted.  
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 HicB HicB-S1-2 
Start 28 45 
End 750 850 
Io Real 3.78E-3 3.44E-2 
Io Reciprocal 3.82E-3 3.42E-2 
Rg Real (Å) 30.12 31.39 
Rg Reciprocal (Å) 30.67 31.74 
R average (Å) 39.7 40.7 
Dmax (Å) 97 107.5 
χ
2
 1.94 1.26 
Appendix Figure 34. SAXS of HicB-S1-2. (A) Log10 SAXS intensity versus scattering vector (q). (B) 
Dimensionless Kratky plot. Cross-hair marks the Guinier-Kratky plot (1.732, 1.1), the main peak for folded 
globular particles. (C) Pair-distance, P(r) distribution function. Maximum dimension, dmax is the largest non-
negative value that supports a smooth distribution function. (D) Fit of the parameters computed by the P(r) 
distribution (red line) to the raw scattering data (green). Within each figure (apart from (D)) HicB and HicB-S1-
2 are highlighted in black and red. (E) Parameters obtained from the P(r) distribution fitting for HicB and HicB-
S1-2. For each particle both the Io (Maximum scattering intensity) and Rg are calculated in the real and 
reciprocal domain, while the R average, Dmax and resulting χ
2
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Appendix Figure 35. Ab initio modelling of the shape envelope of the HicB-S1-2 SAXS profile. (A) Front 
view of the HicB-S1-2 HADDOCK model superimposed on the shape envelope of HicB-S1-2 (white). (B) 90 ° 
view of Panel (A). (C) Side on view of the HicB-S1-2 HADDOCK model on the shape envelope of HicB-S1-2 
(white). (D) Quantitative analysis of the fit of the HicB-S1-2 HADDOCK model (red) to the raw scattering data 
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TA subtype Exception Reference 
Type 1   
LdrD Bactericidal phenotype with observed nucleoid condensation 
91
 
BsrG Bactericidal phenotype (cell lysis): Delocalises MreB (Actin homologue) 
396
 
RalR Not a short hydrophobic peptide, exerts DNase activity 
397
 
SymE Not a short hydrophobic peptide, exerts mRNase activity 
398
 
Type 4   
AbiEii Plasmid stabilisation and phage resistance similar to type 3 systems 
399, 400
 
Appendix Table 1. Non-canonical TA systems. The TA subtype (1-6) and the non-canonical feature 
associated with a specific TA system is detailed. 
 
Cross talk between TA systems Reference 
Type 1 txpA/RatA and the type II mazEF system exhibit transcriptional cross talk 
401
 
Type 2   




MqsRA Directly regulates the type 5 GhoST system 
403
 




RelBE relBE operon is transcriptionally upregulated by MazF, MqsR, HicA and HipA 
405
 
RelBE RelE transcriptionally activates mqsRA, dinJ-yafQ, hicAB and yefm-yoeb  




Type 4   
CbtA, YafW 
and YfiJ 
Each antitoxin interacts with FtsZ and MreB in a protective manner (protein-
protein) to prevent toxicity mediated by their cognate toxins. 
108
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Appendix Table 3. List of protein sequences used in this project. His6-tags (Bold), and protease cleavage 
sequences (Bold, underlined), mutation sites (bold) and additional methionine residues incorporated during 
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Oligonucleotides   
0-48 Primer 1 (*) IDT gatcgtgattggatgtgtataattacacacaagacattcgggggagct 
0-48 Primer 2 (*) IDT agctcccccgaatgtcttgtgtgtaattatacacatccaatcacgatc 
48-96 Primer 1 (*) IDT ataggggcgaaacaatgtgaaaatacgcacggctacacaaaacttgag 
48-96 Primer 2 (*) IDT ctcaagttttgtgtagccgtgcgtattttcacattgtttcgcccctat 
96-144 Primer 1 (*) IDT tcgaggccgcgcgcgatgcttcagtcttgcccagcggacgggataaaa 
96-144 Primer 2 (*) IDT ttttatcccgtccgctgggcaagactgaagcatcgcgcgcggcctcga 
144-196 Primer 1 (*) IDT gccgcccgctggcggcagattacgacgagtggctacacacgaggaatg 
144-196 Primer 2 (*) IDT cattcctcgtgtgtagccactcgtcgtaatctgccgccagcgggcggc 
192-240 Primer 1 (*) IDT gtgccgaataagggtaactatcctgtcaatgttgacgggcaagaggtg 
192-240 Primer 2 (*) IDT cacctcttgcccgtcaacattgacaggatagttacccttattcggcac 
240-279 Primer 1 (*) IDT gccgaatcctcagtggaaaatccgcgaggactttagcac 
240-279 Primer 2 (*) IDT gtgctaaagtcctcgcggattttccactgaggattcggc 
0-20 Primer 1 IDT acaagacattcgggggagct 
0-20 Primer 2 IDT agctcccccgaatgtcttgt 
0-25 Primer 1 IDT tacacacaagacattcgggggagct 
0-25 Primer 2 IDT agctcccccgaatgtcttgtgtgta 
0-30 Primer 1 IDT ataattacacacaagacattcgggggagct 
0-30 Primer 2 IDT agctcccccgaatgtcttgtgtgtaattat 
0-35 Primer 1 IDT tgtgtataattacacacaagacattcgggggagct 
0-35 Primer 2 IDT agctcccccgaatgtcttgtgtgtaattatacaca 
0-40 Primer 1 IDT ttggatgtgtataattacacacaagacattcggggga 
0-40 Primer 2 IDT agctcccccgaatgtcttgtgtgtaattatacacatc 
16-36 Primer 1 (*) IDT atgtgtataattacacacaag 
16-36 Primer 2 (*) IDT cttgtgtgtaattatacacat 
17-36 Primer 1 (*) IDT atgtgtataattacacacaa 
17-36 Primer 2 (*) IDT ttgtgtgtaattatacacat 
17-40 Primer 1 (*) IDT ttggatgtgtataattacacacaa 
17-40 Primer 2 (*) IDT ttgtgtgtaattatacacatccaa 
20-36 Primer 1 (*) IDT atgtgtataattacaca 
20-36 Primer 2 (*) IDT tgtgtaattatacacat 
20-40 Primer 1 (*) IDT ttggatgtgtataattacaca 
20-40 Primer 2 (*) IDT tgtgtaattatacacatccaa 
MS1 Primer 1 IDT atgtgtataattagggacaa 
MS1 Primer 2 IDT ttgtccctaattatacacat 
MS2 Primer 1 IDT atccctataattacacacaa 
MS2 Primer 2 IDT ttgtgtgtaattatagggat 
MS1MS2 Primer 1 IDT atccctataattagggacaa 
MS1MS2 Primer 2 IDT ttgtccctaattatagggat 
Overhang Primer 1 IDT tatgtgtataattacacacaa 
Overhang Primer 2 IDT attgtgtgtaattatacacat 
HicB_FL Primer 1 IDT aggagatataccatgatggaatttcccatcgcagt 
HicB_FL Primer 2 IDT gtgatggtgatgttttgcgtgcctaactttgccttc 
HicB Primer 1 IDT aggagatataccatgatggaatttcccatcgca 
HicB Primer 2 IDT gtgatggtgatgttttttgccttcattaagtgcctc 
HicB-NT Primer 1 IDT aggagatataccatggaatttcccatcgcagtg 
HicB-NT Primer 2 IDT gtgatggtgatgtttaagatcaacgctgacgag 
I51M Primer 1 IDT catgtagagacattgatggagcttggagaagat 
I51M Primer 2 IDT atcttctccaagctccatcaatgtctctacatg 
I99M Primer 1 IDT cggatcaatgtgagtatgcctcgcttcgtgctg 
I99M Primer 2 IDT cagcacgaagcgaggcatactcacattgatccg 
Mutant Primer 1 IDT aggagatataccatgatggaatttccgattgccgtgcat 
Mutant Primer 2 IDT gcactggaagcactgaatgaaggtaaaaaacatcaccatcac 
R94E Primer 1 IDT aaaccggaagaaattaatgttagc 
R94E Primer 2 IDT gctaacattaatttcttccggttt 
S98T Primer 1 IDT cgtattaatgttaccattccgcgtttt 
S98T Primer 2 IDT aaaacgcggaatggtaacattaatacg 
Appendix Table 4. List of primers used throughout the project (*) indidicates DNA that may form mis-
annealed higher order DNA fragments. 
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Monomer Nat Nres Sat Sres Area (Å
2
) G (kcal/mol) 
A 615 80 406 75 5200 -74 
B 655 86 413 81 53004 -79 
C 628 82 383 77 50000 -77 
V 646 85 423 80 5500 -76 
 
Non-stable crystal assemblies 




) G_diss (kcal/mol) G0 (kcal/mol) Composition 
1 
2 1 9300 1230 0.0 0.0 AB 
1 2 5000 0.0 0.0 0.0 C 
1 2 5400.1 0.0 0.0 0.0 V 
 4 26 17000 4215 -8 -2 ABCV 
Appendix table 5. PISA analysis of HicB_NT ASU. Monomers were investigated for their total number of 
atoms (Nat), residues (Nres), total number of surface atoms (Sat) and residues (Sres). The total surface area (Area) 
and solvation energy of folding (G) were calculated. Assemblies (Crystal splits) were investigated with the 
Accessible Solvent Area (ASA), Buried Surface Area (BSA), Standard Free Energy of dissociation into nearest 
stable assemblies (G_diss), Standard Free Energy of dissociation into monomeric units (G0) and 
Composition of assembly reported. It was reported that the 4-chain assembly in the ASU was not stable in 
solution.  Chain A, B, C and V correspond to Subunit 2, Monomer 1, Monomer 2 and Monomer 3 in Figure 
2.10. 
 
Monomer Nat Nres Sat Sres Area (Å
2
) G (kcal/mol) 
C 629 82 387 77 5000 -77.0 
D 646 85 426 80 5500 -77 
 
Metastable crystal assemblies 




) G_diss (kcal/mol) G0 (kcal/mol) Composition 
1 2 1 9200 1300 2 2 CD 
Appendix table 6. PISA analysis of a HicB_NT dimer. Monomers were investigated for their total number of 
atoms (Nat), residues (Nres), total number of surface atoms (Sat) and residues (Sres). The total surface area (Area) 
and solvation energy of folding (G) were calculated. Assemblies (Crystal splits) were investigated with the 
Accessible Solvent Area (ASA), Buried Surface Area (BSA), Standard Free Energy of dissociation into nearest 
stable assemblies (G_diss), Standard Free Energy of dissociation into monomeric units (G0) and 
Composition of assembly reported. It was reported that the dimer had a higher stability than the ASU assembly 
of HicB_NT, however this dimer organisation may also not be stable in solution. Chain C and D refer to Subunit 
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Monomer Nat Nres Sat Sres Area (Å
2
) G (kcal/mol) 
A 1019 132 724 128 9300 -106 
B 1019 132 719 128 9300 -107 
C 1041 135 729 130 9700 -109 
D 1041 135 725 129 9700 -107 
 
Stable crystal assemblies 




) G_diss (kcal/mol) G0 (kcal/mol) Composition 
1 4 1 27000 11000 13 14.0 ABCD 
2 
2 2 15300 3700 22.0 11.0 BC 
2 2 15300 3700 22 11 AD 
Metastable crystal assemblies 
3 
2 3 17000 1600 0.6 1 AC 
2 3 17000 1600 0.0 0.0 BD 
Appendix Table 7. PISA analysis of HicB tetramer observed within the 1.85 Å dataset. Monomers were 
investigated for their total number of atoms (Nat), residues (Nres), total number of surface atoms (Sat) and 
residues (Sres). The total surface area (Area) and solvation energy of folding (G) were calculated. Assemblies 
(Crystal splits) were investigated with the Accessible Solvent Area (ASA), Buried Surface Area (BSA), 
Standard Free Energy of dissociation into nearest stable assemblies (G_diss), Standard Free Energy of 
dissociation into monomeric units (G0) and Composition of assembly reported. It was reported that the 











4P7D 1 4 0.395 0.273 2100 -30 0.844 
4P78 3 4 0.369 0.268 900 -22 0.931 
5YRZ 3 4 0.284 0.194 600 -8 0.268 
3KWR 2 4 0.269 0.096 500 -9 0.815 
Appendix Table 8. Structural conservation of the HicB interfaces within the PDB. The PISA server reports 
the PDB entry, interface number, mmSize (number of macromolecular monomers within the assembly), Q score 
(relates from 0 to 1 for unrelated-identical proteins), Sequence identity (Seq ID), interface area, G and 
Complexation significance score (CSS, relates from 0 to 1 as the interface relevance increases). HicB3 
(PDB:4P7D), HicA3-HicB3 (PDB:4P78), HicAB (PDB:5YRZ) and a uncharacterized RNA binding protein 
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Chain Z score RMSD Identity Description 
4P7D-A 11.8 10.9 25 Antitoxin HicB3 from Y. pestis 
5YRZ-A 9.9 2.6 23 Antitoxin HicB from S. pneumonaie 
3KWR-B 10 3.7 15 Putative RNA binding protein 
2DSY-C 6.1 2.2 21 Hypothetical protein TTHA0281 
3K6Q-A 5.0 2.3 14 Putative ligand binding protein from 
Syntrophomonas Wolfei 
1ZBT-A 4.5 10 13 Peptide chain release factor 
6CI7-F 3.9 14.3 8 YCAO 
5CFF-F 3.7 2.2 10 Miranda/Staufen dsRBD5 complex 
3VYY-A 3.6 3.5 10 ATP-Dependent RNA helicase A 
4WYQ-B 3.5 2.6 8 Endoribonuclease DICER 
2MDR-A 3.5 2.2 4 Double-stranded RNA-specific 
adenosine deaminase 
2LTR-A 3.4 2.6 7 Protein RDE-4 
3P1X-B 3.4 2.0 8 Interleukin enhancer binding factor 3 
3ADL-A 3.3 2.4 14 RISC-loading complex subunit 
TARBP2 
1WHQ-A 3.1 2.9 11 RNA helicase A 
Appendix Table 9. The DALI server search result against a single subunit of HicB. The PDB chain, Z 
score, RMSD, sequence identity and description are highlighted. The Z score relates to the structural similarity 
between proteins. Proteins with a Z score below 3 were not included in this as this represented a low structural 





Structure Z score RMSD (Å) Identity Description 
Arc (PDB:1BAZ) 5.9 1.3 15 Arc repressor 
CopG (PDB: 2CPG) 6.1 1.3 13 Transcriptional repressor CopG 
DinJ (PDB: 4Q2U) 5.2 2.7 13 Antitoxin DinJ 
MazF-4 (PDB:5XE3) 4.9 1.6 8 Endoribonuclease MazF 
ORF Omega (PDB: 2BNZ) 5.7 1.5 15 ORF Omega 
PutA (PDB: 2AY0) 5.9 1.8 13 Bifunctional PutA protein 
RelB (PDB: 4FXE) 4.0 2.7 18 Antitoxin RelB 
VapB26 (PDB: 5X3T) 4.6 1.3 10 Antitoxin VapB26 
Appendix Table 10. The DALI server search result against the RHH domain of HicB. Structures which 
displayed a RMSD between 1.3-2.7 Å are shown, with their Z score, sequence identity and description shown. 
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Data-collection parameters   
Instrument SEC-SAXS at B21 Diamond Light Source 
SEC column Supedex 200 (GE Healthcare) 








) [from P(r)] 3.78E-3 ± 8.9E-6 
 




) (from Guinier) 3.82E-3 ± 8.9E-6 
 
Dmax (Å)  97 
 
Rg (Å) (from Guinier) 30.67 ± 0.37 
 
Porod volume estimate (Å
-3








Molecular-mass determination  












Molecular mass Mr [from I(0)] 67000 
 
Calculated  Mr from sequence (kDa) 62,952 
 
From Porod Volume [Vporod/1.7] (Da) 83,581 
 
Software employed   
Primary data reduction GDA (Diamond Light Source) 
Data processing Scatter 
Ab initio analysis DAMMIN 
Validation and averaging DAMAVER 
Rigid-body modelling N/A 
Computation of model intensities  FoXS 
Three-dimensional graphics representations Pymol 
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Monomer Nat Nres Sat Sres Area (Å
2
) G (kcal/mol) 
A 1019 132 724 128 9300 -106 
B 1019 132 719 128 9300 -107 
C 1041 135 729 130 9700 -109 
D 1041 135 725 129 9700 -107 
E 479 61 297 56 4000 -55 
F 466 60 296 56 4000 -53 
G 472 60 294 56 4000 -55 
H 461 59 305 57 4200 -50 
 
Stable crystal assemblies 




) G_diss (kcal/mol) G0 (kcal/mol) Composition 
1 8 1 36200 17600 9 74 ABCDEFGH 
2 
4 2 19500 700 9 33 ADFH 
4 2 19200 7600 9 33 BCEG 
3 
2 3 11500 1900 5 5 CG 
2 3 11700 1800 5 5 DH 
2 3 11600 1800 5 5 AF 
2 3 11600 1900 4 4 BE 
4 4 4 27400 10000 10 57 ABCD 
Metastable crystal assemblies 
5 
4 5 22000 5000 -1 -1 BDEH 
4 5 22000 5000 -1 -1 ACFG 
Marginally stable Assemblies 
6 4 4 27000 10000 10 57 ABCD 
7 
2 6 17000.6 1200 0 0 BD 
2 6 18000.5 1200 0 0 AC 
Appendix Table 12. PISA analysis of HicAB hetero-octamer. Monomers were investigated for their total 
number of atoms (Nat), residues (Nres), total number of surface atoms (Sat) and residues (Sres). The total surface 
area (Area) and solvation energy of folding (G) were calculated. Assemblies (Crystal splits) were investigated 
with the Accessible Solvent Area (ASA), Buried Surface Area (BSA), Standard Free Energy of dissociation into 
nearest stable assemblies (G_diss), Standard Free Energy of dissociation into monomeric units (G0) and 
Composition of assembly reported. It was reported that the tetramer was stable in solution. Chains A, B,C,D 
refer to Subunit 4, 1, 3 and 2 of HicB, while chains F, E, G and H refer to HicA moieties bound to each 


































Appendix Table 13. List of interactions between HicA and HicB. Residues that have direct equivalents 











5YRZ 6 4 0.782 0.246 1114.5 -7.9 0.468 
4P78 2 4 0.710 0.328 1179.3 -7.5 0.608 
Appendix Table 14. Structural conservation of the HicAB interface within the PDB. mmsize indicates the 
multimeric state of the most probable macromolecular assembly in the PDB entry, Q score is a structure 
alignment score (0-1, where 1 is an identical structure), Sequence identity (fraction), the total accessible surface 
area, DG upon formation of the interface and the Complexation Significance Score (CSS), which determines 























































































Appendix Table 16. List of interactions for HicABSP. Residues that have direct equivalents within the HicAB 




Chain Z score RMSD Identity Description 
4P78-D 6.4 2.1 33 Toxin HicA3 from Y. pestis 
1WHZ-A 5.9 2.1 32 Hypothetical protein 
5YRZ-B 5.8 2.3 26 Toxin HicA 
3P8A-B 4.0 3.9 6 Uncharacterised protein from S. 
aureus 
5HCW-A 3.6 2.7 10 Glyoxalase/ Bleomycine resistance 
protein/ dioxygena 
2P25-A 3.5 2.9 15 Glyoxalase family protein 
3FCD-B 3.3 2.4 8 Lyase 
3HDP-A 3.2 3.0 8 Glyoxalase-I 
5TE2-B 3.2 3.5 13 Adensylmethionine-8-Amino-7-
oxononanoate aminotransferase 
Appendix Table 17. The DALI server search result against a monomer of HicA. The PDB chain, Z score, 
RMSD, sequence identity and description are highlighted. The Z score relates to the structural similarity 
between proteins. Proteins with a Z score below 3 were not included in this table as this represented a low 
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Data-collection parameters     
Instrument SEC-SAXS at B21 Diamond Light Source 
SEC column Supedex 200 (GE Healthcare) 




Structural parameters HicAB 
I(0) (cm
-1
) [from P(r)] 3.49E-6 ± 3.7E-5 
Rg (Å) [from P(r)] 31.31 ± 0.21 
I(0) (cm
-1
) (from Guinier) 3.63E-3 ± 9.2E-6 
Dmax (Å)  100 
Rg (Å) (from Guinier) 31.90 ± 0.47 
Porod volume estimate (Å
-3
)  283,640 
χ2 0.75 
Dry volume calculated from sequence (Å
-3
) 110.149 
Molecular-mass determination    










Molecular mass Mr [from I(0)] 
74,000 
Calculated  Mr from sequence (kDa) 
91,164 
From Porod Volume [Vporod/1.7] (Da) 166,847 
Software employed 
  
Primary data reduction 
GDA (Diamond Light Source) 
Data processing Scatter 
Ab initio analysis DAMMIN 
Validation and averaging DAMAVER 
Rigid-body modelling N/A 
Computation of model intensities  FoXS 
Three-dimensional graphics representations Pymol 
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Data-collection parameters 
    
Instrument SEC-SAXS at B21 Diamond Light Source  
Temperature 25°C  
q range (Å
-1
) 0.006-0.40  
Structural parameters R94A N96A S98A  
I(0) (cm
-1








Rg (Å) [from P(r)] 29.74±0.15 32.21±0.16 31.75±0.15  
I(0) (cm
-1








Dmax (Å) 96 104.5 106.5  








Porod volume estimate (Å
-3
) 134002 15649 142002  
χ2 0.55 1.46 1.87  




75,693 75,896 76,027  
Molecular-mass determination 
   
 




) 0.738384 0.738384 0.738384  




) 3.047 3.047 3.047  
Molecular mass Mr [from I(0)] 65,000 75,000 74,000  
Calculated  Mr from sequence 
(kDa) 
62,612 62,780 62,888  
From Porod Volume 
[Vporod/1.7] (Da) 
78,824 92,022 83,530  
Software employed 
    
Primary data reduction GDA (Diamond Light Source) 
Data processing Scatter 
Ab initio analysis DAMMIN 
Validation and averaging DAMAVER 
Rigid-body modelling N/A 
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Data-collection parameters 
    
Instrument SEC-SAXS at B21 Diamond Light Source  
Temperature 25°C  
q range (Å
-1
) 0.006-0.40  
Structural parameters R94E N96Q S98T  
I(0) (cm
-1








Rg (Å) [from P(r)] 29.54±0.25 30.02±0.21 30.11±0.25  
I(0) (cm
-1








Dmax (Å) 97 97.5 98  








Porod volume estimate (Å
-3
) 133,369 136,319 138,869  
χ2 0.95 0.45 1.51  




75,973 76,172 76,172  
Molecular-mass determination 
   
 




) 0.738384 0.738384 0.738384  




) 3.047 3.047 3.047  
Molecular mass Mr [from I(0)] 66,000 67,000 67,000  
Calculated  Mr from sequence 
(kDa) 
62,844 63,008 63,008  
From Porod Volume 
[Vporod/1.7] (Da) 
78,452 80,187 81,687  
Software employed 
    
Primary data reduction GDA (Diamond Light Source) 
Data processing Scatter 
Ab initio analysis DAMMIN 
Validation and averaging DAMAVER 
Rigid-body modelling N/A 
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Data-collection parameters     
Instrument SEC-SAXS at B21 Diamond Light Source 
SEC column Supedex 200 (GE Healthcare) 




Structural parameters HicB-DNA 
I(0) (cm
-1
) [from P(r)] 3.43E-2 ± 4.3E-4 
Rg (Å) [from P(r)] 31.39 ± 0.26 
I(0) (cm
-1
) (from Guinier) 3.42E-2 ± 8.2E-5 
Dmax (Å)  107.5 
Rg (Å) (from Guinier) 31.74 ± 0.41 
Porod volume estimate (Å
-3
)  280399 
χ2 1.26 
Dry volume calculated from sequence (Å
-3
) 86,104 
Molecular-mass determination    










Molecular mass Mr [from I(0)] 
78,000 
Calculated  Mr from sequence (kDa) 
75,181 
From Porod Volume [Vporod/1.7] (Da) 164,940 
Software employed 
  
Primary data reduction 
GDA (Diamond Light Source) 
Data processing Scatter 
Ab initio analysis DAMMIN 
Validation and averaging DAMAVER 
Rigid-body modelling N/A 
Computation of model intensities  FoXS 
Three-dimensional graphics representations Pymol 
Appendix table 21. Statistics and parameters obtained via SAXS experiments of HicB-S1-2.  
 

























Plasmid PRum 2 palindromes N/A N/A Yes N/A 121 













No No 83 
HicAB E. coli Chromosome 1 palindrome No N/A- 
assumed no 
No Yes 214 
HicAB B. 
pseudomallei 
Chromosome 1 palindrome No No 
Enclosed 
No Yes This 
study 










Chromosome 1 palindrome1 No No 
Enclosed 
Yes N/A 272 
HigBA Vibrio 
cholerae 





























Chromosome 1 palindrome N/A N/A-
assumed no 
N/A N/A 408 
HigBA Acinectobacte
r baumanni 
Plasmid N/A N/A N/A-
assumed no 
Yes N/A 216 
HipAB E. coli 
 





Chromosome 4 operator sites N/A No 
Enclosed 
No No 217 
FitAB Neisseria 
gonorrhoae 




Yes No 142, 218 
Kid-Kis E. coli Plasmid 1 2 operator sites N/A Yes Yes Yes 219 





MqsRA E. coli Chromosome 2 operator sites No No No Yes 148, 223 
ParDE E. coli 
 
 





Chromosome 1 palindromic 
sequence 
N/A N/A Yes No 152 
Phd-Doc Bacteriophage 
P1 
Genome 2 palindromic 
sequences 




RelBE E. coli Chromosome 2 palindromes Yes3 Modelled as 
so 





Chromosome 2 palindromes N/A No Yes No 229 
VapBC Salmonella 
enterica 






Chromosome 2 operator sites N/A No N/A N/A 159 
VapBC Caulobacter 
crescentus 
Chromosome 2 operator sites N/A No N/A N/A 230 
YefM-
YoeB 




Appendix Table 22. List of toxin-antitoxin systems within bacteria where conditional cooperativity has 
been investigated (August 2018).  The location of the genes (Chromosome/Plasmid), number of operators 
within the regulatory promoter region, the presence or absence of an intrinsically disordered domain (IDR) 
within the antitoxin, whether the complex forms an alternating array of toxin:antitoxin T:AT modules and if 
toxins have been observed to act as co-repressors and de-repressors. 
1
 indicates the uncertainty of the specific 
location of the operator sites. 
2
 Operator sites that have not been experimentally confirmed. 
3
 Presence of a IDR 
at the toxin binding site not the DNA binding site. 
 








Appendix Table 23. Partial specific volume for each protein component analysed in both SVAUC and 
SEAUC. These values were calculated via SEDNERPT
380, 381
 based on the molecular weight of the species and 
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